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CHAPTER 1 
GENERAL INTRODUCTION 
L 1 Somatostatin, somatostatin analogues and somatostatin receptors 
Somatostatin (SS,,) is a cyclic disulfide-containing peptide hormone of 14 
amino acids (see figure 1). It is present in fhe hypofhalamus, fhe cerebral cortex, 
fhe brain stem, the gastrointestinal tract, and fhe pancreas. Somatostatin was 
isolated and characterized by investigators working in fhe laboratory of Guillemin 
at fhe Salk Institute in La Jolla (California) in 1973. Somatostatin receptors have 
been identified in fhe gastrointestinal tract, fhe central nervous system and on many 
cells of neuroendocrine origin, including fhe somatotroph cells of fhe anterior 
pituitary gland, fhe fhyroid C cells and fhe D cells of fhe islets of Langerhans 
(1,2). However, also non-neuroendocrine cells, such as lymphocytes (3), possess 
fhese receptors. In fhe central nervous system somatostatin acts as a neuro-
transmitter, while its hormonal activities include the inhibition of fhe release of 
growfh hormone, insulin, glucagon and gastrin (see ref. 4 for a review). 
The general inhibitory effect of somatostatin on hormone secretion of 
various glands led to fhe concept of possible beneficial effects of somatostatin in 
fhe treatment of diseases based on gland hyperfunction or overproduction of 
hormones by endocrine-active tumours. However, fhe tetradecapeptide SS" itself 
turned out to be unsuitable for routine treatment. This is because after intravenous 
administration SS" has a very short half-life of = 3 minutes in man due to rapid 
enzymatic degradation and also because of its diversity of action, such as lowering 
insulin levels. In recent years, successful efforts have been undertaken to 
synfhesize somatostatin analogues fhat are more resistant to enzymatic degradation 
by modifying fhe molecule in various ways wifh preservation of fhe biological 
activity of fhe original molecule. Introduction of D-amioo acids and shortening of 
fhe molecule to fhe bioactive core sequence, resulted in fhe 8 amino acids-contai-
ning somatostatin analogue octreotide (Sandostatin", see figure 1). Nowadays 
octreotide is widely used wifh success in the treatment of fhe symptoms of 
neuroendocrine-active tumours, such as growfh hormone-producing pituitary 
adenomas and gastroenteropancreatic tumours (5-7). The biology and clinical 
application of somatostatin and somatostatin analogues have been described 
extensively (6-10). 
Somatostatin receptor scintigraphy has been performed at fhe University 
Hospital Dijkzigt in Rotterdam since 1987. At first wifh f'''j-Tyr'joctreotide and 
since 1989 wifh [U'In-DTPA-D-Phe'joctreotide as described by Bakker (11). The 
visualization of somatostatin receptor-positive tumours in vivo after fhe administra-
tion of [U'jn-DTPA-D-Phe'joctreotide (Octreoscan") in a large series of patients 
has been reviewed (\2). 
Somatostatin receptors are structurally related integral membrane glycopro-
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teins. Recently, five different human somatostatin receptor types have been cloned. 
All subtypes bind SS" and SS" (a polypeptide of 28 amino acids with SS" making 
up the C-terminus) with higb affinity, while the affmity of numerous somatostatin 
analogues for the five different subtypes differ considerably (13-16). Octreotide 
binds with high affinity to the hSSTRZ (human somatostatin receptor type 2) 
subtype, while this analogue has a relatively low affinity for hSSTR3 and hSSTR5 
and shows no binding to hSSTRI and hSSTR4 (13-17). Octreotide scintigraphy is, 
therefore, based on the visualization of (an) octreotide-binding somatostatin 
receptor(s) (octreotide receptor(s», most probably the hSSTRZ and bSSTR5. 
Table 1. Ie" of octreotide for the five human somatostatin receptor subtypes (17) 
IC" for 
octreotide 
SSTRI SSTRZ SSTR3 
0.4 nM 35 oM 
SSTR4 SSTR5 
> I I'M 7.0nM 
Recently, several reports have been published on the in vitro binding to 
somatostatin receptors of another somatostatin analogue, the octapeptide RC-160, 
which structure is very similar to that of octreotide (figure I) (18-20). It has been 
reported that RC-160 has a higher affinity than octreotide for the somatostatin 
receptor in human breast, ovarian, exocrine pancreatic, prostatic and colonic can-
cer (18-20). For instance, the possible binding of RC-160 to a somatostatin 
receptor subtype on human exocrine pancreatic adenocarcinoma, which does not 
bind octreotide (21), offers a potential advantage for RC-160 over octreotide. 
Nearly one-third of human maliguant gliomas have an intact blood-brain 
barrier to contrast agents, and virtually all malignant gliomas and probably most 
brain metastases have areas of tumour with an intact blood-brain barrier (23-27). 
Unlabelled RC-160 may, in contrast to octreotide (22), also pass the intact 
blood-brain barrier (28). In addition, radiolabelled RC-160 could also represent a 
benefit in visualizing somatostatin receptor -positive brain tumours with an intact 
blood-brain barrier. The identification of several somatostatin receptor subtypes 
enables the development of subtype specific somatostatin analogues, which can be 
used in the diagnosis and selective treatment of somatostatin receptor-positive 
lesions (29). Therefore, the eventual application of this new somatostatin analogue 
will open possibilities, even as a new somatostatin receptor subtype-specific 
radiopharmaceutical. 
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Somatostatin 
I 
Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys 
Octreotide 
I 
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr( 01) 
["'1-Tyr]octreotide 
I 
D-Phe-Cys-Tyr -D-Trp-Lys-Thr-Cys-Thr( 01) 
I 
1231 
['"In-DTPA-D-Phe']octreotide 
I I 
II 'In-DTP A-D-Phe-Cys-Phe-D-Trp-Lys-Thr -Cys-Thr( 01) 
l2'I-RC-160 
D-Phe-Cys-Tyr-D-Trp-Lys-V al-Cys-Trp-NH, 
I 
[lIIln-DTPA-D-Phe']RC-160 
I I 
"'In-DTPA-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH, 
Figure L Sequence of somatostatin and some analogues 
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1.2 Attempts to increase the uptake of tU'In-DTPA-D-Phe'joctreotide in 
somatostatin receptor-positive tissues by varying mass, specific activity, and 
by priming with somatostatin analogues. 
In general, in in vitro experiments involving saturable processes (i.e. radio-
immunoassays and receptor binding studies) the signal to noise (read the target to 
background) ratio is often improved by lowering the mass of the radiotracer andlor 
by increasing its specific radioactivity. In previous studies (30), we reported the 
visualization of somatostatin receptor-positive tumours in rats by gamma camera 
scintigraphy using r'''In-DTPA-D-Phe'Joctreotide (see figure I). In those studies 
the administered mass of peptide and the radioactive dose were such that > 90 
procent of the ligand was unlabelled. Theoretically, the presence of unlabelled 
[DTPA·D-Phe'Joctreotide may have a negative effect on the % dose uptake of 
["'In·DTPA·D-Phe'joctreotide in somatostatin receptor-positive tissues due to 
competition with the same receptor. After the first labelling of ["'In-DTPA·D-
Phe'joctreotide in 1987, the composition of the commercially available '''InCl, has 
improved. The concentration of the non-radioactive nuclides, competing with In" 
for the DTPA-group, has decreased. Therefore the specific radioactivity could be 
increased 5·fold up to 185 MBq "'In per I'g [DTPA-D-Phe'joctreotide. We 
hypothesized that receptor scintigraphy would also show an optimal target to 
background ratio at the lowest possible mass of peptide with the highest specifIc 
radioactivity. Consequently, this would result in a more sensitive imaging 
technique. In the study presented in Chapter 3, this hypothesis was investigated in 
rats. 
Furthermore, several reports (31,32) suggested a positive effect of the prior 
administration of unlabeled peptide on the percentage dose uptake of its radioactive 
counterpart. Therefore, we investigated the effect of intravenous administration of 
2 or 10 I'g urdabeled octreotide or of 2 or 10 I'g unlabeled [DTPA-D-Phe'1-
octreotide at various time points relative to the injection of r"'In-DTPA-D-Phe'J-
octreotide on the uptake of radioactivity in somatostatin receptor·positive and 
-negative tissues. 
1.3 Internalization of radiolabelled ['''I-Tyr'joctreotide and [U'In-DTPA-D-
Phe'Joctreotide 
The fate of labelled somatostatin analogues after binding to their receptors 
is largely unknown. However, this knowledge is essential for a proper choice of 
radionuclides to label somatostatin analogues for radiotherapy. As will be discussed 
in detail in section 1. 6 Radiotherapeutical considerations various radionuclides 
suitable for radiotherapy, e.g. conversion, Auger, and Coster·Kronig electron 
emitters, are only effective in a short distance of only a few nm up to I'm from 
their target, e.g. DNA. Radiotherapy achieves its principal effect~ on both tumours 
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and healthy normal tissues by the destruction of proliferating cells. This is thought 
to be the result from damage to cellular DNA caused by ionizing irradiation, 
especially the production of double strand breaks (33). 
Equivocal data have been described with respect to internalization of SS". 
Receptor-mediated endocytosis of SS" has been demonstrated in rat anterior 
pituitary cells and in rat islet cells (34-41), whereas other investigators found that 
['25I-Tyr'jSS" and [I25J-Tyr"JSS" are not rapidly internalized by GH,C, rat pituitary 
cells and RINm5F insulinoma cells, respectively, probably due to degradation of 
these radioligands at the cell surface (42,43). Data with respect tu metabolism and 
internalization of somatostatin may have been influenced by the susceptibility of 
the somatostatin ligands to degradation. Investigations with more stable radioli-
gands, like [125I-Tyr'Joctreotide (44), provide a better insight in the extent of 
internalization of radiotherapeuticals by somatostatin receptor-positive (tumour) 
cells. 
In the study presented in Chapter 4, it is therefore investigated whether the 
stable somatostatin analogue ['251_ Tyr'joctreotide is internalized by somatostatin 
receptor-positive AtT20/D16V mouse pituitary tumour cells and by human GH-
secreting pituitary tumour cells. As presented in Chapter 3, we recently found that 
accumulation of ['"In-DTPA-D-Phe'Joctreotide in somatostatin receptor-positive 
organs showed a tissue-specific bell-shaped function of the injected mass of the 
radiopharmaceutical. In order to investigate the cellular mechanisms underlying 
these observations, we also studied the effect of different concentrations unlabelled 
octreotide on binding and internalization of [125I-Tyr'joctreotide by the two cell 
culture systems. 
Although still under investigations, some considerations on the 
internalization of ['"In-DTPA-D-Phe'Joctreotide are discussed. We found that 
during the first 30 minutes after the injection of [1231_ Tyr'joctreotide or ['"In-
DTPA-D-Phe'joctreotide in rats specific binding takes place in somatostatin 
receptor-positive tissues and tumours (ref. 45 and Chapter 6). However, the 
residence time of both radionuclides in somatostatin receptor-positive tissues and 
tumours was completely different. Twenty-four hours after the injection of the 
radiopharmaceutical release of radioactivity from somatostatin receptor-positive 
tissues and tumours is slower with ['"In-DTPA-D-Phe'joctreotide than with [1231_ 
Tyr'joctreotide. These results indicate the difference in fate for the two 
radiopharmaceuticals. The differences likely reflect the different biochemical 
pathways for iodotyrosine-labelled versus '"In-DTPA-Iabelled peptides. Several 
pathways for iodotyrosine-Iabelled peptides have been described. LaBadie et al. 
found that 125I-labelled asialofetuin (which still has intact affinity for the 
glycoprotein receptor) was rapidly degraded to mono- and diiodotyrosine in the 
lysosome which were subsequently deiodinated by a cytoplasmic enzyme (46). Of 
course this metabolic pathway does not apply to ['"In-DTPA-D-Phe'joctreotide. 
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As discussed in Chapter 3, in vivo displacement of somatostatin receptor-
positive tissue-associated radioactivity is observed when unlabelled ligand is 
injected 10 min after the radioligand, but not after 20 min, suggesting significant 
internalization of radiopharmaceutical between 10 and 20 min after injection. This 
might be the first in vivo and in vitro indication that ["'In-DTPA-D-Phe']octreotide 
is indeed internalized. '''In-DTPA-labelled receptor targeted proteins are 
transported to lysomes and the ultimal product N,-'''In-DTPA-lysine is trapped in 
the lysosome (47,48). Receptor-mediated internalization of ["'In-DTPA-D-
Phe']octreotide will most probably result in degradation to "'In-DTPA-D-Phe, and 
this metabolite is also not capable passing the lysosomal and/or other cell 
membrane(s) (47). 
Receptor-mediated endocytosis systems have been described (49,50) where 
cell surface receptors capture their ligands from the extracellular milieu. The 
receptor-ligand complex is internalized via invagination of the plasma membrane. 
The resulting intracellular vesicles, termed endosomes, rapidly acidify, which 
causes the ligand to dissociate from the receptor, see also figure 2. The ligand is 
delivered to the lysosome (47) and the receptor recycles back to plasma membrane. 
The whole process takes approximately 15 min (49), and a single receptor can 
deliver numerous ligand molecules to the lysosomes. This metabolic pathway of 
receptor-mediated endocytosis may also hold for the ligand ['''In-DTPA-D-
Phe']octreotide and its octreotide receptor. 
. . 
_-.....J .. ~: 
@ @~~ ~~V="·~.-
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EXTERNAlIZATION! ~Q 
Figure 2. A "basic" model for receptor-mediated endocytosis and receptor 
recycling (50) 
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1.4 Blood-brain barrier 
Receptors for circulating peptides of gastroenteropancreatic or neural origin 
(the neuropeptides) are largely located on the plasma membrane of target tissues 
(51). Owing to the aqueous pores (fenestrae) in capillary walls (52), small peptides 
(e.g. molecular weight 5 leD or less) readily gain access to the interstitial space and 
to the receptors on the plasma membrane of the target cells. Unlike the capillaries 
in any other organ, the microvessels in brain of all vertebrates are characterized by 
high resistance, epithelial-like tight junctions that essentially cement brain 
endothelial cells together (53). The barrier formed by the tight junctions of 
endothelial cells, the blood-brain barrier, prevents all water-soluble substances 
from entering the brain interstitium from blood (54). It is clear that this blood-
brain barrier is an important limiting factor in the application of neuropeptides or 
neurotransmitters as radiopharmaceutical in brain scintigraphy (23-27,55-59). 
Although unlabelled and radioiodinated RC-160 may, in contrast to octreotide, pass 
the blood-brain barrier (21,22), the DTPA-group in the radiopharmaceutical ["IIn_ 
DTPA-D-Phe l ]RC-160 (Chapter 6) increases its polarity and diminishes its blood-
brain barrier permeability. Up to date no DTPA-containing radiopharmaceutical 
has been reported to pass the blood-brain barrier in amounts suitable for gamma 
camera scintigraphy. 
1. 5 Substance P 
Several radiolabelled peptides are potentially applicable for receptor 
scintigraphy, as long as they will meet at least the following characteristics: 
a. high-aftinity and specificity for a characteristic and unique receptor, 
b. intact biological activity after radiolabelling, and 
c. stability in vivo. 
The receptor itself should have an increased expression at the cell surface of 
tumours or specific pathological processes. In that order, the newly synthesiszed 
[DTPA-Arg1jsubstance P was investigated. 
In 1931, von Euler and Gaddum extracted a potent hypotensive and 
contractile agent (on smooth muscle) from equine brain and gut (60). This 
compound was named substance P, where the "P" stands for the "powder" 
obtained after their extraction procedure. The exact chemical structure of substance 
P, shown in figure 3, remained unknown for over 40 years. The chemistry, tissue 
distribution, and pharmacological actions of substance P have been studied 
extensively (for reviews see refs. 61-63). The term tachykinin was introduced to 
describe members of the peptide family because of their relatively rapid initiation 
of smooth muscle contraction, compared with the slower-acting bradykinins. The 
tachykinin ligands comprise a family of low molecular weight peptide 
neurotransmitters that share a common C-terminal amino acid sequence, -Phe-X-
17 
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Gly-Leu-Met-NH" in which X represents either Phe, lie, Tyr or Val (64). The 
mammalian tachykinins are synthesized primarily by neurons and they include 
substance P, neurokinin A, neurokinin B, and two N-terminally extended forms of 
neurokinin A - neuropeptide K and neuropeptide y. Neurokinin A and neurokinin 
B are also referred to as substance K and neuromedin K, respectively. 
Currently accepted tachykinin receptor nomenclature delines three homolo-
gous receptor types: the substance P-preferring NK, receptor, the neurokinin A-
prefening NK, receptor and the neurokinin B-preferring NK, receptor. The NK, 
receptor is present in both brain and peripheral tissues, and substance P has the 
highest affinity (K, 0.5-1 nM) for this receptor. The NK, receptor has recently 
been cloned, and the deduced amino acid sequence, 407 residues, contains seven 
putative membrane-spanning domains and shows a sequence similar to other 
members of the G-protein coupled receptor family (65). The tachykinin receptors 
have a wide tissue distribution, and interaction with their ligands is associated with 
diverse responses such as sensory neufotransmissiofl, immunological responses, 
both contraction and endothelium-dependent relaxation of vascular smooth muscle, 
nociception, histamine release, plasma extravasation, inflammation, sexual 
behaviour and, potentially, nerve regeneration and wound healing. For extensive 
reviews on the history, nomenclature, synthesis and degradation of tachykinins. the 
reader is referred to refs. : 64 and 65. 
Substance P 
Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-G1y-Leu-Met -NH, 
['''In-DTPA-Arg'lsubstance P 
II 'In-DTP A-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH, 
Figure 3. Sequence of substance P and !'llIn-DTPA-Arg'lsubstance P 
The involvement of substance P in the carcinoid syndrome (66) and 
vascular (migraine) headache (67) has been suggested. In rats with adjuvant 
arthritis a high concentration of substance P was found in the synovial fluid and a 
high density of high-affinity substance P receptors in synovial tissue (68). These 
[mdings were confIrmed in patients with rheumatoid arthritis (69). In addition, 
very high levels of substance P receptor are expressed in the germinal center of 
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lymph nodes (70), and on a human astrocytoma cell line (71). Large numbers of 
high-affinity substance P receptor are found in surgical specimens obtained from 
patients with inflammatory bowel disease. The substance P-binding NK, receptor is 
expressed by arterioles and venules located in the submucosa, muscularis mucosa, 
external longitudinal muscle, and serosa (70,72). 
Consequently, in analogy with the development of [DTPA-D-Phe'j-
octreotide and [DTPA-D-Phe'jRC-160, the newly synthesized [DTPA-Arg'j-
substance P was prepared and investigated for its binding characteristics in vitro 
and in vivo. 
Table 2. Radionuclides for therapy: physical propenies 
Nuclide Half-life EJlmax Maximum 
(keV) range 
1311 8 days 606 2.4 mm 
46-330 (IC) 32-850 I'm 
0.9-3.1 (Auger) 0.05-0.33 I'm 
"y 64 hours 2270 12 mm 
1ll6Re 91 hours 930-1070 3.6-4.3 mm 
53-135 (IC) 42-200 I'm 
0.24-7.1 (Auger) 0.009-1.3 I'm 
"p 14 days 1710 8.7 mm 
161Th 6.9 days 135-180 0.8 mm 
3-66 (IC) 0.4-50 I'm 
1-8 (Auger) 0.1-1.5 I'm 
61Ga 78 hours 82-93 (IC) 90-110 I'm 
0.05-9.5 (Auger) 0.002-2.1 I'm 
lllIn 68 hours 144-245 (IC) 200-550 I'm 
0.5-25 (Auger) 0.02-10 I'm 
"51 60 days 3.7-35.5 (IC) 0.4-20 I'm 
0.7-30 (Auger) 0.02-15 I'm 
1. 6 Radiotherapeutical considerations 
Historically, the first example of targeted radionuclide therapy was the 
treatment of well differentiated thyroid carcinoma with ionic "'I. This exploits the 
almost unique property of thyroid cells to concentrate iodide in ionic form (73). 
The radiotherapeutical treatment of neuroblastomas or catecholamine-producing 
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phaechromocytomas with the iodocompound '''I-mIBG (meta-iodo-benzyl-
guanidine), which is preferentially taken up by catecholamine-synthesizing cells of 
the sympathetic nervous tissues, is well established (74). Successful therapy of 
lymphomas with I3IHabelled specific antibodies has been reported (75,76). As soon 
as the success of peptide receptor scintigraphy for tumour visualization became 
clear, the next step was to label these peptides with ex- or Il-particles emitters or 
with Auger, Coster-Kronig or conversion electrons-emitting radionuclides and to 
perform radiotherapy with these radio labelled peptides. 
A (mono-energetic) conversion electron arises when the atomic nucleus 
transfers energy to one of its surrounding electrons, enabling it to leave the atom 
(77). The resulting vacancy is filled by electrons from higher orbitals, which may 
result in emission of an Auger electron (78) or an Coster-Kronig electron (79). In 
addition, Auger and Coster-Kronig electrons may arise when vacancies in the 
electron orbitals is caused by electron capture, in which an orbital electron is 
captured by the nucleus. For a detailed review on this subject the reader is referred 
to Bambyrek et al. (77) and to Howell (80). 
The applicabality of peptides labelled with nuclides suitable for radiotherapy 
has to meet at least the following characterisitics: 
a. high purity of the radionuclide since only a limited amount of the 
(radio )ligand can be administered, 
b. stability of the radioligand in vivo, 
c. a high affinity of the radioligand for its specific receptor, and 
d. a long residence time (biological Ph :> physical t'h) of the radioactivity 
inion the target tissue. 
Even when these characteristics are met, it is well-known that the empiric 
in vivo findings will often differ from the calculated estimated dose, largely due to 
the current short-comings of microdosimetry. For instance, the inhomogeneity of 
the receptors throughout the target and the potential internalization of the ligand, 
and the (sub)cellular localisation of the radionuclide are unknown factors (73). 
Since the energy of conversion, Auger, and Coster-Kronig electrons is usually less 
than that of Il-particles (74), their Linear Energy Transfer (LET) and consequently 
their cell kill probability is larger than that for Jl-particles. When a radionuclide 
with a high LET is located within a few nm of the DNA, its radio-toxicity is very 
high. Therefore, the importance of a given level of heterogeneity depends on the 
radionuclide. Heterogeneity will be most serious for short-range ex-emitters and 
Auger emitters and least serious for long range Il-emitters (73). 
For recent reviews on microdosimetry and the radiobiological ellectiveness 
and quality factor for Auger emitters the reader is referred to refs. 73,81-85. The 
heterogeneity of radionuclide deposition and the short-comings of the MIRD 
calculations with nonuniform distribution of radioactivity have also been discussed 
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(refs. 73 and 70, respectively). 
Empirical findings from in vitro cell survival experiments demonstrated that 
intracellular '''In resulted in a J09-fold higher radiation dose to the cell nucleus 
than extracellular localized "'In (86). For most of the peptide-bound radionuclides, 
theoretically suitable for radiotherapy, the target distribution, their metabolism and 
consequently the (sub )cellular distribution are still unknown. For a recent review 
on this subject the reader is referred to Adelstein (87). Positive in vitro results on 
the therapeutic application of the Auger and conversion electron emitter "Ga have 
been reported (88,89). Dividing cells differ greatly in their response to external 
beam irradiation, radiosensitivity, and this is probably also true with respect to 
radionuclide therapy (33). 
The usefulness of [DTPA-D-Phe']octreotide, labelled with the Auger 
electron emitter '''In or with the JI-emitter '''Tb, which both are potentially suitable 
for radiotherapy is discussed in the appendix papers 1 and 2, respectively. In 
appendix paper 3 various options are discussed to prepare radiolabelled peptides 
for receptor-targeted radiotherapy. The application of the well-known JI-emitter "'I 
is compared with that of various other candidate radionuclides for therapy. 
Various of the above-mentioned data are derived from references 90-92. 
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CHAPTER 2 
AIM OF THE STUDIES 
Octreotide receptor scintigraphy is performed at the University Hospital 
D\jkzigt in Rotterdam since 1987. Initially with ["'I-Tyr']octreotide, later with 
["'In-DTPA-D-Phe'Joctreotide. To date 1400 patients with various forms of 
cancer, both classically known as neuroendocrine and non-neuroendocrine have 
been investigated. Another group of 150 patients with various (auto)immune 
diseases have also been investigated. 
In general in in vitro experiments high specific activities of the radioligand 
will lead to an increase in sensitivity of detection of either low abundance or low 
affinity receptor sites. Therefore, since the quality of the commercially available 
"'InCl, has improved, the possibility was opened to increase the specific activity of 
f"'In-DTPA-D-Phe'loctreotide 5-fold. We hypothesized that receptor scintigraphy 
is best performed using the lowest possible mass with the highest specific activity. 
In chapter 3 this hypothesis is challenged. 
Five different somatostatin receptor subtypes have been cloned sofar. As will 
be explained in detail in Chapters 3, 4 and 7, the affinity of the somatostatin 
analogue octreotide for these five different somatostatin receptors subtypes varies. 
Several report~ suggested a higher affinity for some of these subtypes by another 
somatostatin analogue than octreotide: RC-160. This peptide and its newly 
synthesized analogue, fDTPA-D-Phe'JRC-160, were radiolabelled and compared in 
vivo and in vitro with radiolabelled [Tyr']octreotide and fDTPA-D-Phe'loctreotide, 
as presented in Chapter 5, 6 and 7. 
In analogy of the developments of the above-mentioned radiopharma-
ceuticals, the potential application of another neuropeptide, substance P, and its 
newly synthesized analogue, fDTPA-Arg'jsubstance P, have been investigated for 
receptor scintigraphy and are presented in Chapter 8 and 9. 
As soon as the success of peptide receptor scintigraphy for the visualization 
of pathological lesions became clear, the following step was the labelling of these 
peptides with a- or Jl-particles emitters or with Auger, Coster-Kronig or 
conversion electrons-emitting radionuclides. Several aspects using peptides labelled 
with such radionuclides were investigated, as presented in the appendix papers 1, 2 
and 3. 
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CHAPTER 3 
THE UNEXPECTED EFFECTS OF DOSE AND SPECIFIC 
RADIOACTIVITY ON TISSUE DISTRIBUTION OF 
r!!lIn-DTPA-D-Phe'jOCTREOTIDE IN RATS. 
ATTEMPTS TO OPTIMIZE THE TARGET TO BACKGROUND RATIO 
Wout AP Breeman, Dik J Kwekkeboom, Peter PM Kooij, 
Willem H Bakker, Leo J Hofland, Theo J Visser, 
Geert J Ensing, Steven WJ Lamberts, Eric P Krenning 
Departments of Nuclear Medicine, Internal Medicine III, 
University Hospital "Dijkzigt", Rotterdam, The Netherlands 
and Mallinckrodt MedicaJ, Petten, The Netherlands 
ABSTRACT 
In order to increase the target to backgronnd ratio in receptor scintigraphy, 
we hypothesized that receptor scintigraphy is best performed using the lowest 
possible mass with the highest possible specific radioactivity of the radioJigand. 
Since the non-radiochemicaJ composition of the commercially available "'InCI, has 
been improVed after it was first used to label to [DTPA-D-Phe'joctreotide, it was 
possible to increase the specific radioactivity 5-fold up to 185 MBq '''In per p.g 
[DTPA-D-Phe'Joctreotide. In the present stody we have challenged this hypothesis 
and investigated the effect of the injected mass and specific radioactivity of ['''In-
DTPA·D-Phe'joctreotide in rats. Uptake of ["'In-DTPA-D-Phe'joctreotide showed 
a bell-shaped function of the injected mass; the optimal mass differed between the 
somatostatin receptor-positive tissues stodied. In contrast, varying specific radioac-
tivity at a constant mass had no significant effect. Moreover, varying mass and 
specific radioactivity had no effect on the percentage dose uptake in somatostatin 
receptor-negative organs. Therefore, depending on the tissue, the target to back-
gronnd ratio can be increased by varying the injected mass. 
Several reports suggested a positive effect of the prior administration of 
unlabelled peptide on the percentage dose uptake of its radioactive connterpart. 
Therefore, we investigated the effect of intravenous administration of 2 or 10 p.g 
unlabelled octreotide or of 2 or 10 p.g unlabelled [DTPA-D-Phe'loctreotide from 
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10 min before to 20 min after the injection of [II'ln-DTPA-D-Phe'joctreotide. In 
some of these settings there was a significant increase in the uptake of '1I1n in 
somatostatin receptor-positive organs, in others there was a significant decrease. 
Since no significant differences were found in background radioactivity and in the 
percentage dose uptake of '1I1n in somatostatin receptor-negative organs, these data 
indicate that the target to background ratio can be increased by the administration 
of non-radio labelled peptide under selected conditions. 
In conclusion, in contrast to our hypothesis that receptor scintigraphy shows 
an optimal target to background ratio at the lowest possible mass of the radiophar-
ma-ceutical with the highest specific radioactivity, we found that the uptake of 
['IIIn-DTPA-D-Phe']octreotide in somatostatin receptor-positive organs shows a 
tissue-specific bell-shaped function of the injected mass of the radiopharmaceutical. 
This might also apply to somatostatin receptor-positive tumours, the visualization 
of which may be enhanced by optimizing the mass of ["'In-DTPA-D-Phe']octreoti-
de. 
INTRODUCTION 
In previous animal studies we reported the visualization by gamma camera 
scintigraphy of somatostatin receptor-positive tumours in rats by ['IIIn-DTPA-D-
Phe']octreotide (I). In those studies the administered mass of [IH In-DTP A -D-
Phe']octreotide varied between 0.5 and 1 p.g and the radioactive dose was kept 
constant at 18.5 MBq 'IIIn. However, the non-radioactive composition of 'IIInCI, 
has improved after the first labelling of ['IIIn-DTPA-D-Phe']octreotide in 1987. 
Therefore, it was possible to increase the specific radioactivity 5-fold up to 185 
MBq 'IIIn per p.g [DTPA-D-Phe'Joctreotide, which allows the administration of 
smaller masses of peptide with the same radioactive dose. We hypothesized that 
receptor scintigraphy shows an optimal target to background ratio at the lowest 
possible mass of peptide with the highest specific radioactivity, and this could well 
result in a more sensitive imaging technique. In the present study this hypothesis 
and the effects of mass and specific radioactivity of ["'In-DTPA-D-Phe']octreotide 
on the percentage dose uptake and specific binding in several organs were investi-
gated in rats. 
Therapy with unlabelled octreotide may have a negative influence on the 
target to background ratio in ['lIln-DTPA-D-Phe']octreotide scintigraphy. Surpri-
singly, Dorr et al. recently reported improved visualization of carcinoid liver 
metastases by ['IIIn-DTPA-D-Phe']octreotide scintigraphy during treatment with a 
subcutaneous dose of 600 p.g per day of octreotide (2,3). However, the mecha-
nism(s) and the effect(s) of pretreatment and/or concomitant therapy with unlabel-
led ligand on receptor scintigraphy have yet not been studied in detail. Somatosta-
tin receptors are structurally related integral membrane glycoproteins. Recently, 
five different human somatostatin receptor types have been cloned. All subtypes 
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bind native somatostatin-14 (SS,,) and SS" (pro-somatostatin with 28 aminoacids) 
with high affInity, while their affInity for numerous somatostatiu analogues differ 
considerably (4-7). Octreotide binds with high affInity to the SSTR2 (somatostatin 
receptor type 2) subtype, while this analogue has a relatively low affInity for 
SSTR3 and SSTR5 and shows no binding to SSTR subtypes I and 4 (4-7). 
Octreotide scintigraphy is therefore based on the visualization of octreotide-binding 
somatostatin receptors (octreotide receptors), most probably the SSTR2. In the 
present study, therefore, we also investigated the tissue distribution of 1I1In in 
octreotide receptor-positive (i.e. pituitary, adrenal and pancreas) and octreotide 
receptor-negative tissues (i.e. kidneys, spleen, liver and soft tissue (thigh) muscle) 
(1,8) 24 hours after the injection of 0.5 ",g [DTPA-D-Phe']octreotide labelled with 
3 MBq '''In, while at various time points relative to the injection of the radiophar-
maceutical additionally unlabelled octreotide or [DTPA-D-Phe']octreotide were 
administered intravenously. 
MATERIALS AND METHODS 
Radiolabelling and Quality Control of the Radiopharmaceutical 
[DTPA-D-Phe']octreotide and 1I1InCl, (DRN 4901, 370 MBq/m1 in HCI, 
pH 1.5 - 1.9) were obtained from Mallinckrodt (petten, The Netherlands). Thirty 
minutes after the start of the radiolabelling of [DTPA-D-Phe']octreotide with '''In, 
up to a specifIc radioactivity of 185 MBq 1I1In per ",g [DTPA-D-Phe']octreotide 
(molar excess of 5- to IO-fold of peptide over '''In) the effIciency of labelling was 
over 98 %. The consecutive quality control were performed as described earlier 
(9). Although it is not excluded that additional groups of the peptide participate in 
'''In complexation, radiolabelled product is referred to as ['''In-DTPA-D-Phe']oc-
treotide. 
Tissue Distribution and Specific Binding of [DTPA-D-Phe'joctreotide 
In total 123 male Wistar rats (240-Z60 g) were used in 3 separate experi-
ments (A, B and C, see below). Rats were anaesthetized with ether, and the 
radiopharmaceutical and/or additional peptides were injected into the dorsal vein of 
the penis and/or into a sublingual vein. The volume of injection was kept constant 
at 0.5 mL per rat. 
The radioactivity was measured in a dose calibrator (VDC-20Z, Veenstra, 
loure, The Netherlands). In order to study non-specifIc binding, the rats were 
injected subcutaneously with I mg octreotide in I ml 0.05 M acetic acid in 154 
mM NaCI 45 min before with ["'In-DTPA-D-Phe']octreotide (10). Specitic 
binding was defIned as the difference between the tissue uptake of radioactivity in 
control rats (total binding) and that in animals treated with excess unlabelled 
peptide (non-specifIc binding), expressed as % of the injected radioactivity per 
gram tissue as described before (10). 
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The ratio of % dose uptake in tissue over soft tissue (thigh) and tissue over 
blood were calculated for each individual rat. The rats were sacrificed 24 h after 
administration of ["Iln-DTPA-D-Phel]octreotide. Blood was collected, and the 
octreotide receptor-positive anterior pituitary gland, adrenals and pancreas as well 
as octreotide receptor-negative tissues such as kidneys, spleen, liver and thigh were 
isolated. Tissue and blood radioactivity were determined using a LKB-1282-
Compu-gammasystem (10). 
Experiment A: Effects qf Varying the Dose and Specific Radioactivity of l'" In-
DTPA-D-Phe1joctreotide on Specific Binding 
Experiments were performed with 18 groups of 3 male Wistar rats (240-260 
g). Nine groups of 3 rats each were injected with 0.02, 0.1 or 0.5 /lg [DTPA-D-
PhelJoctreotide with specific activities of 18.5, 55.5 or 185 MBq 11iIn per /lg 
[DTPA-D-PheIJoctreotide. Consequently, the radioactive dose varied between 0.37 
and 92.5 MBq per rat. Non-specific binding in tissue was determined in 9 parallel 
groups of 3 rats each, which were injected with I mg octreotide 45 min before the 
different doses of [IIIIn-DTPA-D-Phel]octreotide as described above. 
Experiment B: Effects of Varying Mass of [DTPA-D-Phe'joctreotide at a Constant 
Radioactive Dose qf l'" In-DTPA-D-Phe' /octreotide 
Because in experiment A both the dose and mass had varied at the same 
time, we also investigated the effect of varying mass at a constant radioactive dose. 
Experiments were performed with 5 groups of 3 male Wistar rats (240-260 g), 
which were injected with 0.02, 0.1, 0.5, 5 or 50 /lg [DTPA-D-Phel]octreotide 
labelled with 3 MBq IIIIn. Consequently, the specific radioactivity varied between 
150 and 0.06 MBq IIIIn per /lg [DTPA-D-Phel]octreotide. 
Experiment C: Effects of Intravenous Injection of Octreotide or [DTPA-D-Phe'joc-
treotide at Various Time Points Relative to Administration qf l'" In-DTPA-D-
Phe'joctreotide 
Sixteen groups of 3 male Wistar rats (240-260 g) each were iI\jected with 2 
or 10 /lg octreotide or [DTPA-D-PheIJoctreotide at -10,0, 10 and 20 min relative 
to the injection of 0.5 /lg [DTPA-D-PheIJoctreotide labelled with 3 MBq '''In. A 
group of 6 rats iI\jected with radiopharmaceutical only was used as controls. The 
values of % dose uptake per gram tissues in treated animals are expressed as % of 
those in the control animals. 
Statistical Analysis 
One-way analysis of variance (ANOV A), was used for statistical analysis. 
Means were compared using Bonferroni's t-test or Newman-Keuls method (11). 
A P value of < 0.05 was considered significant. 
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RESULTS 
Experiment A: Effects of Varying the Dose and Specific Radioactivity of fH In~ 
DTPA~D~Phe'Joctreotide on Specific Binding 
Significant specitic tissue binding of rll'In-DTPA-D-Phe'joctreotide was 
observed in the octreotide receptor-positive anterior pituitary gland, adrenals, and 
pancreas, but not in the octreotide receptor-negative liver, spleen, kidneys or soft 
tissue (1) (data not shown). 
4 % dose per gram pancreas 
• 
3 
2 
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Mass (ug) 0.02 0.1 0.5 0.02 0.1 0.5 
Spec. Activity 18.5 55.5 
0.02 0.1 0.5 
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Figure 1. Effects of varying mass of [DTPA~D~Phe'Joctreotide (0.02, 0.1 and 0.5 
p.g) and specific radioactivity (18.5, 55.5 and 185 MBq per p.g) on specific binding 
of f'Hln-DTPA~D~Phe'Joctreotide, expressed as % injected dose of radioactivity per 
g tissue 24 h after injection, (n=3, mean + SD). 
* P < 0.05 : significantly different from 0.02 p.g 
Figure I shows the effects of mass and specific activity on the specific 
binding of [Il'In-DTPA~D-Phe'loctreotide in the pancreas. A significantly higher % 
dose uptake is observed at increasing mass in the range of 0.02, 0.1 and 0.5 p.g of 
[DTPA-D~Phe'loctreotide independent of the specific radioactivity, varying 
between 18.5 and 185 MBq ll'In per p.g rDTPA~D-Phe'joctreotide. Under these 
conditions the pancreas to soft tissue ratio showed a similar pattern as depicted in 
Figure 1 (data not shown). Similar patterns in specific binding, although not 
statistically significant, were found for the adrenals and the anterior pituitary gland 
(data not shown). 
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Figure 2. Effects of varying mass of [DTPA-D-Phe'Joctreotide labelled with a 
constant amount (3 MBq) of mIn on the 24 h uptake of radioactivity in anterior 
pituitary (A), pancreas (B) and adrenals (C), expressed in % injected dose of 
radioactivity per gram tissue, (n~3, mean + SD). 
* P <0.05,. significantly different from 0.02 fLg 
Experiment B: Effects of Varying Mass of [DTPA-D-Phe' J-octreotide at a Constant 
Radioactive Dose of [mln-DTPA-D-Phe'Joctreotide 
At a constant radioactive dose of 3 MBq pllln-DTPA-D-Phe1Joctreotide, 
there was a biphasic response, i.e. an initial increase followed by a decrease, in a 
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% dose uptake in the octreotide receptor-positive organs, when the mass of 
injected [DTPA-D-Phe'joctreotide was increased from 0.02- 50 I'g. The optimum 
was 0.5 I'g for the anterior pituitary gland (although not significantly different 
from the other masses), and 5 I'g for the pancreas and 0.5 I'g for the adrenals 
(Figs. 2 A, B and C). It is remarkable that the % dose uptake in the adrenals is 
still strongly increased at 50 I'g compared with 0.02 I'g peptide, and in contrast to 
pituitary and pancreas. The corresponding tissue to soft tissue ratio showed similar 
profiles (data not shown). No significant differences were found in the ratio of 
radioactivity in the liver, spleen, blood or kidney versus soft tissue (data not 
shown). 
Experiment C: Effects oj Intravenous Injection oj Octreotide or fDTPA-D-Phe'joc-
treotide at Various Time Points Relative to Administration oj fllIn-DTPA-D-
Phe'loctreotide 
As shown in Figure 3A, the administration of 2 or 10 I'g octreotide or 2 or 
10 I'g fDTPA-D-Phe'joctreotide 10 min prior to the administration of 0.5 I'g 
fDTPA-D-Phe'joctreotide labelled with 3 MBq '''In (further referred to as radiop-
harmaceutical) resulted in significantly lower % dose uptake values in the octreoti-
de receptor-positive anterior pituitary gland. Coinjection of 10 I'g [DTPA-D-
Phe'joctreotide or 2 or 10 I'g octreotide with the radiopharmaceutical also signifi-
cantly lowered the % dose uptake in the pituitary, but coinjection of 2 I'g [DTPA-
D-Phe'Joctreotide was without effect. Injected 10 min after the radiopharmaceuti-
cal, a significant lowering of % dose uptake was observed with 2 or 10 I'g 
octreotide, and 20 min after the radiopharmaceutical only with 2 I'g octreotide but 
not with 10 I'g octreotide. 
Figure 3B shows significantly higher % dose uptake values in the pancreas 
after the administration of 2 I'g [DTPA-D-Pheljoctreotide at 0 or 20 min or of 10 
I'g [DTPA-D-Phe'joctreotide at -10, 0 or 10 min relative to the injection of the 
radiopharmaceutical. Figure 3B also shows the significantly lower % dose uptake 
of radioactivity in the pancreas after the administration of 10 I'g octreotide at -10, 
0, and 10 min, but not at 20 min post injection of the radiopharmaceutical. 
Figure 3C shows that after the administration of 10 I'g fDTPA-D-Phe'Joctreotide at 
-10, 0 and 20 min relative to the injection of the radiopharmaceutical the adrenal 
% dose uptake was significantly lowered. However, after the administration of 2 
I'g [DTPA-D-Phe'joctreotide 10 and 20 min after injection of the radiopharmaceu-
tical there was a significantly higher % dose uptake in the adrenal. 
Figure 3C also presents the significantly lower adrenal % dose uptake after 
the administration of 2 or 10 I'g octreotide at -10, 0 and 10, but not at 20 min post 
injection of the radiopharmaceutical. 
Since the % dose uptake in all the measured octreotide receptor-negative 
tissues was unaffected by the intravenous administration of 2 or 10 I'g octreotide 
or 2 or 10 I'g [DTPA-D-Phe'joctreotide, the calculated ratio of % dose uptake in 
octreotide receptor-positive tissue versus blood or versus soft tissue gave similar 
results as those presented in Figure 3 (data not shown). 
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Figure 3. Effects of intravenous administration of 2 (black bar) and 10 (open bar) 
p.g fDTPA-D-PhelJoctreotide and 2 (hatched) and 10 (cross-hatched) p.g octreotide 
at indicated time intervals relative to the injection of 0.5 p.g (3 MBq) l"'In-DTPA-
D-Phe/octreotide on the 24 h uptake Qf radioactivity in anterior pituitary (A), 
pancreas (8) and adrenals (C). Values are expressed as % dose per g tissue (n~3) 
relative to that in control rats (100%, n~6). The control values (in % dose per g 
tissue) were 0.90 ± O. 20 for the pituitary, 2. 2 ± 0.3 for the pancreas and 5.0 ± 
1.1 for the adrenals. * P <0.05; significantly dijferentfrom control 
DISCUSSION 
In previous animal studies we reported the visualization by gamma camera 
scintigraphy of octreotide receptor-positive tumours in rats with ["lln-DTPA-D-
PhelJoctreotide (1). In those studies the administered mass of [llIln-DTPA-D-
Phel]octreotide varied between 0.5 and 1 p.g while the radioactive dose was kept 
constant. However, the non-radioactive composition of 11IInCl, has improved after 
our first preparation of ["lln-DTPA-D-Phel]octreotide in 1987. Therefore, it was 
possible to increase the specific radioactivity 5-fold up to 185 MBq IIlln per p.g 
[DTPA-D-Phel]octreotide. This increased specific radioactivity would allow the 
administration of smaller masses of peptide with the same radioactive dose. We 
hypothesized that receptor scintigraphy shows an optimal target to background ratio 
at the lowest possible mass of peptide with the highest specific radioactivity, 
resulting in a more sensitive imaging technique. 
To test this hypothesis we investigated whether varying specific radioactivi-
ty of r"ln-DTPA-D-Phe IJoctreotide results in changes in the specific and non-
specific binding in either octreotide receptor-positive or octreotide receptor-
negative tissues, and, consequently, in an altered target to background ratio. We 
evaluated these parameters by varying the mass and the radioactive dose of [llIln_ 
DTPA-D-Phel]octreotide (Exp. A). Unexpectedly, we found that not the lowest 
possible mass of [DTPA-D-Phel]octreotide of maximum specific radioactivity was 
optimal, but that the specific binding to octreotide receptor-positive tissue increased 
at higher mass of the radiopharmaceutical with an optimum in the low microgram 
range, depending on the octreotide receptor-positive tissue under study. Since this 
might also hold for octreotide receptor-positive tumours, an extra parameter has 
become available to increase the target to background ratio, and hence, the 
sensitivity to detect such tumours. This was further substantiated by the findings 
that non-specific binding in the tissues studied did not change with the dose or 
mass of injected radiopharmaceutical. 
Next, we further evaluated the effects of varying mass with a constant 
radioactive dose of ["lln-DTPA-D-Phel]octreotide on the uptake of radioactivity in 
the octreotide receptor-positive and octreotide receptor-negative tissues (Exp. B). In 
this experiment we found an optimal uptake of radioactivity in the anterior 
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pituitary gland, the pancreas and the adrenals at 0.5, 5, and 0.5 I'g [DTPA-D-
Phe'joctreotide, respectively. It remains to be established, however, which peptide 
mass would be optimal for uptake of "'In after the administration of ["'In-DTPA-
D-Phe'Joctreotide in different octreotide receptor-positive organs and tumours in 
humans. The reason for these differences in tissue uptake depending on the injected 
mass of LDTPA-D-Phe'joctreotide has to do with the availability of the radiophar-
maceutical to its receptor as well as the processes following the binding of the 
radiopharmaceutical to its receptor. Relevant factors for receptor accessibilty 
include the capacity of the radiopharmaceutical to pass biomembranes, the competi-
tion by endogenous somatostatin and the rate of blood perfusion of the tissue. For 
instance the production of somatostatin in the pancreas may contribute to the 
relatively high optimal dose of 5 I'g of r"'In-DTPA-D-Phe'joctreotide for uptake in 
the pancreas. This is in contrast to the optimal dose of 0.5 I'g for the highly 
perfused adrenal, which does not produce somatostatin. Other factors include the 
dissociation constant between the radiopharmaceutical and the receptor, the mode 
of administration that might influence the concentration and the exposure time of 
receptor to the radiopharmaceutical, the rate of internalization of the ligand-
receptor complex, and the rate of reexpression and/or upregulation of the receptor. 
All abovementioned parameters illustrate the dynamics and the complexity of the 
ligand-receptor binding process, in particular in vivo (12). 
In a third experiment (Exp. C), finally, we evaluated the effects of the 
intravenous administration of 2 or 10 I'g [DTPA-D-Phe'joctreotide or 2 or 10 I'g 
octreotide at various time intervals relative to the injection of ["' In-DTP A -D-
Phe'joctreotide on the tissue uptake of "'In. Also in vitro findings suggest that the 
optimal ratio between specific and non-specific binding of peptides to the somatos-
tatin receptor-containing cells is not necessarily highest at the lowest ligand 
concentration. Presky et al. found an increase in the number of somatostatin 
receptors on Gli.C, pituitary cells 24 h after the treatment with somatostatin (13). 
The presented experiments were also performed since we recently observed a 
rapid, increased internalization of ["'1_ Tyr'joctreotide in normal and tumour 
pituitary cells by the simultaneous addition of a nanomolar concentration of 
unlabelled octreotide [Hofland et al. unpublishedj. DOff reported improved 
visualization of carcinoid liver metastases in patients by [lUIn-DTPA-D-Phe'joctre-
otide scintigraphy during treatment with a subcutaneous dose of 600 I'g of octreoti-
de per day (2,3). These data in patients therefore may well be in accordance with 
our animal data. 
In all the octreotide receptor-positive organs we found a significantly 
lowered % dose uptake of radioactivity when 10 I'g octreotide was administered 
at -10, 0 and 10 min, but not at 20 min post injection of the radiopharmaceutical. 
This may be an indication of the limited exposure time of the radiopharmaceutical 
to its receptor as well as the rate of binding of the radioligand to its receptor and 
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the subsequent internalization of the peptide-receptor complex. The amount of 
radioactivity in the octreotide receptor-positive tissues is stable, sioce no significant 
differences are found between 4 and 24 h after injection of the radiopharmaceutical 
(8). 
The effects of the administration of octreotide on the inhibition of % uptake 
of [,lIln-DTPA-D-Phe'Joctreotide in the octreotide receptor-positive tissues were 
more pronounced than the effects of [DTPA-D-Phe']octreotide administration. This 
may be due to the difference in affinity between the two somatostatin analogoes for 
the receptor, which is ~ 5-fold lower for [DTPA-D-Phe']octreotide than for 
octreotide, as has been demonstrated previously (9). Further possible differences 
may be due to differences in distribution and metabolism. 
In summary, the results of this third experiment indicate that, depending on the 
type of octreotide receptor-positive tissue, the injection of variable amounts of 
[DTPA-D-Phe'Joctreotide or octreotide at vatious time poiots relative to the 
injection of ['IIIn-DTPA-D-Phe'Joctreotide may be a means to increase the target to 
background ratio. These mechanisms may be applied to increase the target to 
background ratio in somatostatin receptor imagiog in humans. Preliminairy 
fmdings in patients indicate that a specific activity higher than 220 MBq 'IIIn per 5 
{lg [DTPA-D-Phe'Joctreotide will lead to decreased quality of scintigraphy, and 
that uptake io tumours is significantly reduced (14). 
CONCLUSION 
In conclusion, in contrast to the hypothesis that the percentage uptake of 
[DTPA-D-Phe'Joctreotide in octreotide receptor-positive tissues is optimal at the 
lowest possible dose of maximum specific radioactivity, we found in rats that it is 
a bell-shaped function of the injected mass, being optimal between 0.5 - 5 {lg 
f"'In-DTPA-D-Phe']octreotide. This indicates that the sensitivity of the detection of 
somatostatin receptor-positive tumour by receptor scintigraphy may be improved 
by varying the mass of radiopharmaceutical, which has now also been conflfmed in 
patients. 
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CHAPTER 4 
INTERNALIZATION OF A RADlOIODlNATED SOMATOSTATIN 
ANALOGUE, ["'1- Tyr']OCTREOTIDE, BY MOUSE AND HUMAN 
PITUITARY TUMOUR CELLS 
Leo J Hofland, Peter M van Koetsveld, Marlijn Waaijers, Joke Zuyderwijk, 
Wout AP Breeman, Steven WJ Lamberts 
Department of Internal Medicine III and Nnclear Medicine, 
Erasmus University Rotterdam, Rotterdam, The Netherlands 
ABSTRACT 
Recently we developed a technique which allows the in vivo visualization in 
man of somatostatin receptor-positive neuroendocrine tumours after iv injection of 
[ 123I-Tyr']octreotide or ['"In-DTPA-D-Phe'Joctreotide. Radiotherapy of such 
tumours using somatostatin analogues coupled to 01- or Jl-emitting radionuclides has 
been proposed as an application for radiolabelled somatostatin analogues. In order 
to develop this concept further it is of importance to know whether the above 
mentioned radiolabelled somatostatin analogues are internalized by the tumour 
cells, and whether it might be possible to manipulate the degree of internalization. 
In the present study we have investigated the internalization of a stable somatosta-
tin analogue, ['''1-Tyr'Joctreotide, by mouse AtT20/D 16V pituitary tumour cells 
and by primary cultures of human GH-secreting pituitary tumour cells. 
["'1-Tyr'Joctreotide showed a time-dependent increasing accumulation in 
AtT20 cells, with after 4h of incubation, values up to 6-8 % of the dose radioligand 
added. Binding and internalization of ['''1_ Tyr'Joctreotide was temperature-depen-
dent. No internalization was observed at 0 0 C, at 20 0 C only a low amount of 
radioligand was internalized, while at 37 0 C. AtT20 cells showed a high amount of 
internalization of ['''I-Tyr']octreotide. Three out of four human GH-adenoma cell 
cultures also showed a specific-, time-dependent increasing internalization of ['''1-
Tyr'loctreotide with values of 0.38, 0.54 and 5% of the dose radioligand added. 
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The simultaneous addition of I nM unlabelled octreotide induced a rapid two-fold 
increase in membrane-binding and internalization of the radioligand in AtT20 cells, 
while it also significantly increased internalization in two out of three GH-adenoma 
cell cultures which showed internalization of the radioligand (6- and 0.5- fold, 
respectively). In one GH-adenoma cell culture 1 nM unlabelled octreotide also 
induced a significant increase in the amount of membrane-bound radioligand. 
In conclusion, a high amount of ["'I-Tyr'loctreotide is internalized, in a 
specit1c-, time-, and temperature-dependent manner by mouse AtT20- and human 
GH-secreting pituitary tumour cells. A nanomoIar concentration unlabelled 
octreotide induces a rapid increase in the amount of L"'l-Tyr'joctreotide internali-
zed by AtT20- and in two out of three human GH-adenoma cell cultures which 
showed internalization of the radioligand. Because membrane-binding was also 
increased, this is suggested to be caused by a rapid recruitment of somatostatin 
receptors at the outer tumour cell membrane. 
INTRODUCTION 
Somatostatin receptors (SS-R) are present in all normal target tissues of the 
peptide, such as the brain, the anterior pituitary gland, and the pancreas. In a 
variety of human tumours, frequently originating from normal somatostatin (SS)-
target tissues, high numbers of SS-R can be detected by classical biochemical 
binding techniques, as well as by in vitro autoradiography. These tumours include 
those with amine precursor uptake and decarboxylation (APUD) characteristics 
(pituitary tumours, endocrine pancreatic tumours, carcinoids, paragangliomas, 
small cell lung cancers, medullary thyroid carcinomas, pheochromocytomas), as 
well as meningiomas, well-differentiated brain tumours (astrocytomas), neurohlas-
tomas, lymphomas and some human breast cancers (I). Recently we developed a 
technique which allows the in vivo visualization in man of the above mentioned 
SS-R positive tumours after iv injection of ["'I-Tyr'joctreotide (2,3) or ["'In-
DTPA-D-Phe'joctreotide (4). Using this technique we showed that certain tumours, 
especially those with a high number of SS-R's, could still be visualized 48h after 
injection (1-4). This rather long residence time of radioactivity on human tumours 
in vivo may suggest that the radioligand is internalized by the tumour cells. 
Internalization of radioligand is of special importance when radiotherapy of certain 
SS-R positive human cancers with C/- or 6-emitting isotopes coupled to SS analogu-
es is considered (5,6). 
At present, equivocal data have been described with respect to internalizati-
on of SS. Receptor-mediated endocytosis of SS has been demonstrated in rat 
anterior pituitary cells and in rat islet cells (7-14), whereas other investigators 
found that ["'I-Tyr'jSS" and ['''I-Tyr''jSS" are not rapidly internalized by GH4C, 
rat pituitary cells and RINm5F insulinoma cells, respectively, probably due to 
degradation of these radioligands at the cell surface (15,16). Since data with 
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respect to internalization of SS may have been influenced by the susceptibility to 
degradation of the SS ligands used in the above-mentioned studies, investigations 
with respect to internalization of more stable radioligands, like f"'I-Tyr']octreotide 
(17), may provide a better insight in the amount of internalization by SS-R positive 
(tumour) cells. 
In the present study we therefore investigated whether the stable SS-
analogue ["'I-Tyr']octreotide is internalized by SS-R positive AtT20lDl6V mouse 
pituitary tumour cells and by human GH-secreting pituitary tumour cells. We 
recently found that accumulation of fWIn-DTPA-D-Phe'joctreotide in SS-R positive 
organs showed a tissue-specific bell-shaped function of the injected mass of the 
radiopharmaceutical (18). In order to investigate the cellular mechanisms underly-
ing these observations we also studied the effect of different concentrations 
unlabelled octreotide on binding and internalization of f"'I-Tyr'joctreotide by the 
two cell culture systems. 
MATERIALS and METHODS 
Cell culture 
AtT20lD16V mouse pituitary tumour cells were obtained from Dr. J. Tooze 
(European Molecular Biology Organization, Heidelberg, Germany). The cells were 
cultured in DMEM supplemented with sodium pyruvate (ImM), 10% fetal calf 
serum (FCS) , fungizone (0.5 mg/L) , penicillin (10' U/L), and sodium bicarbonate 
(2.2 giL final concentration). The medium was adjusted to pH 7.4 with 1 N 
NaOH. The cells were passaged once a week using trypsin (0.05 %) and EDT A 
(0.02%). For internalization experiments, the cells were seeded in a density of 0.5 
x 10' cells per well in 12-well multiwell plates (Costar, Cambridge, MA) and 
grown to confluency for 2 days. 
Human GH-secreting pituitary tumour tissue from four acromegalic patients 
was obtained by transsphenoidal operation. A single tumour cell suspension was 
prepared by enzymatic dispersion of the tissue as described in detail previously 
(19). The tumour cells were cultured for 4 days at a density of 10' cells per 3 mJ 
in 12-well multiwell plates (Costar) in Minimal Essential Medium (MEM) supple-
mented with non-essential amino acids, sodium pyruvate (1 mM), 10% FCS, peni-
cillin (10' DlL), fungizone (0.5 mg/L) , L-glutamine (2mM) , and sodium bicarbo-
nate (2.2 giL final concentration). The medium was adjusted to pH 7.4 with 1 N 
NaOH. 
All cells were cultured at 37 0 C in a water-jacketed incubator in humidified 
air with 5% Co,. The media and supplements were obtained from GIBCO 
(Paisley, UK). 
Radioligands 
The SS analogue [Tyr'joctreotide was iodinated with "'I by the chloramine-
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T method and puritied by HPLC, as described previously in detail (20). Specitic 
radioactivity of the radioligand yielded approximately 2000 Ciimmol. 
Internalization experiments 
On the day of the experiment the AtT20 cells were washed twice with 
internalization medium. The internalization medium consisted of DMEM supple-
mented with HEPES (30mM), L-glutamine (2 mM), sodium pyruvate (I mM), 
penicillin (10' u/L), fungizone (0.5 mgiL) and 0.2 % bovine serum albumin (Frac-
tion V, Sigma Chemical Co., St. Louis). The medium was a<liusted to pH 7.4 with 
I N KOH. The cells were allowed to adjust to the medium for I h at 37 0 C. 
Thereafter approximately 200.000 cpm l"'I-Tyr'loctreotide (approximately o. I nM 
tinal concentration) was added to the medium and the cells were incubated at 37 
o C (or other temperatures when indicated) for a period up to 4 h in quadruplicate 
without or with excess unlabelled octreotide (I I'M) in order to determine non-
specitic membrane binding and internalization. Binding and internalization of ["'1-
Tyr'loctreotide was blocked by excess unlabelled peptide, while unrelated peptides 
such as GnRH (lI'M) and TRH (lI'M) did not exert any influence. 
After the incubation period the cells were washed twice with ice-cold 
internalization medium. Thereafter, I mL sodium acetate (20 mM) in Hanks' 
Balanced Salt Solution, pH 5.0 (HBSS-Ac), was added to the cells. The cells were 
then incubated during 10 min. at 37 0 C. After 10 min. the supernatant was col-
lected. Thereafter, the cells were washed with HBSS-Ac, and the supernatant was 
pooled with the supernatant of the previous step. Tltis pooled supernatant fraction, 
acid-extractable radioactivity, represents membrane-bound radioligand. At the end 
of the incubation, after the HBSS-Ac treatment, the cells were extracted in I N 
NaOH. The radioactivity in this fraction represents internalized radioligand. This 
method of separation of membrane bound and internalized radioligand has been 
described previously by others (21). 
Human GH-secreting pituitary tumour cells, which had attached to the 
bottom of the wells during the 4-day culture (see above), were rinsed twice with 
internalization medium. 1 mL of this medium was then added to the cells, and 
incubations were performed as described for the AtT20 cells. 
Both cell types studied remained viable in internalization medium during the 
4 h incubation period, as determined by trypan blue exclusion. 
SS-R binding studies 
SS-R binding studies were carried out using [12'I-Tyr'loctreotide as radioli-
gand as described previously (22). Rat brain cortex- or AtT20 cell membrane 
preparations (corresponding to 15-30 I'g protein) were incubated in a total volume 
of 100 1'1 at room temperature for 60 min with 30,000-50,000 cpm radioligand and 
increasing concentrations of unlabelled octreotide in HEPES buffer (10 mM 
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HEPES, 5mM MgCl" 0.2 giL bacitracin, pH 7.6) containing 0.2% BSA (Sigma). 
After the incubation, I mL ice-cold HEPES buffer was added to the assay mixture, 
and membrane-bound radioactivity was separated from unbound by centrifugation 
during 2 min at 14,000 rpm in an Eppendorf microcentrifuge. The remaining pellet 
was washed twice with ice-cold HEPES buffer, and the final pellet was counted in 
a gamma-counter. Specific binding was taken to be total binding minus binding in 
the presence of excess (l I'M) unlabelled octreotide. Unrelated compounds (TRH, 
LHRH, EGF), added in a lOOO-fold excess were not able to displace ['251_ Tyr'loc-
treotide binding. 
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Figure 1. 
Upper panel: 
Displacement of binding of t" J-
Tyr Joctreotide (upper panel): 
by unlabelled octreotide to rat 
brain cortex membranes in 
internalization medium (0; see 
Muterials and methods section) 
and in HEPES buffer (0) 
Lower panel: 
Dose-dependent inhibition by 
octreotide qt growth hormone 
release by cultured female rat 
anterior pituitary cells in inter-
nalization medium. Normal 
female rat anterior pituitary 
cells were cultured for 7 days 
in MEM + 10% FCS. On day 
4 of culture, the medium was 
changed. On day 7 of culture 
4h incubations with increasing 
concentrations qt octreotide 
were performed in quadruplica-
te in internalization medium. 
GH concentrations in the media 
were determined as described 
previously in detail (24) 
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Analysis ~f data 
Statistical analysis of the data was performed using one-way analysis of 
variance (ANOV A). When significant overall effects were obtained by ANOV A, 
multiple comparisons were made by the Newman-Keuls test (23). All data are 
expressed as the mean ± SE, n~4 wells per time-point or treatment group. 
IC50 values for displacement of I"'I-Tyr']octreotide binding and for inhibiti-
on of GH release by cultured rat anterior pituitary cells, were determined by the 
computerized program GraphPad (lSI Software, Philadelphia, PA, USA). 
RESULTS 
Establishment of the incubation conditions for the study of internalization of f"l-
Tyrjoctreotide 
In initial experiments we have compared binding of ["'1-Tyr'loctreotide to 
rat brain cortex membranes in a regular binding buffer (20 mM HEPES, 5 mM 
MgCl" 20 mg/L bacitracin, 0.2% BSA, pH 7.4) with binding of the same radioli-
gand in internalization medium (see Materials and Methods section). We found that 
the amount of specific binding in internalization medium was approximately 10% 
of the specific binding measured to membranes diluted in the HEPES-buffer. 
Displacement of ["'1-Tyr'loctreotide with increasing concentrations of unlabelled 
octreotide showed an IC50 value of 0.2 nM, which is similar to that found in 
HEPES-buffer (Figure I, upper panel). Growth hormone release by normal rat 
anterior pituitary cells incubated in internalization medium was inhibited in a dose-
dependent manner by octreotide. The IC50 value of inhibition of GH release was 54 
pM (Figure I, lower panel), which is comparable to that of cells cultured in 
regular culture medium supplemented with fetal calf serum (25). These data 
demonstrate that, although the number of SS-binding sites that is measured in 
internalization medium is lower as compared to that in regular binding buffer, 
those SS-R which are detected have a dissociation constant in the low nanomolar 
range and are biologically active. 
In order to verify that the method of separation of internalized (acid-
resistant) and surface-bound extracellular (acid-releasable) ligand indeed released 
all binding of radioligand from membrane-receptors, rat brain cortex membranes 
were incubated with [' 25I-Tyr'loctreotide without or with excess unlabelled octreoti-
de to determine non-specific binding for Ih at 20 0 C. 
Thereafter, the membranes were washed twice with ice-cold binding buffer and 
subsequently incubated for 10 min. at 37 0 C with HBSS-HAc as described in the 
materials and methods section. This acid-treatment completely abolished specific 
binding of ["'I-Tyr'loctreotide, demonstrating that all membrane-bound radioligand 
is acid-releasable. 
Scatchard analysis of ["'I-Tyr'joctreotide binding to AtT20 cell membranes 
revealed a high number of high affinity SS-R (2815 ± 317 fmoles/mg membrane 
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protein, K.,= 0.35 ± 0.05 nM; valnes are the mean ± SE of four independent 
determinations) . 
Internalization of f"1- Tyr'joctreotide by mouse AtnO anterior pituitary tumour 
cells 
Figure 2 shows time-dependent specific membrane-binding and internalizati-
on of [12'I-Tyr']octreotide by AtT20 cells. f"'I-Tyr']octreotide showed time-
dependent increasing accumulation in these cells. The amount of ["'I-Tyr'Joctreoti-
de internalized was approximately 5 % of the dose radioligand added, after 240 min 
of incubation, and at all time-points studied significantly higher than the amount of 
radioligand which was membrane-bound. Internalization of ['''1-Tyr']octreotide by 
AtT20 cells was temperature-dependent. At 0 0 C, no binding and internalization of 
["'I-Tyr'joctreotide was seen, while the amount of internalized radioligand 
increased with increasing temperature (20 and 37 0 C, respectively; Figure 3). 
o 30 60 90 120 150 180 210 240 
lime (min.) 
Figure 2. Membrane-
binding and internaliza-
tion of f"I-Tyr'joctreoti-
de by AtnO mouse pi-
tuitary tumour cells. 
(0 " membrane-bound; 
• " internalized) 
Values are expressed as 
specific binding and 
internalization and are 
the mean ± SE of the 
percentage ~f dose of 
radioligand added of 
three independent expe-
riments 
We also investigated the effect of 1 nM of unlabelled octreotide on binding and 
internalization of the radioligand. Surprisingly we found an increased internalizati-
on of ["'I-Tyr'joctreotide induced by this low amount of unlabelled octreotide 
(Figure 4, lower panel). I"M unlabelled octreotide completely blocked internaliza-
tion of the radioligand after 15 min. of incubation (P < 0.01 vs control cells), 
while I nM octreotide nearly doubled internalization already after 15 min. of 
incubation (P<O.01 vs control cells). At these time-points, however, 1 nM octreo-
tide did not significantly increase the amount of membrane-bound radioligand 
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(Figure 4, upper panel). Because the increased internalization seems to occur very 
rapidly, we also studied the effect of I nM unlabelled octreotide at several time-
points between 0-2.5 minutes of incubation. The results of these experiments are 
shown in figure 5. Again, I nM unlabelled octreotide induced a very rapid (within 
I min. of incubation) two-fold increase in the amount of internalized radioligand 
(figure 5, lower panel). At the same time however, membrane-bound I'''I-Tyr'joc-
treotide was also significantly increased (figure 5, upper panel). 
Figure 3. Temperature-
~ 10 dependency of internali-
'0 zation and membrane-
~ binding qf !"'I-Tyrloc-0. 
• 
~ B treotide by AtT20 mouse 
• 0 pituitary tumour cells. 
" 
~ 6 Values are expressed as 
~ specific binding and 
" :;:: internalization as the 0 
~ 4 
mean ± SE of the per-c ~ 
" 
..2- centage of the dose of 
~ 
c 2 radioligand added. 
" .... , Open bars: membrane-
:0 ND ~ 0 bound radio ligand,' 
0 C 20 C 37 C filled bars: internalized 
temperature radioligand; ND means 
undetectable 
Table I. Membrane-binding and internalization of f"I-Tyrjoctreotide 
by cultured GH-secreting pituitary adenoma cells from patient 2 
control 
octreotide (\,..M) 
octreotide (10M) 
['''I-Tyr'joctreotide (% dose ± SE) 
membrane-bound internalized 
1.39 ± 0.07 
1.03 ± 0.01 * 
1.33 ± 0.10 
0.79 ± 0.04 
0.25 ± 0.02 * 
0.64 ± 0.03 ** 
10' cells per well were incubated in quadruplicate during 60 min with 
approximately 0.1 nM ("1-Tyr'joctreotide. Thereafter membrane-bound 
and internalized radioligand was determined as described in the 
materials and methods section. * P<O.OI and ** P<0.05 vs control cells 
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Internalization of {'''I-Tyr'joctreotide by human GH-secreting pituitary adenoma 
cells 
Similar to the observations in AtT20 cells, human GH-secreting pitnitary 
adenoma cells from patient I also showed a time-dependent specific membrane-
binding (Figure 6, upper panel) and internalization of ["'1-Tyr'joctreotide (Figure 
6, lower panel). In the presence of 1 oM unlabelled octreotide a rapid increase in 
both membrane-bound and internalized radioligand was observed. A statistically 
significant higher amount of radioligand was bound and internalized at all time-
points stndied. After 60 min. of incubation an approximately six-fold higher 
amount of radioligand was bound and internalized in the presence of 1 oM 
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unlabelled octreotide as compared to control cells. The total amount of radioligand 
that was bound and internalized after 4 h of incubation was also considerably high 
in the GH-secreting pituitary adenoma cells of this patient (approximately 1.5 and 
5%, respectively, of the dose radioligand added). 
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Figure 5. 
Rapid increase of mem-
brane-binding (upper 
panel) and internali-
zation (lower panel) 
of r"'I-Tyr'/octreotide 
induced by J nM unla-
belled octreotide. 
• : control; 
o : 1 nM unlabelled 
octreotide. 
* P<O.OJ vs control 
cells. 
Values are expressed as 
specific binding and 
internalization and as 
the mean ± SE of the 
percentage of dose of 
radio ligand added of 
three independent expe-
riments 
Cultured turnoUT cells from patient 2, also showed after 60 min. of incubation a 
relative high amount of P"I-Tyr]octreotide binding and internalization. However, 
1 oM of unlabelled octreotide had in these tumour cells no effect on the amount of 
membrane-bound radioligand, and inhibited the amount of internalized radioligand 
slightly, but significantly (Table 1). Unfortunately not enough tumour cells had 
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been obtained from this patient at operation to allow the study of more time-points. 
Cultured cells of patient no.3 did not bind, nor internalized ['251_ Tyr']octreotide 
between 30 and 240 min. of incubation (data not shown). Cultured cells from 
patient 4 showed a time-dependent increasing internalization and membrane-
binding of l"'I-Tyr'joctreotide between 30 and 240 min. of incubation (0.38 and 
0.09% of the dose radioligand added, respectively, after 240 min. of incubation). 
The amount of radio ligand which was internalized and membrane-bound was 
lower, however, as compared to the values measured in cells from patients 1 and 
2. Using cells from patient 4 we also studied the full dose-response relationship of 
increasing concentrations of unlabelled octreotide (0.01 to 100 nM) on internaliza-
tion and membrane binding of the radioligand. Table 2 shows that, after 240 min. 
of incubation, unlabelled octreotide inhibited in a dose-dependent manner binding 
of ['25I-Tyr']octreotide by cells from this patient, while the amount of radioligand 
which was internalized was significantly increased in the presence of 1 nM unla-
belled octreotide and significantly inhibited by 100 nM octreotide at the same time. 
Table 2. Membrane-binding and internalization of f"'I-Tyr'loctreotide 
by human GH-secreting pituitary tumor cells from patient 4 
[ '251_ Tyr'joctreotide (% control specific) 
octreotide (nM) membrane-bound internalized 
0 100 ± 8 100 ± 4 
0.01 96 ± 6 103 ± 3 
0.1 107 ± 4 104 ± 6 
104 ± 21 142 ± 4 * 
10 61 ± 6 ** 117 ± 7 
100 45 ± 8 * 35 ± 3 * 
Values are expressed as mean ± SE of the percentage of specific membrane-
binding and internalization by control cells (0 nM octreotide). The amount of 
radioligand bound to membranes and internalized after 4 h of incubation yielded 
0.09 ± 0.01 and 0.38 ± 0.02, respectively, of the dose added. 
* P<O.OI and ** P<0.05 vs control 
Interestingly, we found that the preoperative subcutaneous administration of 50 I'g 
octreotide induced a significant lowering of serum GH levels in patients 1 and 2, 
while patients 3 and 4 showed no response of GH levels to octreotide in vivo 
(Figure 7). 
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In support of this low sensitivity to octreotide in vivo, we also observed that the 
cultured ceIls from patients I and 2 were significantly more sensitive to octreotide 
in vitro, as compared to the cultured tumour cells from patients 3 and 4. GH 
release by the cultured tumour ceIls from patients I, 2, 3, and 4 was inhibited by 
56 
patienl I patienl 2 
"5 10. 
10. 80 
1 
~ 75 80 
• ] 
50 40 
" [ 
25 20 
, .. 9 10 II 12f" 13 14 , .. 9 10 II 12p .. 13 I. 
patienl 3 palient 4 
100 100 
" 
80 ~ 80 ! g 80 80 ~ • ~ ~ .. 40 
" ~ 20 20 
• , .. 9 I. II 12,. 13 I. 7 , .. • I' 11 12, .. 13 I. 
time lime 
Figure 7. Effect of the administration of 50 p.g octreotide subcutaneously on the 
serum GH levels in four acromegalic patients 
8: placebo at 8.15 am; 0: 50 p.g octreotide sc. at 8.15 am 
octreotide (10 nM) by 83 ± 9, 43 ± 2, 27 ± 1, and 16 ± 0 %, respectively. 
Thus, the cells of patient 1, which showed the highest amount of internalization of 
[1'51_ Tyr'joctreotide, also showed the highest response of GH release to octreotide 
in vitro. 
DISCUSSION 
A variety of human neuroendocrine tumours contain receptors for the 
tetradecapeptide SSI. (1). The presence of SS-R on these tumours enabled us to 
develop a technique which allows in vivo visualization in man of SS-R positive 
tumours using the radiolabelled SS analogues [123I-Tyr'joctreotide and [Illln-DTPA-
D-Pheljoctreotide (2-6). In several tumours (i.e. carcinoids and paragangliomas) 
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expressing a high amount of SS-R, binding of radioactivity in vivo exceeds 
estimates of 0.1 % of the administered dose per g of tumour tissue. Radiotherapy 
using SS analogues coupled to 0'- or ll-emitting isotopes has been proposed as an 
application for radiolabelled SS analogues and has recently been carried out in one 
patient (5,6,26). In order to develop this concept further it is of importance to 
know to which extent the above mentioned radiolabelled SS analogues are interna-
lized by SS-R positive tumour cells, and whether it might be possible to manipula-
te the degree of internalization. 
In the present study we demonstrated a specific-, time- and temperature-
dependent high amount of internalization of [1251_ Tyr3joctreotide by mouse AtT20 
pituitary tumour cells. In addition, internalization of ['''I-Tyrjoctreotide by human 
GH-secreting pituitary tumour cells was found. Several studies have demonstrated 
receptor-mediated endocytosis of SS in rat anterior pituitary cells (7,9,11,12), in 
rat islet cells (10,14), and in AtT20 cells (8). Other investigators, however, 
showed that ['''1-Tyr'jSS" and ["'1_ Tyr"jSS", unlike ["'Ijepidermal growth factor, 
are not rapidly internalized by GH,C, rat pituitary cells and RINm5F insulinoma 
cells, respectively (15,16). These investigators suggested that the radioligands they 
used were rapidly degraded by membrane proteases. From our present study it is 
clear that the radioiodinated SS analogue Tyr-octreotide is internalized in a high 
amount by AtT20- and human GH-secreting pituitary tumour cells. This is 
probably related to the high stability of ["'I-Tyr3joctreotide (17). The parental 
cyclic octapeptide analogue octreotide (SMS 201-995) was shown to be highly 
resistant to degradation by pure enzymes and by tissue homogenates (27). Our data 
are in favor of a further development of the concept of radiotherapy using radio la-
belled SS-analogues. 
Another interesting observation of our present study is the rapid increased 
internalization of ["'1-Tyr3joctreotide when AtT20 cells and human GH-adenoma 
cells were simultaneously incubated with a low concentration of unlabelled 
octreotide. We found that I nM of unlabelled octreotide caused a very rapid 
increase in the amount of internalization of ['''1-Tyr3]octreotide by AtT20 cells (a 
2-fold increase within I min. of incubation) and by two out of three cultures of 
human GH-secreting pituitary tumours (up to 6- and 0.5- fold increase respecti-
vely) which showed internalization of the radioligand. In the same experiments 
excess unlabelled octreotide (lI'M) completely blocked internalization of the 
radioligand. In AtT20 pituitary tumour cells and in one of the human GH-adenoma 
cell cultures the increased internalization induced by the addition of a low concen-
tration of unlabelled octreotide was accompanied by an increase in the amount of 
membrane-bound radioligand, which suggests a very rapid increase in the number 
of SS-R on these cells. 
Little is known with respect to the homologues regulation of SS-R expressi-
on. In GH,C, cells Presky and Schonbrnnn demonstrated a time-dependent increase 
in ["'I-Tyr'jSS" binding by the addition of unlabelled SS", which reached a 
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maximum value of approximately 200% after 20h (21). In contrast, Srikant and 
Heisler (28) showed a decrease in the number of SS-R in AtT20 cells after 
preincubation for 4h with SS" or SS". Finally, in 7315b rat prolactinoma cells 
chronic exposure (up to 5 weeks) results in a reversible down-regulation of SS-R 
(29). At present, we have no explanation for the mechanism of the increased 
binding and subsequent internalization of ["'1-Tyr'Joctreotide by AtT20 tumour 
cells and by human GH-adenoma cells, induced by a low concentration of unlabe-
lled octreotide. The rapid increase in ["'I-Tyrjoctreotide binding and internaliza-
tion seems unlikely to be caused by de novo synthesis of SS-R's, because this 
increase occurred already within several minutes of incubation with 1 nM unlabel-
led octreotide. Therefore, the most likely explanation for this phenomenon seems a 
rapid recruitment of cellular SS-R's to the outside of the cell membrane, although 
an effect of octreotide on SS-R synthesis cannot be fully excluded. In this respect 
it is of interest to mention that glucose has been shown to increase the amount of 
internalized SS in pancreatic islets, probably due in part to the increase in the cell 
surface SS-R concentration by migration of the secretion vesicles during emiocyto-
sis, which thereby promotes increased transport of SS-R's (30). 
Recently, at least five different SS-R subtypes have been cloned. All 
subtypes bind SS" and SS" with high affinity, while their affinity for numerous 
SS-analogues differs considerably (31-35). Octreotide binds with high affinity to 
the human SSTR2 (hSSTR2) subtype, while this analogue has a moderate affinity 
to hSSTR3 and hSSTR5 subtypes and shows no binding to the hSSTR subtypes 1 
and 4 (31-35). More than one hSSTR subtype is expressed in human GH-adeno-
mas. Greenman and Melmed (36) showed in 3 out of 7 and in 9 out of 10 human 
GH-adenomas expression of hSSTRI and hSSTR2, respectively. In addition Reubi 
et a!. (37) recently demonstrated in GH-adenomas, by in situ hybridization 
autoradiography, hSSTR2- (7 out of 7 cases) and hSSTR3- (3 out of 7), but not 
hSSTRl expression. In AtT20 cells four SSTR genes (subtypes 1, 2, 4 and 5) are 
expressed, of which SSTR2 expression predominates (38). At present it is unclear 
which SSTR subtype is involved in receptor-mediated endocytosis in human GH-
adenoma- and AtT20 cells. Studies on internalization of ["'1-Tyrjoctreotide by cell 
lines stably expressing SSTR subtypes may help to answer this question. 
Our observation of a higher amount of binding and internalization of ["'1-
Tyrjoctreotide when the cells are simultaneously incubated with a low concentrati-
on of unlabelled octreotide may explain the results of a recent in vivo study by our 
group, in which we found that uptake of [lHln-DTPA-D-Phe'Joctreotide in SS-R 
positive organs (pituitary, pancreas, adrenals) in rats, showed a bell-shaped 
function of the injected mass (18). Therefore, the highest specific radioactivity may 
not automatically result in the highest binding and subsequent internalization of the 
radioligand by the tumour in in vivo SS-R imaging using radiolabelled SS-analogu-
es in patients with SS-R positive tumours. Indeed, preliminary fmdings in patients 
indicate that scintigraphy with a specific activity higher than 220 MBq IH In per 5 
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I"g IDTPA-D-Phe'joctreotide will lead to decreased quality, and that uptake in 
tumours will be significantly reduced (39). Moreover, Dorr et a!., recently demon-
strated an improved visualization of carcinoid liver metastases in patients by ['''In-
DTPA-D-Phe'joctreotide during octreotide treatment (40), which might be due to 
upregulation of SS-R's by octreotide. Finally it should be mentioned that we have 
used ["'I-Tyr']octreotide as a radioligand in our study. It still has to be established, 
however, whether radiolabelled DTPA-conjugated SS analogues, such as ['"In-
DTPA-D-Phe'joctreotide, are internalized to the same extent by SS-R positive 
tumour cells as non-DTPA conjugated SS-analogues. 
In conclusion, a high amount of 1"'1-Tyr']octreotide is internalized, in a 
specific-, time-, and temperature-dependent manner by mouse AtT20 cells and by 
human GH-secreting pituitary tumour cells. The amount of internalized ['251_ 
Tyr']octreotide by the human GH-adenoma cell cultures correlated well with their 
in vivo and in vitro responsiveness of GH secretion to octreotide. A nanomolar 
concentration of unlabelled octreotide induces a very rapid increase in membrane-
binding and in the amount of internalization of [125I-Tyr']octreotide by AtT20 cells. 
Two out of three human GH-adenoma cell cultures also responded to this low 
concentration of unlabelled octreotide with an increase in the amount of internali-
zed radioligand. Thus, a variability exists between human GH-adenomas in the 
amount of radioligand internalized, and in their response to low concentrations of 
unlabelled octreotide. It remains to be established therefore, whether our present 
conclusions also apply to other types of human SS-R positive neuroendocrine 
tumours. 
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CHAPTER 5 
RADIOIODINATED SOMATOSTATIN ANALOGUE RC-160: 
PREPARATION, BIOLOGIC ACTIVITY, IN VIVO APPLICATION IN 
RATS, AND COMPARISON WiTH ['''I-Tyr'jOCTREOTIDE 
Wout AP Breeman, Leo J Hofland, WiIlem H Bakker, Marcel Evan der Pluijm, 
Peter M van Koetsveld, Marion de Jong, Buddy Setyono-Han, Dik J Kwekke-
boom, Theo J Visser, Steven WJ Lamberts, Eric P Krenning 
Departments of Nuclear Medicine and Internal Medicine III, University Hospital 
"Dijkzigt", and Dr Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands 
ABSTRACT 
We have evaluated the potential usefulness of the radioiodinated octapeptide 
RC-160, a somatostatin analogue, which might serve as a radiopharmaceutical for 
the in vivo detection of somatostatin receptor-positive tumours. For this purpose 
"'1- and "'I-labelled RC-160 were tested for their biologic activity, and applied in 
vivo in rats bearing the transplantable rat pancreatic tumour CA20948, which 
expresses somatostatin receptors. Our group has recently described the in vivo 
visualization of such tumours in rats and in humans with the radioiodinated 
somatostatin analogue [Tyr'joctreotide. 
Like f"'I-Tyr']octreotide, "'I-RC-160 showed uptake in and specific binding 
in vivo to somatostatin receptor-positive organs and tumours. However, blood 
radioactivity (background) was higher, resulting in a lower tumour to blood 
(background) ratio. We therefore conclude that in this animal model 123I-RC-160 
has no advantage over f"'I-Tyr']octreotide as a radiopharmaceutical for the in vivo 
use as a somatostatin-receptor imager, although, like [123I-Tyr'Joctreotide, "'I-RC-
160 shows specific binding to different somatostatin receptor -positive organs. 
Recently differences were reported in atfInity between somatostatin and it~ 
analogues for somatostatin receptors expressed in different human cancers, like 
those of the breast, ovary, exocrine pancreas, prostate and colon. Therefore "'1-
RC-160 might be of interest for future use in humans as a radiopharmaceutical for 
imaging octreotide receptor-negative tumours. 
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INTRODUCTION 
High numbers of high-affinity somatostatin receptors for both native 
somatostatin (for structure, see Fig. I) and the synthetic octapeptide octreotide 
(Sandostatin®), have been detected on most endocrine tomours, like endocrine 
pancreatic tomours aod carcinoids (1-4). We have recently described the visualiza-
tion of somatostatin receptor-positive tomours in vivo after the intravenous 
adntinistration of [1231_ Tyr']octreotide (5-9), which results have been confirmed by 
others (10-12). Radioiodinated [Tyr']octreotide is frequently used for the in vitro 
determination of the presence of somatostatin receptors (13). Recently, several 
reports have been published on the in vitro binding to somatostatin receptors of 
aoother somatostatin aoalogue, the octapeptide RC-160 (14-16). It has been 
reported that RC-160 has a higher affinity than octreotide for the somatostatin 
receptor in human breast, ovarian, exocrine pancreatic, prostatic and colonic 
cancers (14-16). A phase I clinical trial with RC-160 in patients with advanced 
exocrine paocreatic cancer is being performed, aod it appears that RC-160 is well 
tolerated at doses up to 1500 J.'g/day (17,18). The possibility of RC-160 binding to 
a somatostatin receptor subtype on human exocrine pancreatic adenocarcinoma, 
which does not bind octreotide (19), offers a potential advaotage for RC-160 over 
octreotide as radiolabelled tomour tracer. RC-160 may, in contrast to octreotide 
(20), also pass the blood-brain barrier (21). This could represent a benefit in 
visualizing somatostatin receptor-positive brain tomours with ao intact blood-brain 
barrier. We investigated radioiodinated RC-160 (for structore see Fig. I) for the 
potential use in scintigraphy in normal rats and in rats bearing the transplantable 
paocreatic somatostatin receptor-positive tomour CA20948 (13,19,22). A compari-
son was made with ['23I-Tyr']octreotide, aod the possible additional value of "'1-
RC-160 as a radiopharmaceutical was evaluated. 
MATERIALS AND METHODS 
Radiopharmaceuticals 
RC-160 was obtained from Peninsula Laboratories (Belmont, Ca, USA). 
Radioiodination aod purification was performed using the technique described by 
Bakker (6). 
[Tyr']octreotide and RC-160 were labelled with "'I (specific activity 3.7 
TBq 123I/mg, Medgenix, Belgium) and "'I (specific activity 0.62 TBq "'I/mg, 
Amersham, UK). For the in vivo stodies we used the somatostatin aoalogues 
labelled with "'I. The in vitro binding stodies were performed with HPLC-purified 
mono-iodinated somatostatin analogues, since carrier-free radioligaods are required 
for these assays. 
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Somatostatin 
I I 
Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr -Phe-Thr -Ser -Cys 
Octreotide 
I 
D-Phe-Cys-Phe-D-Trp-Lys-Thr -Cys-Thr( 01) 
[ 1231_ Tyr']octreotide 
H-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr( 01) 
I 
1231 
"'I-RC-160 
H -D-Phe-Cys-Tyr -D-Trp-Lys-Val-Cys-Trp-NH, 
I 
1231 
Figure 1. Stuctural formulae of native somatostatin and some analogues. In 
[I'yr'Joctreotide the amino acid Tyr replaces Phe to make radioiodination possible. 
In RC-J60 Tyr is naturally present 
The radioiodination was carried out by adding 2.5 Ilg RC-160 in 35 III 0.05 
M acetic acid and 1.6 Ilg chloramine-T in 20 III 0.05 M phosphate buffer (pH 7.5) 
to 200 MBq (= 60 Ill) "'lor 80 MBq (20 Ill) '''I in the form of sodiumiodide. The 
reaction was started by the addition of chloramine-T, representing an only 2.5-fold 
molar excess over peptide in order to prevent oxidation of the disulfide-bridge of 
RC-160. The mixture was then vortexed for 1 min. The radioiodination was 
stopped by adding 1 mI 10 % human serum albumin (Merieux, Lyon, France). 
After vortexing for 30 s, 20 ml 5 mM ammonium acetate was added. Purification 
was performed using a SEP-PAK C" reversed-phase extraction cartridge (Waters 
Associates, Milford, MA), which was washed with 5 ml 70 % ethanol, 5 mI 2-
propanol and 5 ml distilled water. After application of the sample, the SEP-PAK 
cartridge was washed with 5 ml distilled water and radioiodinated RC-160 was 
eluted with 5 mI 96 % ethanol. The solveut was evaporated at 40 0 C under a 
gentle stream of nitrogen. The residue (approximately 0.5 ml) was diluted with 2.5 
mI 154 mM NaCI and 0.05 M acetic acid (PH 3), and the mixture was passed 
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through a low protein-binding 0.22-l'm Millex-GV filter (Millipore, Milford, 
MA). The labelling of [Tyr']octreotide, and the measurements of radioactivity in 
all fractions were carried out as described before (6). The "'I-labelled somatostatin 
analogues for in vivo use were not purified by HPLC and, hence, consisted of 
mixtures of mono- and di-radioiodinated and non-iodinated peptides (see Results, 
Radiolabelling of RC-J60). 
All chemicals used were of the highest purity available. 
Biologic activity 
The biologic activity of HPLC-purified mono-"'I-RC-160 and ["'1_ Tyr'joc-
treotide was assessed by measuring their potency to inhibit the secretion of rat 
growth hormone (rGH) from cultured rat pituitary cells as described previously 
(23). 
Table 1. Effect of mJ-RC-J60 and f"J-Tyrloctreotide on secretion of rat growth 
hormone from cultured rat pituitary cells (n~4) 
Peptide Concentration Rat growth 
(nM) hormone 
(ng/ml ± SD) (%) 
Control 89.1 ± 9.0 (100) 
"'I-RC-160 .01 91.7 ± 4.6 (103) 
.1 95.5 ± 3.0 (107) 
77.2 ± 11.1 (87) * 
P"I -Tyr']octreotide .01 90.0 ± 4.8 (101) 
.1 79.9 ± 11.3 (90) 
I 64.8 ± 4.6 (73) * 
* p < O. 05 vs control 
Animals and tumours 
Twenty-four male Lewis rats (250-300 gram) were inoculated in both upper 
hindlegs with the transplantable rat pancreatic tumour CA20948, which has 
previously been shown to possess somatostatin receptors (19). Sixteen male Lewis 
rats (250-300 gram) without tumour were used as controls. The rats were anaesthe-
tized with ether. The radiopharmaceuticals were injected in the dorsal vein of the 
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penis, using siliconized syringes (Sigmacoat, Sigma, St Louis, MO). The dose was 
18.5 MBq (0.5 "g) for the l"I-analogue. The radioactivity of the syringes was 
measured in a dose calibrator (VDC-202, Veenstra, Joure, The Netherlands) in a 
standard geometry before and after the injection. 
Table 2. Tissue distributions (% of injected dose/g tissue) and specific 
binding (4) qf"'I-RC-160 in tumour-bearing rats after intravenous 
administration (mean ± SD) 
Tissue 0.5 h p.i. 4 h p.i. 24 h p.i. 
Pancreas - 0.91 ± 0.38 0.32 ± 0.08 0.06 ± 0.02 
+ 0.10 ± 0.01 0.07 ± 0.02 0.021 ± 0.002 
Ii 0.81 ± 0.38 * 0.25 ± 0.08 * 0.040 ± 0.019 * 
Adrenals - 1.17 ± 0.06 0.54 ± 0.09 0.06 ± 0.03 
+ 0.20 ± 0.06 0.07 ± 0.01 0.038 ± 0.009 
Ii 0.97 ± 0.06 * 0.47 ± 0.09 * 0.022 ± 0.028 
Pituitary - 0.16 ± 0.06 0.08 ± 0.02 0.05 ± 0.05 
+ 0.021 ± 0.003 0.013 ± 0.002 0.004 ± 0.000 
Ii 0.13 ± 0.06 * 0.064 ± 0.020 * 0.044 ± 0.048 
Brain 0.014 ± 0.002 0.008 ± 0.002 0.0019 ± 0.0009 
Cortex + 0.008 ± 0.001 0.003 ± 0.000 0.0013 ± 0.0003 
Ii 0.007 ± 0.003 * 0.005 ± 0.002 * 0.0006 ± 0.0009 
Tumour 0.23 ± 0.07 0.20 ± 0.05 0.037 ± 0.021 
+ 0.11 ± 0.02 0.08 ± 0.02 0.036 ± 0.003 
Ii 0.11 ± 0.07 0.12 ± 0.05 * 0.001 ± 0.021 
Kidneys - 0.74 ± 0.13 0.43 ± 0.13 0.11 ± 0.03 
+ 0.53 ± 0.04 0.22 ± 0.05 0.10 ± 0.02 
Ii 0.21 ± 0.13 0.21 ± 0.13 0.01 ± 0.03 
Each group contained 4 rats; -: no pretreatment; +: pretreatment with J mg 
unlabelled RC-J60 subcutanenously 45 min prior to the injection with 
"'1-RC-J60; * P<O.01, specific binding significantly different from zero 
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In order to study the organ distribution of "'I-RC-160 and [' 23I-Tyr']octreo-
tide in the 16 control rats, the rats were allocated to 2 groups for each radiophar-
maceuticaL Four rats were injected subcutaneously between the scapulae with I ml 
0.01 M acetic acid containing 154 mM NaC!, and 4 other rats were injected with I 
mg of RC-160 in the same solvent in order to saturate the somatostatin receptors. 
Forty-five minutes later the rats were injected with "'I-RC-160. Similarly, the 2 
other groups of 4 rats were pretreated with vehicle or I mg of octreotide, and were 
subsequently injected intravenously with [,23I-Tyr']octreotide. The rats were 
sacrificed 4 h after administration of I23I-RC-160 or ['23I-Tyr']octreotide. 
The 24 tumour -bearing Lewis rats were divided in 3 groups of 8 rats. In 
each group 4 rats were injected subcutaneously with I mg RC-160 in order to 
saturate the somatostatin receptor, as mentioned above. The 3 groups of 8 rats 
were sacrificed at 30 min, 4 h or 24 h after administration of I23I-RC-160. The 
radioactivity concentration in various tissues was subsequently measured. 
The specific binding was defined as the difference between the individual 
uptake in the non-saturated tissues and the mean uptake in the saturated tissues, 
which are expressed as percentages of the injected radioactivity per gram tissue in 
the respective organs (mean ± SD) after administration of "'1-RC-160 or ["'1_ 
Tyr']octreotide. 
Data acquisition and statistical analysis 
All results are expressed as the mean ± SD. Tissue-binding values and 
effects of rat growth hormone secretion for both radiolabelled petides were 
evaluated using Student's t-test. A P value of < 0.05 was considered significant. 
The tissue distribution and metabolism of I23I-RC-160 and ["'1-Tyr'joctreotide in 
vivo were studied by gamma camera (Rota-II, Siemens) scintigraphy and measure-
ment of isolated organs in a LKB-1282-Compugammasystem (6). The radioactivity 
in blood and urine was analyzed as described previously (6). 
RESULTS 
Radiolabelling of RC-J60 
The efficiency of labelling of RC-160 was 40-60 % for "'I and 70-90 % for 
"'I, in agreement with the radioiodination data of [Tyr'joctreotide, as described 
previously [6]. Purification of the iodination mixture using the SEP-PAK CIS 
reversed-phase cartridge resulted in mainly non-peptide bound radioiodine in the 
water fraction and more than 99 % peptide-bound radioiodine in the ethanol 
fraction, revealed by HPLC. In Fig. 2 a typical HPLC elution pattern of the 
peptides eluted in the ethanol fraction is shown, indicating a radiochemical purity 
of more than 95 % of mono-radioiodinated RC-160. The simultaneously measured 
absorbance at 254 nm and radioactivity show a clear separation between radioio-
dinated RC-160 and non-radioiodinated RC-160. 
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Figure 2. HPLC-elution pattern of the ethanol fraction of SEP-PAK C18 pUrifi-
cation. Non-radioiodinated RC-J60 is measured by UV-absorbance (A ~254 nm,--), 
radioiodinated RC-160 andfree radioiodide by gamma detection (--). The gamma 
detected peak at 27 min is the di-iodinated compound 
The acetic acid wash, included in the SEP-PAK purification of ["'1_ 
Tyr'joctreotide, was omitted from the isolation procedure for "'I-RC-160, since 
this wash was found to contain already a substantial fraction (= 5-10%) of the 
radioiodinated RC-160, while only negligible amounts of free radioiodide were 
detected. 
Since the radiolabelling and the SEP-P AK C" separation technique appeared 
adequate (more than 95 % radiochemical purity of mono-radioiodinated [Tyr'joc-
treotide and RC-160) HPLC-purification of the radiolabelled somatostatin analogu-
es were not performed. These results were in agreement with the radiolabelling 
reults of [Tyr'joctreotide (6). 
Receptor binding and specific biologic activity 
In Table I the effects are shown of I25I-RC-160 and [1251-Tyr']octreotide on 
the secretion of rGH by cultured rat pituitary cells. Both iodinated somatostatin 
analogues significantly inhibited rGH secretion at I nM. Both radioiodinated 
analogues caused a similar dose-response as the non-radioiodinated counterparts 
(data not shown). 
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Animal studies 
Dynamic scintigraphy of tumour-bearing and control rats after i. v. admi-
nistration of "'I-RC-160 and I"'I-Tyr']octreotide showed a fast disappearance of 
the radioactivity from the circulation. With both radioiodinated analogues radioacti-
vity in the blood circulation, as measured above the heart with the gamma camera, 
decreased in less than 2 min to 50 % of the highest measured radioactivity. This 
rapid drop of the blood activity can be explained by the phenomenon of distributi-
on of the activity over the whole blood and the interstitial space. 
Thirty minutes after injection static images showed a clear uptake of 
radioactivity in the liver and intestines. The left kidney was seen, as well as 
excreted activity in the urinary bladder. The right kidney was overprojected by the 
liver. 
Dynamic tumour uptake in situ in the rat during the fIrst 30 min after 
injection of "'I-RC-160 was analyzed with the gamma camera. After background 
correction, using aC\jacent tissue as reference, no increased uptake in the tumour 
was found whereas specifIc binding in the isolated tumour became statistically 
signifIcant at 4 h (Table 2). As can be seen in Table 2, there is signifIcant specifIc 
binding in all the somatostatin receptor-positive tissues analyzed, i.e. pancreas, 
adrenals, pituitary and brain cortex at 0.5 and 4 h, and in the tumour at 4 h after 
injection. After 24 h there was still signifIcant specifIc binding in the pancreas. 
From 30 min after the administration of "'I-RC-160, total radioactivity disappeared 
rapidly from the measured organs and tumours. Statistically signifIcant specifIc 
binding was still present 24 h after ["'I-Tyr'Joctreotide injection, in the pancreas, 
adrenal and pituitary gland (data not shown). 
In Table 3 the tissue distributions, 4 h after injection, are compared 
between pretreated and non-pretreated, non tumour-bearing rats. We found a 
higher uptake of ['''I-Tyr']octreotide in the adrenals, the pancreas and the pituitary 
gland, than found when using "'I-RC-160. The effect of pretreatment with 
unlabelled RC-160 or octreotide is evident in the somatostatin receptor-positive 
organs for both "'I-RC-160 and ["'I-Tyr'loctreotide. SignifIcantly higher specifIc 
binding of radioactivity was found after administration ofl"'I-Tyr'joctreotide in the 
adrenals, the pancreas and the pituitary gland than after administration of "'I-RC-
160. In the rat brain cortex "'I-RC-160 has a higher uptake and specifIc binding 
than ["'I-Tyr']octreotide. 
Urine samples were obtained 30 min p.i. from tumour-bearing rats (n=4), 
showing a 13 % ± 1 % of the total radioactivity in the form of peptide-bound 
radioiodine. Twenty-four h p.i. the percentage of peptide-bound radioiodine in 
urine and blood had dropped to 1.3 ± 0.2 and 1.1 ± 0.3, respectively, and more 
than 95 % of the radioactivity in the urine was free radioiodide, which is compara-
ble with the results obtained using ["'I-Tyr'joctreotide as radioligand (data not 
shown). 
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Table 3. TIssue distribution (with (+) and without (-) pretreatment of rats with 
unlabelled RC-160J, and specific binding (,1) in somatostatin receptor-positive 
organs (mean ± SD) in non-tumour bearing rats (n~4), 4 h after injection of 
l2JI-RC-J60. The rats in the parallel experiment with ,"'I-TyrJoctreotide 
were pretreated with J mg octreotide 
Tissue '''I-RC-160 ["'1-Tyr']octreotide 
Pancreas 0.21 ± 0.05 1.03 ± 0.15 * 
+ 0.025 ± 0.006 0.023 ± 0.002 
11 0.17 ± 0.01 t 1.01 ± 0.00 *t 
Adrenals 0.19 ± 0.03 0.26 ± 0.02 * 
+ 0.042 ± 0.010 0.027 ± 0.002 
11 0.15 ± 0.01 t 0.23 ± 0.00 *1' 
Pituitary 0.066 ± 0.007 0.32 ± 0.09 * 
+ 0.0078 ± 0.0020 0.0067 ± 0.001 
11 0.063 ± 0.002 t 0.31 ± 0.00 *1' 
Brain 0.0052 ±0.0014 * 0.0019 ± 0.0002 
cortex + 0.0019 ± 0.0003 0.0012 ± 0.0002 
11 0.0033 ±0.0003 *t 0.0007 ± 0.0002 
* P<0.OJ 1"I-RC-J60 vs /"'I-TyrJoctreotide; 
t P< O. OJ specific binding significantly different from zero 
A comparison of the tissue radioactivity concentrations 24 h after injection 
of "'J-RC-160 and ["'I-Tyr']octreotide is presented in Table 4. ["'I-Tyr']octreotide 
had a higher clearance of radioactivity from somatostatin receptor-negative tissues, 
such as liver, thymus, blood and lungs and a significantly higher binding in the 
somatostatin receptor-positive pituitary than "'J-RC-160. Only in the tumour there 
was significantly higher binding of radioactivity for "'1-RC-160 compared to ["'1-
Tyr']octreotide, but as can be seen from table 2, this is not specific binding. 
DISCUSSION 
RC-160 is, like octreotide, a somatostatin analogue with potent hormone 
secretion-inhibiting characteristics in vivo and in vitro. However, discrepancies 
with octreotide have been described, especially with regard to binding to a number 
of human cancers, like those of the breast, ovary, exocrine pancreas, prostate and 
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colon (14-18,21). Therefore, radioiodinated RC-)60 might be an important 
radiopharmacentical, having potential advantages over radioiodinated octreotide for 
the in vivo detection of the last mentioned somatostatin receptor-positive tumours. 
In literatnre no data are available on tissue distribution of the somatostatin 
analogue RC-160, either in animals or humans. In the present stndy, therefore, we 
evaluated the potential use of radioiodinated RC-160 for somatostatin receptor 
scintigraphy. There was significantly higher uptake and specific binding in 
somatostatin receptor-positive organs, such as the pancreas, the adrenal and the 
anterior pitnitary gland of "'I after administration of ["'1-Tyr'loctreotide than after 
"'1-RC-160. 
Table 4. Tissue distribution (% q(injected dose/g tissue, mean ± SD) 
in tumour-bearing rats (n~4) 24 h after intravenous injection of 
0.5 p.g q( radioiodinated somatostatin analogue 
Tissue 
Spleen 
Kidneys 
Liver 
Intestines 
Thyroid 
Thymus 
Lungs 
Blood 
Pancreas 
Adrenals 
Pituitary 
Brain Cortex 
Tumour 
"'I-RC-160 
0.06 ± 0.03 
0.12 ± 0.03 
0.17 ± 0.03 
0.2 ± 0.0 
320 ± 70 
0.068 ± 0.032 
0.12 ± 0.04 
0.13 ± 0.08 
0.06 ± 0.02 
0.06 ± 0.03 
0.05 ± 0.05 
0.0019 ± 0.0009 
0.037 ± 0.021 
["'1-Tyr'joctreotide 
0.028 ± 0.021 
0.13 ± 0.0) 
* 0.027 ± 0.005 
* 0.03 ± 0.01 
180 ± 50 
* 0.016 ± 0.007 
* 0.033 ± 0.006 
* 0.006 ± 0.000 
0.11 ± 0.04 
0.04 ± 0.01 
* 0.17 ± 0.02 
0.002 ± 0.001 
* 0.007 ± 0.001 
* P<O.OJ "'I-RC-J60 vs f"I-Tyr'/octreotide 
In brain cortex of control rats we found at 4 h a low, but statistically 
signiticant specific binding of 1"I-RC-160. However, this was caused by a very 
low amount of tracer (0.0052 % of injected dose per gram) in comparison with 
other somatostatin receptor-positive tissues, such as the pancreas (0.21 % of 
injected dose per gram). Since we found a significant difference between the 
uptake of radioactivity in saturated and non-satnrated brain cortex, these data 
suggests that, in contrast to octreotide, RC-160 and radioiodinated RC-160 are able 
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to cross the blood-brain barrier, as it has also been reported for cold RC-160 and 
radioiodinated RC-160 by Banks and Schally (21,24). The presence of the C-
terminal amino acid tryptophan io RC-160 (see Fig. 1) enhances the lipophilicity 
of the molecule, and this might also explain it~ increased blood-brain barrier 
permeability and reduced clearance from the tissues and blood. 
Duriog the first 30 min after the injection of 123I-RC-160 no statistically 
significant uptake was measured io the tumour as measured by gamma camera 
scintigraphy, and neither after a background correction. This fiodiog is in contrast 
with the results of the experiments with [1'31_ Tyr'joctreotide as described by Bakker 
(6). However, 30 min after the injection of 1'3I-RC-160, statistically significant 
specific bioding in the isolated tumour was found. Since there is no significant 
difference between the uptake or specific binding after the injection of [1231_ 
Tyr')octreotide and 1'3I-RC-160 in the isolated tumour at 30 min, the relatively low 
tumour to blood ratio in these experiments is probably the reason for this discre-
pancy. 
CONCLUSION 
123I-RC-160 does not seem to have advantages over e23I-Tyr'joctreotide as a 
radiopharmaceutical for somatostatin-receptor scintigraphy, despite the fact that 1231_ 
RC-I60 shows specific ltigh-affinity biodiog to various somatostatin receptor-
positive organs. In contrast to radioiodioated (Tyr'joctreotide and octreotide, which 
do not pass the blood-braio barrier, our experiments confirm that RC-160 and 
radioiodinated RC-160 iodeed do pass the blood-brain barrier. However, this 
occurs in low quantities, and consequently the application of radioiodinated RC-
160 io nuclear medicine for visualiziog somatostatin receptor-positive braio 
tumours with an intact blood-braio barrier is hampered. In comparison with e23I-
Tyr'joctreotide the maio disadvantage of 1'3I-RC-160 is it~ relatively low tumour to 
blood (background) ratio, implying poorer in vivo tumour detection. 
Apart from the discussed data, it must be emphasized that it has been 
described by several authors that io comparison to octreotide RC-160 has superior 
bioding characteristics in some human tumours. Therefore, RC-160 and, io spite of 
its disadvantages, 1'3I-RC-160 could open new diagnostic and/or therapeutic 
applications for patients bearing such tumours. Therefore, io analogy to the 
development of the 11 1 In-labelled [DTPA-D-Phe1joctreotide analogue, lllIn-labelled 
[DTPA-D-Phe1)RC-160 is beiog prepared and investigated. 
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CHAPTER 6 
A NEW RADIOLABELLED SOMATOSTATIN ANALOGUE 
[IHIn-DTPA-D-Phe'jRC-160: PREPARATION, BIOLOGICAL ACTIVITY, 
RECEPTOR SCINTIGRAPHY IN RATS AND COMPARISON WITH 
['''In-DTPA-D-Phe'jOCTREOTIDE 
Wout AP Breeman, Leo J Hofland, Marcel Evan der Plu(jm, Peter M van 
Koetsveld, Marion de Jong, Buddy Setyono-Han, Willem H Bakker, Dik J 
Kwekkeboom, Theo J Visser, Steven WJ Lamberts, Eric P Krenning 
Department of Nuclear Medicine, and Department of Internal Medicine III, 
University Hospital "Dijkzigt", Rotterdam, The Netherlands and the 
Dr. Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands 
ABSTRACT 
We have evaluated the potential usefulness of '''In-labelled [DTPA-D-
Phe'jRC-I60, derived from the octapeptide somatostatin analogue RC-160, as a 
radiopharma-ceutical for the in vivo detection of somatostatin receptor-positive 
tumours. For this purpose IHln- and "'In-labelled [DTPA-D-Phe']RC-160 was 
tested for its biological activity, and applied for somatostatin receptor scintigraphy 
in vivo to rats bearing the transplantable rat pancreatic tumour CA20948, which 
expresses somatostatin receptors. We previously described the development of the 
'''In-labelled somatostatin analogue [DTPA-D-Phe'joctreotide and it~ use in the in 
vivo visualization of somatostatin receptor-positive tumours in rats and in humans. 
Like ["'In-DTPA-D-Phe'joctreotide, ['''In-DTPA-D-Phe')RC-160 showed 
uptake in and specific binding in vivo to somatostatin receptor-positive organs and 
tumours, and the tumours were clearly visualized by gamma camera scintigraphy. 
However, as compared to ["'In-DTPA-D-Phe'joctreotide, blood radioactivity 
(background) was higher, resulting in a lower tumour to blood (background) ratio. 
Using this animal model we therefore conclude that ["'In-DTPA-D-Phe'jRC-160 
has no advantage over ["'In-DTPA-D-Phe')octreotide as a radiopharmaceutical in 
the visualization of somatostatin receptors which bind both analogues. However, 
recent reports suggests the existence of different somatostatin receptor subtypes on 
some human cancers, which differentially bind RC-160 and not octreotide. These 
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tumours include cancers of the breast, ovary, exocrine pancreas, prostate and 
colon. ['''In-DTPA-D-Phe']RC-160 might be of interest for future use in such 
cancer patients as a radiopharmaceutical for imaging somatostatin receptor-positive 
tumours, which do not bind octreotide. 
INTRODUCTION 
High numbers of high-affinity somatostatin receptors for both native 
somatostatin (for structures, see Fig. I) and the synthetic octapeptide octreotide 
(Sandostatin"), have been detected on most neuro-endocrine tumours, like endocri-
ne pancreatic tumours and carcinoids [1-4]. We, and also others have recently 
described the visualization of somatostatin receptor-positive tumours in vivo after 
the intravenous administration of ["'I-Tyr'joctreotide [5-12] and ['''In-DTPA-D-
Phe'joctreotide [13-20]. Several reports have also been published on the in vitro 
binding to somatostatin receptors of another somatostatin analogue, the octapeptide 
RC-160 [21-23J. It has been reported that RC-160 has a higher affinity than 
octreotide for somatostatin receptors in human breast, ovarian, exocrine pancreatic, 
prostatic and colonic cancers [21-23]. A phase 1 clinical trial with RC-160 in 
patient' with advanced exocrine pancreatic cancer suggests that RC-160 is well 
tolerated at doses up to 1500 I'gfday [24-25]. The possibility of RC-160 binding to 
a somatostatin receptor subtype, which does not bind octreotide, for example on 
human exocrine pancreatic adenocarcinomas [26], offers a potential advantage for 
RC-160 over octreotide as radiolabelled tumour- tracer. Furtbermore, RC-160 and 
radioiodinated RC-160 may, in contrast to octreotide [27], also pass the blood-
brain harrier [28-30]. This could represent a benefit in visualizing somatostatin 
receptor-positive brain tumours with an intact blood-brain barrier. We recently 
reported [301 our results with tumour visualization with '''I-RC-160 in tumour-
bearing rats and concluded that, despite the fact that '''I-RC-160 shows high-
affmity binding to various somatostatin receptor-positive tissues and tumours, there 
was no advantage over [123I-Tyr']octreotide found in binding to the somatostatin 
receptor-positive tissues and tumours studied sofar. 
Therefore, we compared ['''In-DTPA-D-Phe']RC-160 with ['''In-DTPA-D-
Phe'joctreotide (for structure see Fig. I), as radiopharmaceuticals for scintigraphy 
in normal rats and in rats bearing the transplantable pancreatic somatostatin 
receptor-positive tumour CA20948 [26,31,32j. 
MATERIALS AND METHODS 
Preparation and purification of the radio pharmaceuticals 
RC-160 and [DTPA-D-Phe']RC-160 were purchased from Sanbio (Uden, 
The Netherlands). [DTPA-D-Phe']octreotide and "'In-CI, (DRN 4901) were 
obtained from Mallinckrodt (Petten, The Netherlands). The radiolabelling of 
[DTPA-D-Phe'Joctreotide and [DTPA-D-Phe']RC-160 with "'In and consecutive 
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quality control were performed as described earlier [33]. Although it is not 
excluded that additional groups of the peptides participate in "'In complexation, the 
labelled products are referred to as [H'In-DTPA-D-Phe']RC-160 and ["'In-DTPA-
D-Phe']octreotide. 
Somatostatin 
I I 
Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr -Ser-Cys 
Octreotide 
I 
D-Phe-Cys-Phe-D-Trp-L ys-Thr -Cys-Thr( 01) 
Tyr' -octreotide 
I 
D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr( 01) 
rH 'In-DTP A-D-Phe' Joctreotide 
j i 
'HIn_ DTP A -D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr( 01) 
RC-160 
I 
D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH, 
['HIn-DTPA-D-Phe'JRC-160 
I I 
'HIn_ DTP A -D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH, 
Figure 1. Structural formulae of native somatostatin, octreotide, Tyr-octreotide, 
f" In-DTPA -D-Ph,! Joctreotide, RC-J60 and f" In-DTPA -D-Ph,! JRC-J60 
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The radiochemical purity of the radio labelled somatostatin analogues was greater 
than 95 %. All chemicals used were of the highest purity available. 
Animals and tumours 
Male Lewis rats (240-260 g) were inoculated in both upper hind legs with 
the transplantable rat pancreatic tumour CA20948, which has previously been 
shown to possess somatostatin receptors [26]. Male Lewis rats (240-260 g), not 
bearing the CA20948 tumour, were used as control rats. 
For injection and scintigraphy the rats were anaesthetized with ether. 
In order to study specific binding, the rats were injected subcutaneously with I mg 
RC-160 or I mg octreotide in I ml 0.05 M acetic acid containing 154 mM NaCI 
or solvent. Forty-five minutes later the rats were injected with either ['UIn-DTPA-
D-Phe'JRC-160 or l,uIn-DTPA-D-Phe']octreotide. Specific binding was defmed as 
the difference between the tissue uptake in tumour-inoculated rats and that in 
similar animals treated with excess of unlabelled peptide, expressed as percentages 
of the injected radioactivity per gram tissue (mean ± SD). 
The tracer agents were injected into the dorsal vein of the penis. The dose 
was 18.5 MBq (0.5 I'g) for both analogues, measured in a dose calibrator (VDC-
202, Veenstra, Joure, The Netherlands). The rats were sacrificed 2, or 4, or 24, or 
48, or 72 h after administration of the radiolabelled somatostatin analogue. The 
concentration of radioactivity in various tissues, urine and blood was subsequently 
measured. 
["'In-DTPA-D-Phe']octreotide and ["'In-DTPA-D-Phe']RC-160 binds to 
SEP-PAK CIS stationary phase and is, using the separation technique as described 
by Bakker [6], only eluted with ethanol, while "'In-DTPA does not retain on SEP-
PAK CIS columns. Radioactivity in plasma and urine samples which is also eluted 
with ethanol from the SEP-PAK CIS column is termed peptide-bound radioactivity, 
but is not further characterized. 
The radioactivity in blood and urine was analysed as described previously 
[6]. 
Biological activity and radioligand binding studies 
[In-DTPA-D-Phe']octreotide (labelled with natural indium, i.e. a mixture of 
4.23 % non radioactive "'In and 95.77 % u'In, t'12=6.1O" years, further on 
referred to as H5ln) and [USln-DTPA-D-Phe']RC-160 were prepared by mixing the 
respective JDTPA-D-Phe']-somatostatin analogues (stock concentration of 10-4 M) 
with 10.3 M u'InCl, (Aldrich) in 0.05 M acetic acid, to a 80-fold molar excess ratio 
of indium over peptide. The biological activity of [DTPA-D-Phe']octreotide, [USIn-
DTPA-D-Phe']octreotide, [DTPA-D-Phe']RC-160 and ["'In-DTPA-D-Phe']RC-160 
was assessed by measuring its potency to inhibit the secretion of rat growth 
hormone (rGH) from cultured rat pituitary cells. The preparation of dispersed 
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female rat anterior pituitary cells and cell culture conditions have been described 
earlier [341. 
Receptor binding assays were carried out using ["'I-Tyr'1octreotide as 
described earlier [351. Binding curves and Ie" for displacement of ["'1-Tyr'loctre-
olide binding by unlabelled peptide were calculated from 2 experiments (triplicate 
determinations) using the computer fitting program of Graphpad (lSI software, 
Philadelphia, PA, USA). 
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Figure 2. Binding of f"I- Tyr'Joctreotide to rat brain cortex membranes in the 
presence of increasing concentrations of [DTPA-D-Phe' /RC-J60 (0) and [DTPA-D-
Phe'joctreotide (0), expressed as the percentage of binding in the absence of 
competing compounds (n=3, maximal SD < 10 %). No significant differences 
were found at equimolar concentrations 
Data acquisition and analysis 
All results are expressed as the mean ± SD. 
One-way analysis of variance (ANOV A), was used for statistical analysis. For the 
comparison of means the Newman-Keuls or Bonferroni t-test were applied [36]. A 
P value of < 0.05 was considered significant. The tissue distribution and metabo-
lism of the "'In-labelled somatostatin analogues in vivo were studied by gamma 
camera scintigraphy (Rota-II, Siemens)[13] and measurement of Illln in isolated 
83 
(l'In-DTPA-D-Phe'jRC-160 
organs were performed using a LKB-1282-Compugammasystem [6j. 
The ratio of tissue-binding values of tissue over soft tissue (thigh) and the 
radioactivity concentration ratio of tumour over soft tissue were calculated for each 
individual organ and for the tumours. 
RESULTS 
Quality control, radiolabelling and preparation of the radiophannaceutical 
Amino acid analysis of RC-160 and ['"In-DTPA-D-Phe'JRC-160 yielded a 
peptide content of more than 95 % of the correct amino acid composition. The 
identity of the peptides was confirmed by fast atom bombardment mass spectrome-
try, showing molecular weight of 1131 and 1507 dalton for RC-160 and [DTPA-
D-Phe'JRC-160, respectively. 
Over 95 % efficiency of labelling, tested by ITLC and confirmed by high-
performance liquid chromatography (HPLC), was assured when a molar excess of 
5- to IO-fold of peptide over '"ln was used, resulting in the formation of ["'In-
DTPA-D-Phe'JRC-160 with a specific activity of 150 MBq '''In per JLgram 
[DTPA-D-Phe'JRC-160. The ["'In-DTPA-D-Phe'JRC-160 was stable for at least 4 
h after preparation, and for longer than 24 h if stabilised by either dilution, with 
for instance saline, or addition of a quencher, such as gentisic acid. 
Receptor binding studies and biological activity 
Fig. 2 shows binding of 11251_ Tyr'joctreotide to rat brain cortex membranes 
in the presence of increasing concentrations of unlabelled [DTPA-D-Phe'joctreotide 
or [DTPA-D-Phe'JRC-160, with IC" values of 20 and 30 nM, respectively. 
In Fig. 3 the effects of [' 15ln-DTPA-D-Phe'Joctreotide, [DTPA-D-Phe'joc-
treotide, ['''In-DTPA-D-Phe'JRC-160 and [DTPA-D-Phe'JRC-160 on the secretion 
of rat growth hormone by cultured rat anterior pituitary cells are shown. There is a 
dose dependant inhibition of basal rat growth hormone release by these cells, with 
IC" values of 3, 8, 5 and 15 nM, respectively for the four compounds mentioned 
above. There were no significant differences between the effects of the two "'In-
labelled and the two non-labelled somatostatin analogues, (P > 0.05, Student's t-
test). Trivalent indium ions, up to a concentration of 8.10·' M, did not influence 
rat growth hormone assay (data not shown). 
Tissue distribution and specific binding 
The radioactivities measured in the isolated tumour and organs, 24 h after 
injection of f'''In-DTPA-D-Phe'Joctreotide and 24, 48 and 72 h after injection of 
f"'ln-DTPA-D-Phe'JRC-160 are shown in Table 1. Between 24 and 48 hours after 
injection of ["'In-DTPA-D-Phe'jRC-J60 there is a decrease of radioactivity in most 
tissues, accompanied by an increase of radioactivity in rat kidney. The uptakes in 
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the kidney, in the somatostatin receptor-positive tissues and in the tumour were 
higher for [,IlIn-DTPA-D-Phe'jRC-160 than for rll'In-DTPA-D-Phe']octreotide. 
The ratios of tumour over blood and tumour over soft tissue for [,IlIn-DTPA-D-
Phe']RC-160 were significantly lower than those found for ll'In-DTPA-D-Phe'joc-
treotide, mainly because of the very low uptake of radioactivity in soft tissue after 
injection of r"'In-DTPA-D-Phe']octreotide (Table I). Table 1 also shows that even 
72 h after injection of r"'In-DTPA-D-Phe']RC-160 the remaining radioactivity in 
blood is still twice the value 24 h after injection of rll'In-DTPA-D-Phe'joctreotide, 
0.0061 % vs 0.0035 % injected dose per gram. For soft tissue the relative 
difference is even higher, 0.013 % vs 0.002 % injected dose per gram (Table 1) . 
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Figure 3. Effects of t"In-DTPA-D-PhCjRC-J60 (-), {DTPA-D-Phe' jRC-160 (0), 
f"In-DTPA-D-Phe?octreotide (0) and [DTPA-D-Phe'loctreotide (0) on the 
secretion of rat growth hormone from cultured rat pituitary cells (n=4, maximal 
SD < 15 %). No significant differences were found at equimolar concentrations 
Despite the decrease in radioactivity in most tissues, which are somatostatin 
receptor-negative tissues, total body radioactivity does not decrease between 24 and 
48 h after the injection of ["'In-DTPA-D-Phe'jRC-160, due to an increase of 
radioactivity in the kidneys (Table I). This results in a significantly higher body 
retention of radioactivity after injection of [,IlIn-DTPA-D-Phe']RC-I60 than with 
["'In-DTPA-D-Phe'joctreotide. This higher concentration of radioactivity in the 
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kidneys after L"'ln-DTPA-D-Phe']RC-160 is striking, since renal excretion is also 
the predominant route for clearance of ['''In-DTPA-D-Phe']octreotide. For instance 
even about 50 procent of the injected f'''ln-DTPA-D-Phe']octreotide is excreted via 
the kidneys in the first 30 min after injection of ['''In-DTPA-D-Phe']octreotide, as 
described earlier by Bakker [13]. 
Table 1. Tissue distribution (% injected dose per gram tissue, mean ± SD) and 
tissue ratios in tumour-bean'ng rats (n;2: 4) at indicated time intervals after 
intravenous administration of 0.5 JLg of WIn-labelled somatostatin analogue 
Tissue In-octreotide In-RC In-RC In-RC 
24 h 24 h 48 h 72h 
Adrenals 2.2 ± 0.4 7.1 ± 2.6 0.87 ± 0.12 0.73 ± 0.Q3 
Pancreas 0.92 ± 0.08 0.97 ± 0.28 0.42 ± 0.14 0.46 ± 0.14 
Tumours 0.20 ± 0.02 0.69 ± 0.12 0.21 ± 0.08 0.20 ± 0.08 
Pituitary 0.11 ± 0.02 0.35 ± 0.Q2 0.11 ± 0.02 0.13 ± 0.01 
Brain cortex 0.00]] ± 0.0001 0.011 ± 0.001 0.0015 ± 0.0002 0.0016± 0.0002 
Kidneys 2.9 t 0.3 5.3 ± 0.8 12 ± I 12 ± 2 
Liver 0.031 * 0.006 0.74 ± 0.04 0.22 ± 0.Q3 0.26 ± 0.Q7 
Spleen 0.033 ± 0.018 0.93 ± 0.08 0.36 t 0.08 0.30 ± 0.04 
Intestines 0.05 ± 0.01 0.37 t 0.09 0.12 ± 0.Q3 0.18 ± 0.04 
Soft tissue 0.0022 ± 0.0003 0.046 t 0.003 0.0]] ± 0.004 0.013 t 0.001 
Blood 0.0035 ± 0.0006 0.16 ± 0.Q2 0.0067 ± 0.0006 0.0061 ± 0.0012 
In toto 13 ± 2 50 ± 4 51 ± 5 49 t 2 
Tumours vs 97 ± 9 12 ± 3 25 ± 9 13 ± 7 
soft tissue 
Tumours vs 58 ± 9 3.6 ± 0.8 32 t 8 30 ± 11 
blood 
In-RC : ('IIIn-DTPA-D-Phe']RC-l60 
In-octreotide : f"'In-DTPA-D-Phe'Joctreotide 
In Table 2 the specific binding at several time intervals after injection of 
['''In-DTPA-D-Phe']RC-160 and ['''In-DTPA-D-Pbe']octreotide is given for the 
somatostatin receptor-positive tissues and tumour. There were no significant 
differences in binding of either peptide to these sites. Also, no specific binding of 
either analogue was found in the brain, suggesting that they were unable to pass 
the blood-brain barrier. 
Metabolism 
SEP-PAK C" columns were used for measuring peptide-bound radioactivity 
in blood and urine of 4 control rats at 4 hand 24 h after the injection of 1'''ln-
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DTPA-D-Phe']RC-160. The percentages peptide-bound radioactivity in blood were 
23 ± 2 at 4 h p.i. and 18 ± 1 at 24 h p.i .. HPLC-analysis of the ethanol-fractions 
of the SEP-PAK C" columns of these blood samples confIrmed that more than 90 
% of this peptide-bound '''In was intact ["'In-DTPA-D-Phe']RC-160 and at 24 h 
p.i. this fIgure had dropped below 50 %. The nature of the metabolites of both 
'"In-labelled radiopharmaceuticals was not further investigated. The percentage of 
peptide-bound "'In in urine-samples was respectively 73 ± 4 at 4 h , and 75 ± 2 
at 24 h after injection of ["'In-DTPA-D-Phe']RC-160. In the urine-samples from 
two control rats, 24 h after injection of ["'In-DTPA-D-Phe'Joctreotide, when most 
of the radioactivity already has been excreted, more than 90 % of the '''In was not 
peptide-bound, as described earlier by Bakker [13]. 
Figure 4. Static posterior images in rats with unilateral implanted somatostatin 
receptor-positive CA 20948 tumour, located at the upper pan of the right hind leg, 
24 h after injection of flllln-DTPA-D-Phe'JRC-160. Note the normal uptake of 
a b 
radioactivity in 
liver and kid-
neys in both 
images. There is 
accumulation of 
radioactivity in 
the tumour 
(a, no preteat-
ment). 
Notice the ab-
sence ~f accu-
mulation of 
radioactivity in 
the tumour in 
(b). 
In (b) the rat 
was pretreated 
s. c. with 1 mg 
RC-160 45 min 
prior to the 
injection with 
["'In-DTPA-D-
Phe'JRC-160 in 
order to satura-
te the somatos-
tatin receptors 
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Imaging 
Dynamic images during the first 20 min after injection l"'In-DTPA-D-
Phe'lRC-160 or ["'In-DTPA-D-Phe'joctreotide showed a rapid distribution of 
radioactivity over the whole body. Pretreatment with excess unlabelled RC-160 or 
octreotide did not affect the blood clearance. Immediately after injection of ["'In-
DTPA-D-Phe'jRC-160 or ["'In-DTPA-D-Phe'joctreotide, an increasing amount of 
radioactivity was measured over the tumours. 
From digital static images obtained 24, 48 and 72 h after injection of ["'In-
DTPA-D-Phe']RC-160, whole body retention was found to be approximately 50 
procent of the injected dose after 48 h and 72 h, and this retention was predomi-
nantly accounted for by radioactivity in the kidneys, see also Table 1. Figure 4 
present, static analog images of 2 rats with unilateral somatostatin receptor-positive 
CA20948 tumours, 24 h after the injection of ['''In-DTPA-D-Phe'jRC-I60. 
Accumulation of radioactivity in the tumour and kidneys was observed. The uptake 
of radioactivity by the tumour was succesfully inhibited by the pretreatment of 
unlabelled RC-160 (Fig. 4). 
Table 2. Specific binding in somatostatin receptor-posltlve organs and tumours 
(percentage injected dose per gram tissue, mean ± SD) in tumour-bearing rats 
(n ~4), at indicated time intervals after intravenous administration of 0.5 p.g of 
WIn-labelled somatostatin analogue 
Tissue In-RC In-RC In-octreotide In-octreotide 
4h 24 h 4h 24 h 
Adrenals 5.0 ± 0.3 6.1 ± 2.6 2.1 ± 0.5 1.8 ± 004 
Pancreas 0.44 ± 0.22 0.56 ± 0.28 0047 ± 0.20 0044 ± 0.15 
Tumours 0.30 ± 0.14 0.35 ± 0.12 0.21 ± 0.09 0.19 ± 0.05 
Pituitary 0040 ± 0.05 0.23 ± 0.02 0.16 ± 0.06 0.12 ± 0.02 
Brain cortex <0.001 <0.001 <0.001 <0.001 
Except for the brain cortex, all organs and tumours had specific binding 
significantly different from zero, P< 0.05 
In-RC " f'''In-DTPA-D-Phe'jRC-160 
In-octreotide " l'''In-DTPA-D-Phe'joctreotide 
DISCUSSION 
Like octreotide, RC-160 is a somatostatin analogue with potent hormone 
secretion-inhibitory and anti-proliferative characteristics in vivo and in vitro. 
However, discrepancies with octreotide have been described, with regard to 
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binding to a number of human cancers, such as breast, ovarian, exocrine pancreas, 
prostate and colon carcinomas [21-23J. Because radiolabelled RC-160 could have 
advantages over radiolabelled octreotide for the in vivo detection of some of these 
somatostatin receptor-positive tumours, at first we evaluated radioiodinated RC-160 
as a radiopharmaceutical. These studies revealed some major drawbacks of the 1231_ 
RC-160 as compared to ['23I-Tyi'Joctreotide. The main disadvantage of I23I-RC-160 
was its relatively low tumour to background ratio, implying poorer in vivo tumour 
detection [30]. In analogy with the development of [lIIln-DTPA-D-Phe']octreotide 
we therefore evaluated ['"In-DTPA-D-Phe']RC-160. Since for use in animal 
models no somatostatin receptor-positive tumours are available displaying binding 
specificity for RC-160 and not for octreotide, we investigated both somatostatin 
analogues in the CA20948 tumour-model. 
The radiolabeIling of [DTPA-D-Phe']RC-160 with (high quality) '"In is a 
simple single-step procedure with a high effiency of labelling (> 95 %) and does 
not require special skills nor equipment. We found no significant differences in 
biological activity between [II5In_ DTP A -D-Phe']RC- I 60 and [II5In_ DTP A -D-
Phe']octreotide and the two non-labelled [DTPA-D-Phe']-somatostatin analogues, 
as measured by inhibition of rat growth hormone secretion. Recently, however, we 
found that the non-DTPA conjugated RC-160 was significantly more potent in 
inhibiting hormone release by normal and tumourous pituitary cells (37). Therefo-
re, a direct comparison between somatostatin analogues with their DTPA-conjuga-
ted counterpart~ should be made with care. The results in the binding studies 
demonstrated that both non-labelled [DTPA-D-Phe']-somatostatin analogues are 
high-affinity and selective ligands for the somatostatin receptor. This was also 
demonstrated in the in vivo experiments after injection of ['"In-DTPA-D-Phe']oc-
treotide and [lIIln-DTPA-D-Phe'JRC-160, in which uptake and specific binding in 
somatostatin receptor-positive tissues and tumours were found. Also, the somatos-
tatin receptor-positive tumours were clearly visualized by gamma camera scinti-
graphy. However, we did fmd differences in metabolism and clearance of radioac-
tivity from the blood compartment, soft tissue and other somatostatin receptor-
negative tissues. A higher radioactivity concentration and a slower clearance from 
these tissues were demonstrated for ['"In-DTPA-D-Phe']RC-160. The difference in 
uptake of radioactivity in the liver and excretion in the intestines after injection of 
['"In-DTPA-D-Phe']RC-160 or ['"In-DTPA-D-Phe']octreotide was probably due to 
a difference in handling of both analogues by the liver [38J. In the perfused rat 
liver uptake of radioactivity from the medium was 20 % of the dose in the liver 
during the first hour of perfusion with ['"In-DTPA-D-Phe']RC-160, while this was 
2 % of the dose for ['"In-DTPA-D-Phe']octreotide. Less than I % of the dose of 
both radiolabelled somatostatin analogues were excreted in the bile, where they 
were in the peptide-bound form. 
The presence of the C-terminal amino acid tryptophan in RC-160 (see Fig. 
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I) enhances the lipophilicity of the molecule, and this may explain the enhanced 
uptake of 1'''In-DTPA-D-Phe'jRC-160 andlor its metabolites from the liver and its 
reduced clearance from tissues and blood. The ratios of tumour over blood and 
tumour over soft tissue for ['''In-DTPA-D-Phe']RC-160 are lower than those for 
['''In-DTPA-D-Phe'Joctreotide. Although the uptake of radioactivity in the tumour 
after ['''In-DTPA-D-Phe'jRC-160 experiment' is higher, the clearance of radioacti-
vity from the blood compartment and soft tissue is much slower than for ["'In-
DTPA-D-Phe']octreotide. This implies a poorer visualization of tumours when the 
former somatostatin analogue is used. The lack of uptake in brain cortex suggests 
the inability to penetrate an intact blood-brain barrier for both [DTPA-D-Phe']-
somatostatin analogues. This contrasts with earlier data on RC-160 and radioiodi-
nated RC-160 [28-30], and implies that 1"'In-DTPA-D-Phe']RC-160 is most 
probably not suitable for visiualizing human brain tumours with intact blood-brain 
barrier. However, because mention has been made of somatostatin receptor-
positive tumours with other subtypes which do not bind (labelled) octreotide, we 
want to hypothesize that ['''In-DTPA-D-Phe'JRC-160 might be applicable in the 
field of nuclear medicine in the visualization of some human cancers. We currently 
investigate patient' with a negative ["'In-DTPA-D-Phe'loctreotide gamma camera 
scintigraphy who have tumours which do not bind octreotide, but belong to the 
group of tumours which Schally et al. suggested to have a high affinity for RC-160 
[21-231. The therapeutic possibilities of I"'I-Tyr']octreotide are low [71, since the 
residence time of "'I in the tumour is short. This is because radioiodinated 
[Tyr']octreotide is rapidly metabolised with release of "'I in the circulation, as was 
demonstrated previously in rats [6,30] and patients [7]. 
Since the residence time inion the tumourcells of somatostatin analogues 
with a DTPA-group appears prolonged, it seems worthwhile to investigate if 
DTPA-peptides labelled with "'lor other fl-emitting radionuclides would be 
suitable for radiotherapy. Therefore, [DTPA-D-Phe', "'I-Tyr'joctreotide or 
[DTPA-D-Phe', "'1-Tyr']RC-160 could open new therapeutic applications for 
patients bearing somatostatin receptor-positive tumours. However, whether the 
residence time of the radioiodinated somatostatin analogues with a DTPA-group is 
also prolonged remains to be established, since deiodination of the molecule will 
than hamper the therapeutic application. 
CONCLUSION 
['''In-DTPA-D-Phe']RC-160 does not seem to have advantages over l"'ln-
DTPA-D-Phe']octreotide as a radiopharmaceutical for somatostatin receptor 
scintigraphy, despite the fact that ['''In-DTPA-D-Phe']RC-160 shows specific high-
affinity binding to various somatostatin receptor-positive organs. In contrast to 
radioiodinated [Tyr']RC-160 and RC-160 which do pass the blood-brain barrier, 
our experiments show that ['''In-DTPA-D-Phe']RC-160 and ["'In-DTPA-D-
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Phe'joctreotide do not pass the blood-brain balTier. In comparison with ['''In-
DTPA-D-Phe'joctreotide the main disadvantage of ['''In-DTPA-D-Phe'jRC-160 (as 
we recently also showed for "'I-RC-160) is its relatively low tumour to blood 
(background) ratio, implying poorer in vivo tumour detection. 
However, previous studies suggest that RC-160 might bind to several 
human cancer types, which do not bind octreotide. If the existence of different 
somatostatin receptor subtypes is confirmed, RC-160 and, in spite of its disadvan-
tages, ["'In-DTPA-D-Phe'jRC-160 may open new diagnostic andlor therapeutic 
applications for patients bearing such tumours. Further studies in patients need to 
be performed, with special attention to patients with a negative ["'In-DTPA-D-
Phe'joctreotide gamma camera scintigraphy scan andlor patients with tumours with 
a higher affinity for RC-160. 
Since the DTPA-group appears to prolong the residence time of somatosta-
tin analogues inion the tumourcells, it seems worthwhile to investigate if DTPA-
peptides labelled with "'lor other 6-emitting radionuclides and a likewise prolon-
ged residence time inion the tumourcells, would be suitable for radiotherapy. 
Consequently, [DTPA-D-Phe', "'I-Tyr'joctreotide or [DTPA-D-Phe', "'1_ 
Tyr'jRC-160 could then open new therapeutic applications for patients bearing 
somatostatin receptor-positive tumours. 
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CHAPTER 1 
SOMATOSTATIN RECEPTOR SCINTIGRAPHY USING ["'In-DTPA-D-
Phe'jOCTREOTIDE AND ["'In-DTPA-D-Phe'IRC-160 
Wout AP Breeman, Theo J Visser, Dik J Kwekkeboom, Leo J Hofland, 
Steven WJ Lamberts, Willem H Bakker, Eric P Krenning 
Departments of Nnclear and Internal Medicine III, 
University Hospital "Dijk:zigt", Rotterdam, The Netherlands 
Somatostatin, somatostatin-analogues and somatostatin receptors 
Somatostatin (SS,,) is a disulfide-containing peptide hormone of 14 amino· 
acids (for strncture, see Fig. 1). It is present in the hypothalamus, the cerebral 
cortex, the brain stem, the gastrointestinal tract, and the pancreas. In the central 
nervous system it acts as a neurotransmitter, while its hormonal activities include 
the inhibition of the release of growth hormone, insulin, glucagon and gastrin (see 
[11 for a review). Somatostatin receptors have been identified on many cells of 
neuroendocrine origin, including the somatotroph cells of the anterior pituitary 
gland, the thyroid C cells and the pancretic islet cells (2,3). However, also non-
neuroendocrine, such as lymphocytes (4), may possess these receptors. 
The general inhibitory effect of somatostatin on hormone production by 
various glands led to the concept of possible beneficial effects of somatostatin in 
the treatment of diseases based on gland hyperfunction or overproduction of 
hormones by (endocrine-active) tumours. However, the tetradecapeptide somatosta· 
tin itself turned out to be unsuitable for routine treatment. After intravenous 
administration somatostatin has a half-life of = 3 min in man, due to enzymatic 
degradation. In recent years successful efforts have been undertaken to prepare 
somatostatin analogues that are more resistant to enzymatic degradation by 
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modifying the molecule in various ways with preservation of the biological activity 
of the original molecule. Introduction of D-aminoacids and shortening of the 
molecule to the bioactive core sequence, resulted in the 8 aminoacids-containing 
somatostatin analogue octreotide (Sandostatin®). Octreotide is currently widely 
used successfully in the treatment of neuroendocrine-active tumours such as growth 
hormone-producing pituitary adenomas and gastroenteropancreatic tumours (5,6). 
Somatostatin receptors are structurally related integral membrane glycopro-
teins. Recently, five different human somatostatin receptor types have been cloned. 
All subtypes bind SS" and SS" (pro-somatostatin with 28 aminoacids) with high 
affinity, while their affmity for numerous somatostatin analogues differ considera-
bly (7-10). Octreotide binds with high affmity to the hSSTR2 (somatostatin 
receptor type 2) subtype, while this analogue has a relatively low affmity for 
hSSTR3 and hSSTR5 and shows no binding to hSSTR subtypes I and 4 (7-10). 
Octreotide scintigraphy is therefore based on the visualization of an octreotide-
binding somatostatin receptor (octreotide receptor), most probably the hSSTR2. 
Recently, several reports have been published on the in vitro binding to 
somatostatin receptors of another somatostatin analogue, the octapeptide RC-160, 
which structure is very similar to that of octreotide (Fig. 1) (11-13). It has been 
reported that RC-160 has a higher affinity than octreotide for the somatostatin 
receptor in human breast, ovarian, exocrine pancreatic, prostatic and colonic can-
cer (11-13). We and others have recently described the visualization of soma-
tostatin receptor-positive tumours in vivo after the administration of ["'In-DTPA-
D-Phe']octreotide (Octreoscan"; see for a review [14]) or ["'In-DTPA-D-Phe'JRC-
160 (15). 
We currently investigate patients with a negative ["'In-DTPA-D-Phe']octre-
otide scintigram who have tumours, which do not bind octreotide but belong to the 
group of tumours which Schally et al. suggested to have a high affmity for RC-160 
(11-13). 
Factors that influence uptake of [IIIIn-DTPA-D-Phe']octreotide in somatosta-
tin receptor-positive tissue, and the target to background ratio 
In nuclear medicine the uptake of radioactivity and its residence time in the 
target, and the target to background ratio are important for visualization. Relevant 
factors which influence this process include the capacity of the radiopharmaceutical 
to pass biomembranes, the competition by endogenous ligand and the rate of blood 
perfusion of the tissue. For instance, the production of somatostatin in the pancreas 
may be a contributing factor in the relative high optimal dose of 5 p.g of ["'In-
DTPA-D-Phe']octreotide required for maximum specific binding of the radiophar-
maceutical in the rat pancreas (16). This is in contrast to the optimal dose of 0.5 
p.g for the highly perfused adrenal, which does not produce somatostatin (16). 
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Other factors include the dissociation constant between the radiopharmaceutical and 
the receptor, the rate of internalization andlor degradation of the ligand-receptor 
complex, and the rate of reexpression andlor upregulation of the receptor. All 
above-mentioned parameters illustrate the dynamics and the complexity of the 
ligand-receptor interaction, particular in vivo. A preliminairy study in patients (17) 
confirmed our data in rats, indicating that uptake of ['''In-DTPA-D-Phe']octreotide 
in somatostatin receptor-positive tissue is a bell-shaped function of the injected 
mass of the radiopharmaceutical, but further studies are needed to determine which 
peptide mass is optimal for the uptake of '''In after the administration of ['" In-
DTPA-D-Phe']octreotide in different somatostatin receptor-positive organs and 
tumours in humans. These findings imply that the hypothesis that (somatostatin) 
receptor scintigraphy shows an optimal target to background ratio at the lowest 
possible mass of the radiopharmaceutical labelled with the highest specific radioac-
tivity is not correct. 
The mode of administration of the radiopharmaceutical is another factor that 
influences its effective concentration and exposure time to the receptor. In experi-
ments with rats the radiopharmaceutical (3 MBq "'In labelled with 0.5 fLg [DTPA-
D-Phe']octreotide) was injected over periods of 3, 45 or 180 seconds. The 
octreotide receptor-positive anterior pituitary, adrenal and pancreas and the 
octreotide receptor-negative kidneys, liver, spleen, soft tissue (thigh) and blood 
were isolated after 24 h. The tissue uptake (% injected dose per gram) and the 
octreotide receptor-positive target to background (blood or soft tissue) ratio were 
calculated. Ordy in the adrenal a significant increase in uptake and its target to 
background ratio was found when the radiopharmaceutical was slowly injected, 
with a significant increase from 3 to 45 sec, and optimum at 180 seconds. No 
significant alterations were detected in other tis~lIes. 
Radiotherapy 
The therapeutic possibilities of [mI-Tyr']octreotide are limited (18), since 
the residence time of "'I in the tumour is short. This is because radioiodinated 
[Tyr3]octreotide is rapidly metabolised with release of "'I in the circulation, as was 
demonstrated previously in rats (19,20) and in patients (18). Since the residence 
time inion the tumour cells of somatostatin analogues with a DTP A -group appears 
prolonged (14,19), it seems worthwhile to investigate if DTPA-peptides labelled 
with "'lor other Jl-emitting radionuclides would be suitable for radiotherapy. 
Therefore, [DTP A-D-Phe', "'1-Tyr3]octreotide or [DTP A-D-Phe', "'1-Tyr3]RC-160 
could open new therapeutic applications for patients bearing somatostatin receptor-
positive tumours. However, whether the residence time of the radioiodinated 
DTPA-somatostatin analogues is also prolonged remains to be established, since 
deiodination may still hamper the therapeutic application. 
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Somatostatin 
I 
Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr -Ser -Cys 
Octreotide 
I 
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr( 01) 
["'In-DTPA-D-Phe']octreotide 
I I 
'"In_ DTP A -D-Phe-Cys-Phe-D-Trp-Lys-Thr -Cys-Thr( 01) 
rlllln-DTPA-D-Phe'IRC-160 
I I 
'"In-DTPA-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH, 
Figure 1. Structural formula of somatostatin, octreotide, rln-DTPA-D-Phe' joc-
treotide and rln-DTPA-D-Pht!jRC-160 
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CHAPTER 8 
SUBSTANCE P RECEPTOR SCINTIGRAPHY: 
INITIAL STUDIES IN VITRO AND IN RATS 
Wout AP Breeman, Martin P VanHagen, Heleen A Visser-Wisselaar, Marcel E 
van der Pluijm, Jan W Koper, Buddy Setyono-Han, Willem H Bakker, Dik J 
Kwekkeboom, Steven WJ Lamberts, Theo J Visser, Eric P Krenning, 
Departments of Nuclear Medicine, Immunology and Internal Medicine III, 
University Hospital "Dijkzigt", and Dr. Daniel den Hoed Cancer Centre, 
Rotterdam, The Netherlands 
ABSTRACT 
We have evaluated the potential usefulness of a new radiolabelled substance 
P (SP) analogue, ['IIIn-DTPA-Arg']SP, as a radiopharmaceutical for the in vivo 
detection of SP receptor-positive (SPR +) immunological disorders and tumours. 
SP, [DTPA-Arg']SP, and [3-(p-hydroxyphenyl)propionyl-Arg']SP (Bolton-Hunter-
SP,[BH-SPl), inhibited dose-dependently the binding of '''I-BH-SP to the SPR in 
rat brain cortex membranes with IC" values of 0.2, 4 and 2 nM, respectively. In 
an autoradiographic displacement study of the submandibular gland with "'I-BH-SP 
as radioligand, an IC" of 2.7 nM was found for [DTPA-Arg']SP. In vivo metabo-
lism of the radiopharmaceutical in the rat revealed a renal clearance of 50 % of the 
injected radioactive dose in 30 min, and a rapid enzymatic degradation of the 
radiopharmaceutical, resulting in an effective t'h of the radiopharmaceutical in 
blood of ~ 3 min. Four and 24 h post injection of III'In-DTPA-Arg']SP uptake in 
and specific binding to SPR + organs and tumours were found, with a (SPR + ) 
target to background optimum at 24 h. Tissue distribution and ex vivo autoradio-
graphic studies in rats, with and without pretreatment with the selective non-
peptide NK,-receptor antagonist CP96,345, showed uptake and specific binding of 
radioactivity in isolated tumours, submandibular and parotid glands. Visualization 
of normal SPR + tissues such as the salivary glands by gamma camera scintigraphy, 
after adntinistration of [II'In-DTPA-Arg']SP, was demonstrated in untreated rats. 
Pathological SPR + processes were visualized in rats bearing the transplantable 
pancreatic tumour CA20948, and in rats with adjuvant arthritis, induced by 
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injecting a homogenate of mycobacteria tuberculosis. 
In conclusion: ["'In-DTPA-Arg'lSP can be used successfully to visualize 
SPR + processes in vivo by gamma camera scintigraphy. 
INTRODUCTION 
Tachykinins are a family of peptides which share a common C-terminal 
amino acid sequence, -Phe-X-Gly-Leu-Met-NH" where X represents either Phe, 
I1e, or Val (I). The mammalian tachykinins include substance P (SP), neurokinin 
A, nem·okinin B, and two N-terminally extended forms of neurokinin A - neuro-
peptide K and neuropeptide y. Currently accepted tachykinin receptor nomenclatu-
re defmes three homologous receptor types: the SP-preferring NK, receptor, the 
neurokinin A-preferring NK, receptor and the neurokinin B-preferring NK, 
receptor. The tachykinin receptors have a wide tissue distribution, and interaction 
with their ligands is associated with diverse responses such as sensory neurotrans-
mission, immunological responses, both contraction and endothelium-dependent 
relaxation of vascular smooth muscle, nociception, histamine release, plasma 
extravasation, intlammation, sexual behaviour and, potentially, nerve regeneration 
and wound healing (for reviews see refs.: 1,2). 
Substance P 
Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met -NH, 
rlllln-DTPA-Arg'jsubstance P 
"'In-DTPA-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH, 
Sendide 
Tyr-D-Phe-Phe-D-His-Leu-Met-NH, 
[IllIn-DTPA-Tyr' [Sendide 
"'In-DTPA-Tyr-D-Phe-Phe-D-His-Leu-Met-NH, 
Figure 1. Sequences Qf synthetic substance P, rHln-DTPA-Arg'lsubstance P, 
sendide and t"In-DTPA-Tyrlsendide 
The involvement of SP in the carcinoid syndrome (3) and vascular (migrai-
ne) headache (4) has been suggested. In rats with adjuvant arthritis the synovium 
was found positive for high-affinity substance Preceptors (SPR) (5) and was also 
found in patient, with rheumatoid arthritis (6). In addition, very high concentrati-
ons of SPR are expressed in the germinal center of lymph nodes (7), and on a 
human astrocytoma cell line (8). Large numbers of high-aftinity SPR are found in 
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surgical specimen obtained from patient' with inflammatory bowel disease. The 
SPR binding NK, receptor is expressed by arterioles and venules located in the 
submucosa, muscularis mucosa, external longitudinal muscle, and serosa (7,9). 
In the present study several animal models were used to evaluate the 
potential usefulness of ['''In-DTPA-Arg']SP as radiopharmaceutical for in vivo 
detection of SPR + tissues. Firstly, the SPR + submandibular and parotid gland 
(10-12) were studied in normal rats. As a second model, rats bearing the SPR + 
transplantable rat pancreatic tumour CA20948 (as presented in this paper) were 
investigated. Thirdly, the possible accumulation of ['''In-DTPA-Arg']SP was 
studied in the joints of rat, with adjuvant arthritis, induced by the mycobacteria 
tuberculosis (13). The specific non-peptide NK, receptor antagonist CP96,345 (14) 
was used in these models in order to block specitic binding of ['''In-DTPA-
Arg']SP to SPR. 
MATERIALS AND METHODS 
Preparation and Purification qf the Radiopharmaceutical 
[3-(p-hydroxyphenyl)propionyl-Arg']SP, (Bolton-Hunter-SP, BH-SP), 
[OTPA-Arg']SP, the SP antagonist sendide (15) and [DTPA-Tyr']sendide were 
purchased from Sanbio (Uden, The Netherlands). For structural formulae, see Fig. 
1. Amino acid analysis yielded a peptide content of more than 95 %. The identity 
of the peptides was confirmed by amino acid analysis and fast atom bombardment 
mass spectrometry. "'lnCI, (ORN 4901, 370 MBq/mL in HCl, pH= 1.5 - 1.9) 
was obtained from Mallinckrodt (petten, The Netherlands). The radiolabelling of 
[DTPA-Arg']SP with '''In to a specific activity of 150 MBq "'In per p.g [DTPA-
Arg']SP, and consecutive quality control by instant thin layer chromatography 
(ITLC, Silica-gel) and SEP-PAK CIS reversed-phase extraction were performed as 
described earlier (16). High performance liquid chromatography (HPLC) was 
performed with a Waters 600E multisolvent delivery system, connected to a 
p.Bondapak CIS reversed-phase column (300*3.9 mm, particle size 10 p.m). Elution 
was carried out at a flow of 1.5 mUmin with a linear gradient of 10 to 50 % 
acetonitril in 0.1 % trifluoroacetic acid in 30 ntin, and the latter composition was 
kept constant for another 5 min. 
The radiochemical purity of the radiolabelled SP analogues was greater than 
98 %. Although it is not excluded that additional groups of the peptide participate 
in "'In complexation, the labelled product is referred to as ['''In-DTPA-Arg']SP. 
[' 15ln-OTPA-Arg']SP was prepared by mixing [DTPA-Arg']SP (stock 
concentration of 10-' M) with a 80-fold molar excess of '''lnCI, (Aldrich) in 0.05 
M acetic acid, as described earlier (17). The binding characteristics of [DTPA-
Arg']SP and f' 15ln-DTPA-Arg']SP to the SPR were examined. 
"'I-BH-SP was purchased from Amersham (UK) and also prepared in our 
laboratory essentially as described earlier (18). The radioiodination was carried out 
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by adding 105 JLg BH-SP in 150 JLI 0.05 M acetic acid and 8 JLg chloramine-Tin 
100 JLI 0.05 M phosphate butler (pH 7.5) to 185 MBq (50 JLI) Na'''I (specific 
activity 0.62 TBq "'I/mg, Amersham, UK). The mixture was then vortexed for 1 
min. The radioiodination was stopped by adding 1 mL 10 % human serum albumin 
(Merieux, Lyon, France). After vortexing for 30 s, 2 mL 5 mM ammonium 
acetate was added. Purification was performed using a SEP-PAK CIS reversed-
phase extraction cartridge (Waters Associates, Milford, MA), which was washed 
successively with 5 mL 70 % ethanol, 5 mL 2-propanol and 5 mL distilled water. 
After application of the sample, the SEP-PAK CIS cartridge was washed with 5 mL 
distilled water and 5 mL 0.5 M acetic acid, and radioiodinated BH-SP was eluted 
with I mL 96 % ethanol. The solvent was evaporated at 25 0 C under a gentle 
stream of nitrogen. HPLC of "'I-BH-SP was performed on an identical JLBondapak 
CIS reversed phase column as mentioned above, and elution was carried out at a 
flow of I mLimin with a linear gradient of 40 to 70 % methanol in 0.05 mM 
acetate (PH 5.5) in 50 min, and the latter composition was kept constant for 
another 5 min. The in vitro binding and autoradiography studies were performed 
with HPLC-purified mono-iodinated "'I-BH-SP C"I-BH-SP). 
Reagents 
The selective non-peptide NK,-receptor antagonist CP96,345 (14) was 
kindly provided by Pfizer (Capelle aan de ijssel, The Netherlands). Substance P 
was purchased from Saxon-Biochemicals GMBH (Germany) and luteinizing-
hormone-releasing hormone (LHRH), thyrotropin-releasing hormone (TRH) from 
Hoechst (Germany). Octreotide was from Sandoz (Switzerland) and [DTPA-D-
Phe']octreotide from Mallinckrodt (The Netherlands). 
All chemicals used were of the highest purity available. 
Receptor Binding Studies and Autoradiography 
Receptor binding studies were performed with membrane fractions of the 
submandibular gland, brain stem, brain cortex and the CA20948 tumour. The 
incubation mixture consisted of 40 kcpm of "'l-BH-SP, while the remainder of the 
incubation mixture was identical as described earlier (19). Binding curves and IC" 
values for displacement of "'I-BH-SP binding by unlabelled peptide were calcula-
ted using the computer fitting program of Graphpad (lSI software, Philadelphia, 
PA, USA). 
Receptor autoradiography was carried out as described earlier (20) with 
some moditications. In short, the tissue samples were cut on a cryostat (Jung 
CM3000, Leica, Germany) in 10 JLm sections. The sections were mounted onto 
preeleaned gelatin coated microscope slides, and stored at -80 0 C. To wash out 
endogenous SP, sections were preincubated for 15 minutes at roomtemperature 
with 50 mM Tris-HCI buffer pH 7.4. Thereafter, sections were incubated for I h 
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at 20 °c in 50 mM Tris-HCl buffer pH 7.4 containing 200 mg/L BSA, 40 mg/L 
bacitracin, and 5 mM MnCl, to inhibit endogenous proteases, in the presence of 
iodinated ligand (400 kcpm/mL = 0.1 nM). Non-'l'ecific binding was determined 
on parallel sections by adding unlabelled native SP at a concentration of I fLM. 
Incubated sections were washed four times 5 seconds in ice cold 50 mM Tris-H C! 
buffer pH 7.4 and four times 5 seconds in ice cold distilled water to remove salt, 
dried quickly, and exposed to HyperfilmTM-'H (Amersham) for I week in X-ray 
cassettes without intensifying screens at -80 0 C. Histology was performed on 
hematoxylin-azophloxine stained sequential cryosections. Specificity of binding was 
tested by addition of IfLM SP, [DTPA-Arg'jSP, CP96,345, LHRH, TRH and 
octreotide. 
Autoradiographic displacement experiments in the submandibular gland 
were performed as described earlier (21). 
Ex vivo autoradiography was performed on kidney, parotid and submandi-
bular gland and tumour tissue from male Lewis CA20948 tumour-bearing rats. For 
this study rats were injected intravenously with 3.4 mg CP96,345 per kg body 
weight (BW) or with vehicle. After 10 minutes the rats were injected with 37 MBq 
(l fLg) ["'In-DTPA-Arg'jSP and exsanguinated 24 h later. 
Tissue Distribution and Specific Binding in Control Rats 
Male Wistar rats (220-260 g) were injected under ether anaesthesia into the 
dorsal vein of the penis and/or into a sublingual vein. In order to find the optimal 
injected mass of [DTPA-Arg'jSP groups of 3-4 rat~ were injected with 0.1, 1 or 5 
fLg [DTPA-Arg'jSP labelled with 3 MBq '''In. Parallel groups of 3-4 rat~ were 
injected similarly 10 min after intravenous administration of 3.4 mg CP96,345 per 
kg BW in 0.05 M acetic acid in 154 mM NaC!, as described by Bertrand (22). 
Specific binding was defined as the difference in tissue uptake of radioacti-
vity between untreated (total binding) and CP96,345-treated (non-specific binding) 
rats, expressed as percentages of the injected radioactivity per gram tissue, as 
described before (17). Twenty-four h after administration of [WIn-DTPA-Arg'jSP 
the rats were exsanguinated. The following organs and tissues were isolated and 
subsequently analyzed for radioactivity content: blood, bronchi, lungs, thymus, 
pancreas, spleen, adrenals, kidneys, aorta, esophagus, jejunum, colon, thigh (soft 
tissue), liver, exorbital lacrimal gland, parotid and submandibular glands, neck 
lymph nodes, anterior pituitary gland, brain cortex and striatum. The tissue 
distribution and metabolism of the WIn-labelled SP analogues in vivo were also 
studied by gamma camera scintigraphy (Rota-II, Siemens) (23). 
Imaging in Anhritic and Tumour-bearing Rats 
Adjuvant arthritis was induced in female rats by injection a homogenate of 
mycobacteria tuberculosis, as described earlier (13). Seventeen days after inoculati-
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on the rats had developed an adjuvant reactive arthritis, mostly located in the hind 
leg joints and at the site of inoculation a granuloma, as confirmed by light 
microscopy, These rats were injected with 37 MBq (I I"g) I "'In-DTPA-Arg'ISP. 
Since granuloma can be visualized by octreotide scintigraphy (24) rats were 
injected with 37 MBq (0.5 I"g) 1"'ln-DTPA-D-Phe1Ioctreotide (Octreoscan, 
Mallinckrodt, Petten, The Netherlands). Imaging was performed 24 h after 
injection of the radiopharmaceutical. 
In a second imaging study two groups of 4 male Lewis rat" bearing the 
transplantable rat pancreatic tumour CA20948, were also used for imaging. One 
group was treated intravenously with 3.4 mg CP96,345 per kg BW 10 min prior to 
the administration of ['"In-DTPA-ArgljSP in order to block specific receptor 
binding of the latter. The other group was similarly treated with vehicle prior to 
the radiopharmaceutical. 
Metabolism 
Male Wistar rats (220-280 g) were sacrificed at 15 min, 1 h, or 24 h after 
administration of the radiolabelled SP analogue. Blood was collected in EDT A 
containing tubes and immediately cooled on ice. Since SP is readily metabolized 
by various enzymes in blood (25,26) samples were immediately centrifugated at 0 0 
C and plasma components were separated by SEP-PAK C18 chromatography. Using 
the separation technique described above (17), [11lIn-DTPA-Arg1ISP binds to SEP-
PAK C18 stationary phase and is only eluted with ethanol, while lllin-DTPA is not 
retained on SEP-PAK C18 columns. The radioactivity in plasma and urine samples, 
which was eluted with ethanol from the SEP-PAK C18 column, is termed peptide-
bound radioactivity but was not further characterized. 
Data AcqUisition and Analysis 
All results are expressed as the mean ± SD. One-way analysis of variance 
(ANOV A), was used for statistical analysis. Means were compared using Bonferro-
ni or Newman-Keuls (27). Tissue-binding values were evaluated using Student's t-
test. A P value of < 0.05 was considered significant. 
RESULTS 
Radiolabelling and Quality Control of the Radioligand 
The efficiency of labelling of BH-SP with "'I was 30-35 %. Purification of 
the iodination mixture using the SEP-PAK Ct, reversed-phase cartridge resulted in 
the elution of mainly radioiodide in the water fraction and peptide-bound radioiodi-
ne in the ethanol fraction, as revealed by HPLC. Figure 2 shows a typical HPLC 
analysis of peptide(s) eluted in the SEP-PAK C18 ethanol fraction, indicating a 
radiochemical purity of > 95 % of mono-radioiodinated BH-SP. Simultaneous 
measurement UV -absorbance at 254 nm and radioactivity shows a clear separation 
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between unlabelled BH-SP, mono- and di-iodinated "'I-BH-SP with retention 
volumes of 37, 35.5 and 45 mL, respectively, using the methanol gradient. The 
retention volume of the commercially available "'I-BH-SP (specific activity = 
2000 Ci per mmol, Amersham, UK) was identical with our mono-iodinated "'1_ 
BH-SP (data not shown). Since our HPLC-purified mono-iodinated '''I-BH-SP is 
carrier-free, its specific activity will also reach this value of = 2000 Ci per mmol 
for carrier-free mono-iodinated "'I-labelled peptides. 
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Figure 2. HPLC-elution pattern of the ethanol fraction after SEP-PAK C" 
purification of the BH-SP radioiodination mixture. Non-radioiodinared BH-SP is 
measured by UV-absorbance (1=254 nm, broken line, with a retention volume of 
37 mL), mono- and di-iodinated "'I-BH-SP are detected by gamma detection (solid 
line) at 35.5 and 45 mL, respectively 
Receptor Binding Studies and Autoradiography 
Studies of the binding of "'I-BH-SP to the SPR in rat parotid gland 
membranes in the presence of increasing concentrations of SP, IDTPA-Arg']SP 
and [ll5In-DTPA-Arg']SP revealed IC" values of I, 35 and 31 nM, respectively. 
In brain stem membranes IC" values for SP and IDTPA-Arg'ISP were 0.5 
and 5 nM, respectively, while for sendide and IDTPA-Tyr']sendide IC" values 
were found in the /Lmolar range. In another study with membrane fractions of the 
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CA20948 tumour the binding of "'I-BH-SP was inhibited in the presence of 1 I'M 
of SP, fDTPA-Arg'lSP or CP96,345 to 67 ± 6 %, 66 ± 6 % and 66 ± 0 %, 
respectively, of the control value in the absence of competitive ligand. In a study 
with rat brain cortex membranes IC" values of 0.2, 4 and 2 nM were found for 
SP, fDTPA-Arg'lSP and BH-SP, respectively. 
Figure 3. 
A utoradio-
grams showing 
specific label-
ling of SPR in 
the serous part 
of the rat 
submandibular 
A B gland. (A) shows 
IOtal binding 
of "'I-BH-SP 
in the absence 
of unlabelled 
SP, and (B) 
non -s p e c ifi c 
binding in the 
presence of I 
C D pMSP. 
No displace-
ment occurred 
in the presence 
1 pM octreoti-
de (C), LHRH 
(D) or TRH 
(E). 
Bar represents 
1 mm 
E 
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Figure 4. Distribu-
tion of SPR in rat 
submandibular gland 
m (A-D) and in rat 
parotid gland (E-H). 
s A and E are hema-
toxy lin-azophloxine 
stained sections. The 
A E autoradiograms show 
total binding of m I-
BH-SP (B,F) or non-
specific binding in 
the presence of 1 p.M 
SP (C,G) or CP96,-
345 (D,H). The 
serous part of the rat 
submandibular gland 
B F 
(B) has a high densi-
ty of high-affinity 
binding sites to the 
SPR, whereas the 
mucous part of the 
gland has a less high 
density. The rat 
parotid gland (F) 
also has a high den-
sity of high-affinity 
C G binding sites to the 
SPR. Some non-spe-
cific binding is pre-
sent on the skeletal 
musele tissue, which 
is located in the 
section of the parotid 
~ 
gland. M, mucous; S, 
serous; MU, skeletal 
0 H musele. Bar repre-
sents 1 mm 
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Autoradiography of submandibular gland slices incubated with "'I-BH-SP 
demonstrated a high density of SPR in the serous part (Fig. 3), in contrast to the 
lack of SPR in the mucous part (Fig. 3 and 4). In the presence of 1 I'M SP the 
binding of 125I-BH-SP was completely inhibited (Fig. 3B), while in parallel 
incubations with II'M octreotide (Fig. 3C), LHRH or TRH binding of radioactivity 
was not affected (3D and 3E, respectively). The exorbital lacrimal gland and 
lymph nodes adjacent to the submandibular gland showed low non-specific binding 
of I"I-BH-SP (data not shown). Figure 4 shows the binding of "'I-BH-SP to SPR 
in rat submandibular (A-D) and parotid (E-H) gland in the absence (total binding; 
B,F), or the presence (non-specific binding) of I I'M SP (C,G) or 1 I'M CP96,345 
(D,H). 
Figure 5 shows an autoradiographic displacement study using 10 I'm slices 
of the submandibular gland and an IC" value of 2.7 nM was found for [DTPA-
ArgIISP. 
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Figure 5. Autoradiographic displacement of "'/-BH'SP on 10 I'm slices of rat 
submandibular gland. The uptake Cit radioactivity in the tissue slices was assessed 
at increasing concentrations of the ligand [DTPA-Arl! jSP 
Preparation, Radiolabelling, and Quality Control of the Radiopharmaceutical 
An over 98 % efficiency of labelling of the DTP A-conjugated peptides was 
assured within 15 min, as revealed by ITLC and HPLC, when a 5- to lO-fold 
molar excess peptide over IHIn was used. Therefore, a specific activity of over 150 
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MBq 111m per fig [DTPA-ArgljSP or IDTPA-Tyr'lsendide could be achieved. 
1"'In-DTPA-Arg'1SP and ["IIn-DTPA-Tyr'Jsendide were stable for at least I h 
after preparation, and for longer than 4 h if stabilised by addition of the quencher 
gentisic acid at a final concentration of 2 mg per mL The retention volumes for 
["IIn-DTPA-ArgljSP and [DTPA-Arg'jSP with the acetonitrile gradient were 31 
and 34 mL, respectively (Fig. 6). 
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Figure 6. HPLC-elution profile qt f"ln-DTPA-Arg' /SP (--, counts) and [DTPA-
Arg'/SP (---, absorbance at 254 nm) with a 10 to 50 % acetonitrile elution 
gradient. The dotted line represents a HPLC-pattern of the ethanol fraction fit 
SEP-PAK C" extract of serum collected 15 min after injection of the radiophanna-
ceutical 
Tissue Distribution and Specific Binding 
The target to background ratio increased between 4 and 24 h, as measured 
by the uptake of radioactivity in isolated SPR-positive tissues (salivary 
glands=target) compared with the radioactivity in blood (background). This 
calculated ratio increased from 23 ± 11 at 4 h up to 200 ± 16 at 24 h after the 
administration of the radiopharmaceuticaL 
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Table I. Tissue distributions (% injected dose per gram. mean ± SD) 
in male Wistar rats 24 h qfter intravenous administration ~f 3 MBq 
111In labelled with indicated mass ~f /DTPA-Arg'/substance P 
0.1 p.g I p.g 5 p.g 
Tissue (n=3) (n=3) (n=4) 
Blood 0.0062 ± 0.0009 0.0055 ± 0.002 0.0054 ± 0.0005 
Lungs 0.022 ± 0.004 0.020 ± 0.004 0.020 ± 0.003 
Bronchi 0.068 ± 0.011 0.089 ± 0.020 0.069 ± 0.011 
Thymus 0.049 ± 0.004 0.088 ± 0.015 0.048 ± 0.011 
Pancreas 0.019 ± 0.004 0.023 ± 0.005 0.022 ± 0.006 
Spleen 0.31 ± 0.07 0.32 ± 0.11 0.25 ± 0.06 
Adrenals 0.029 ± 0.006 0.033 ± 0.001 0.055 ± 0.013 
Kidneys 1.1 ± 0.1 1.9 ± 0.3 2.9 ± 1.1 
Aorta 0.023 ± 0.008 0.018 ± 0.008 0.044 ± 0.009 
Esophagus 0.049 ± 0.009 0.069 ± 0.020 0.030 ± 0.005 
Jejunum 1.1 ± 0.11 1.4 ± 0.2 1.0 ± 0.21 
Colon 0.24 ± 0.03 0.22 ± 0.04 0.33 ± 0.10 
Soft tissue 0.011 ± 0.002 0.019 ± 0.003 0.015 ± 0.003 
Liver 0.18 ± 0.03 0.24 ± 0.02 0.17 ± 0.04 
Exorb Lacr 0.055 ± 0.0004 0.095 ± 0.030 0.081 ± 0.011 
Submandib 0.65 ± 0.07 1.1 ± 0.0 1.3 ± 0.2 
Parotid 0.16 ± 0.02 0.29 ± 0.05 0.32 ± 0.08 
Pituitary 0.020 ± 0.001 0.041 ± 0.008 0.015 ± 0.004 
Brain cortex < 0.001 < 0.001 < 0.001 
Striatum < 0.001 < 0.001 < 0.001 
The radioactivity measured in the isolated tissues, 24 h after injection of 0.1, 1 or 
5 p.g IDTPA-Arg']SP labelled with 3 MBq "'In is shown in Table 1. A high 
concentration of radioactivity in the kidneys after 1'''In-DTPA-Arg']SP is evident, 
since renal excretion is also the predominant route for clearance of ['''In-DTPA-
Arg']SP. For instance, about 50 % of radioactivity is excreted via the kidneys in 
the fIrst 30 min after injection of rmIn-DTPA-Arg'ISP. Most of the tissues 
mentioned in Table 1 and 2 were selected from the literature because of their SPR 
content as potential targets, while blood and soft tissue were selected as SPR-
negative background. These background values are low, sintilar to corresponding 
values after the administration of ["'In-DTPA-D-Phe']octreotide (23). The uptake 
of radioactivity in the SPR + colon, jejunum, and submandibular and parotid 
glands is also similar to the values found in somatostatin receptor-positive organs 
with I '''In-DTPA-D-Phe'loctreotide scintigraphy (23). However, the uptake of 
radioactivity in SPR + adrenals, pituitary, aorta, esophagus and lungs is low. Table 
1 shows the total binding and Table 2 the specifIc binding of varying 
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amounts of [DTPA-Arg']SP (0.1, 1 and 5 I'g) labelled with a constant amount of 
"'In (3 MBq). In various tissues total and specific binding are optimal with the 
intermediate mass of the radiopharmaceutical. No significant uptake nor specific 
binding of ["'In-DTPA-Arg']SP was found in the brain cortex and striatum, 
suggesting that ['''In-DTPA-Arg']SP was unable to pass the blood-brain barrier. 
In CA20948 tumour -bearing male Lewis rats total uptake amounted to O. 13 
± 0.01 % injected dose per gram tumour and specific binding to 0.07 ± 0.01 % 
dose per g. 
Table 2. Specific binding in tissues (% injected dose per gram, 
mean ± SD) in male Wistar rats 24 h after intravenous administration 
of 3 MBq mIn labeled with indicated mass qf [DTPA-Arg' /substance P 
Tissue 0.1 I'g 1 I'g 5 I'g 
Bronchi 0.044 ± 0.011 * 0.047 ± 0.020 * 0.048 ± 0.011 
Thymus 0.029 ± 0.004 * 0.058 ± 0.015 * 0.000 ± 0.011 
Spleen 0.19 ± 0.07 * 0.27 ± 0.04 * 0.03 ± 0.06 
Esophagus 0.029 ± 0.009 * 0.063 ± 0.020 * 0.002 ± 0.005 
Jejunum 0.86 ± 0.11 * 0.60 ± 0.25 * 0.0 ± 0.2 
Colon 0.17 ± 0.03 * 0.062 ± 0.037 0.0 ± 0.1 
Submandibul 0.52 ± 0.07 * 0.83 ± 0.04 * 0.77 ± 0.15 
Parotid 0.15 ± 0.04 * 0.21 ± 0.08 * 0.16 ± 0.09 
Pituitary 0.008 ± 0.004 * 0.033 ± 0.008 * 0.004 ± 0.004 
Exorb Lacri 0.011 ± 0.011 0.042 ± 0.030 0.011 ± 0.011 
* P < O. 05, specific binding significantly different from zero 
Metabolism 
* 
* 
SEP-PAK CIS columns were used for analysis of peptide-bound radioactivity 
in blood and urine of rats 15 min, 1 hand 24 h after the injection of ["'In-DTPA-
Arg']SP. The percentage peptide-bound radioactivity in blood was 10 ± 2, 4 ± I 
and 0.5 ± 0.1 respectively. HPLC-analysis of the ethanol-fractions of the SEP-
PAK CIS extractions of these blood samples showed that less than 25, 15 and 5 %, 
respectively, of this peptide-bound "'In was intact ["'In-DTPA-Arg']SP. The 
subsequent t 1/, of the intact radiopharmaceutical in the first 15 min after the 
injection was approximately 3 min. This is illustrated for the 15 min serom sample 
in Fig. 6. The nature of the metabolites of [1"In-DTPA-Arg']SP was not further 
investigated. 
The percentage of peptide-bound "'In in urine-samples collected I and 24 h 
after injection of ['''In-DTPA-Argl]SP was less than 10 and 5 %, respectively, of 
the total radioactivity. More than 90 % of the radioactivity excreted in the urine 
collected 1 h after injection of the radiopharmaceutical had a molecular weight of 
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less than 1500 dalton, as shown by PD-IO gel chromatography, i.e. smaller than 
that of the injected f"'In-DTPA-Arg'JSP (data not shown). 
A 
B 
Imaging 
Figure 1. 
Static posterior images 
in rats with adjuvant 
arthritis, 24 h after 
injection of 37 MBq 
(1 p.g) (1Iln-DTPA-
ArgI1SP (A) or 37 MBq 
(0.5 p.g) [IIIIn-DTPA-D-
PheIJoctreotide (B). 
Adjuvant arthritis loca-
ted in the hind leg joints 
was induced by injection 
of a homogenate of 
mycobacteria tuberculo-
sis. 
Note the uptake of radi-
oactivity in liver and 
kidneys in both images. 
There is accumulation of 
f"ln-DTPA-Arg'lSP in 
the adjuvant arthritis 
affected hind leg joints 
(A), as well as salivary 
glands (A). There is less 
uptake of (1I In-DTPA-
D-Phe'10ctreotide at 
these sites (B). 
The granuloma (arrow) 
at the site of inoculation 
is clearly visualized by 
f"ln-DTPA-D-PheI/oc-
treotide (B) but not by 
rIlIln-DTPA-Arg'JSP (A) 
Dynamic images during the first 20 min after injection of f"'In-DTPA-
Arg'jSP showed a rapid distribution of radioactivity over the whole body. In the 
ftrst minutes after the injection of ["'In-DTPA-Arg'lSP the kidneys were rapidly 
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visualized and excretion of radioactivity in the urme was demonstrated. The 
dynamic images were comparable to the those obtained with l"'In-DTPA-D-
Phe'loctreotide (23) and r"'ln-DTPA-D-Phe'1RC-160 (17). From digital static 
images obtained 24 h after injection of rIIlIn-DTPA-Arg'1SP whole body retention 
was found to be less than 7 procent of the injected dose, and this retention was 
predominantly accounted for by radioactivity in the kidneys, liver, salivary glands, 
jejunum and colon (see also Table I). Figure 7 represent, static analog images of 2 
rats with ac!iuvant arthritis and an intlammation granuloma at the site of injection 
obtained 24 h after the injection of 37 MBq (ll'g) [IIIIn-DTPA-Arg'1SP (A) or 37 
MBq (0.5 I'g) [IIIIn-DTPA-D-Phe'loctreotide (B). The differences in tissue uptake 
of these radiopharmaceutical are evident. The radio labelled SP has a high uptake in 
salivary glands and in the arthritic hind leg joints, but shows less uptake in the 
granuloma. These findings are in contrast to the rat injected with r'llln-DTPA-D-
Phe'loctreotide (B), which shows no uptake in salivary glands and in the arthritic 
hind leg joints, but a high uptake at the site of the granuloma. 
A B 
Figure 8. Static lateral images qf CA20948 tumour-bearing rats 24 h post 
injection 37 MBq (1 I'g) ['''1n-DTPA-Arg'jSP. Without (A) or with (B) pretreatment 
CP96,345. The arrows indicate the salivary gland and the tumour, located at the 
back of the rat 
Figure 8 presents static lateral analog images of 2 CA20948 tumour-bearing 
rats 24 h after injection of 37 MBq (ll'g) 1"IIn-DTPA-Arg11SP. Accumulation of 
radioactivity is observed in the tumour, kidneys and salivary glands (A). Uptake of 
radioactivity in the tumour, parotid and submandibular gland is reduced by 50 % 
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after the pretreatment of 3.4 mg per kg BW of the SP antagonist CP96,345 (B), 
and in agreement with measurement of radioactivity concentrations in the isolated 
organs. The uptake of radioactivity in the kidneys and liver was not affected by 
this intervention. 
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Figure 9. 
Ex vivo autoradio-
graphy of SPR on 
a transplantable 
pancreatic tumour 
alter administrati-
on of f"ln-DTPA-
Arg'ISP without 
(B) or with CP96,-
345 (D). 
Hematoxylin-
azophloxine stai-
ned sections are 
shown in A,C,E 
and G for compa-
rison. Apart from 
the tumour, accu-
mulation of 1m In-
DTPA-Arg'jSP is 
seen in the serous 
part qf the sub-
mandibular gland 
(F) and in the 
cortex of the kid-
ney (H) of the 
untreated animal 
Figure 9 presents ex vivo autoradiography of the transplantable pancreatic 
tumour CA20948 without (B) or with (D) pretreatment of 3.4 mg CP96,345 per kg 
BW, submandibular gland (F) and kidney (H), after injection of 37 MBq (l/Lg) 
118 
p"ln-DTPA-Arg'ISP. Hematoxylin-azophloxine stained sections (A,C,E,G) are 
presented for orientation. The autoradiograph of the submandibular gland (F) 
shows the uptake of radioactivity in the serous acini, and the reduced uptake in the 
mucous acini, as also demonstrated by morphological staining and in the above-
mentioned in vitro autoradiographic study. The parotid gland has mainly serous 
acini. In the mucous part of the submandibular gland serous and some paneth cells 
are localised, and these cells seem responsible for the uptake of radioactivity in the 
mucous part of the gland. The autoradiograph of the kidney (H) demonstrates the 
uptake of radioactivity in the proximal tubuli and this was not affected by the 
pretreatment of CP96,345 (data not shown). 
DISCUSSION 
"'I-BH-SP has been shown to be a specitic, high affinity radioligand for the 
NK, receptor (SPR), and in the present study it was demonstrated that [DTPA-
Arg'ISP was a potent competitor for "'I-BH-SP binding to SPR in isolated 
membranes from cerebral cortex, brain stem and salivary glands as well as in 
tissue sections of the submandibular gland. These results suggested that l"'In-
DTPA-Arg'ISP is an attractive pharmaceutical for SPR scintigraphy. Table I 
shows low uptake of ['"In-DTPA-Arg'ISP in blood and soft tissue (background), 
while SPR + organs such as colon, jejunum, submandibular and parotid gland 
(targets) have higher uptake of radioactivity. Uptake of ['"In-DTPA-Arg'ISP in the 
pituitary is low, corresponding to the small number of SPR detected in this tissue 
(28,29). In contrast to the findings of several other groups (30,31) we could not 
demonstrate specific uptake in the lungs, although we did find uptake and specitic 
binding in the bronchi. The presence of SPR in smooth muscle, arterioles, and 
venules has been detected by autoradiography with "'I-BH-SP as radioligand (7,9), 
but these represent only a minor part of the total mass of the investigated tissues 
such as the aorta, bronchi and esophagus; hence the total uptake of radioactivity is 
low. 
The lack of uptake in brain cortex and striatum suggests an inability for 
[DTPA-Arg'ISP and ["'In-DTPA-Arg'ISP to penetrate the intact blood-brain 
barrier, and both analogues are inable to visualize SPR in the central nervous 
system. These data suggests that only when the blood-brain barrier is affected 
SPR + brain tumours, such as astrocytoma and glioma, might be visualized by 
gamma camera scintigraphy. 
The relatively high non-specific binding in comparison to the total uptake of 
radioactivity in SPR+ tissues (Tables 1,2), is in contrast to octreotide receptor 
scintigraphy in animals, which is characterized by high specific uptake of radioacti-
vity in the somatostatin receptor-positive tissues. Since homologous blocking of the 
SPR is not possible for pharmacological reasons, we investigated CP96,345 up to a 
dose of 3.4 mg i.v. per kg BW, as described by Bertrand (22). 
The high level of non-specific tissue uptake of ['"In-DTPA-Arg'ISP in rats, 
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as measured in rats pretreated with CP96,345, may be due in part to incomplete 
blockade of the SPR, since CP96,345 has been shown to have higher affmity for 
human SPR (K; 0.5 nM) than for rat SPR (K; 35 nM) (32-34). 
Fmihermore, little is known about the pharmacokinetics of CP96,345 in 
rats. The non-specific binding of "'I-BH-SP in the presence of CP96,345 in the in 
vitro autoradiography tissue was relatively low, but the antagonist was added at a 
high concentration (I I'M). It is unknown if the concentration required to saturate 
SPR is reached in vivo after administration of 3.4 mg CP96,345 per kg BW. 
Therefore, our estimates of the non-specific binding of ["'In-DTPA-Arg'jSP in 
tissues using this dose of CP96,345 represent overestimations of the true values. 
However, also total uptake of 1"'In-DTPA-Arg'jSP in SPR+ tissues remains very 
low compared with results obtained by octreotide receptor scintigraphy in somatos-
tatin receptor-positive tissues. 
We also studied the tissue distribution of 1"'ln-DTPA-Arg'jSP after the 
administration of varying masses of IDTPA-Arg'ISP labelled with a constant 
amount of "'In (3MBq) (Tables 1,2). In contrast to general belief that receptor 
scintigraphy shows an optimal target to background ratio at the lowest possible 
mass of the radiopharmaceutical with the highest specific radioactivity, we found 
that the uptake of 1"'In-DTPA-Arg'jSP in SPR+ tissue is usually optimal at 
intermediate doses. 
This might also apply to SPR + immunological disorders, the visualization 
of which may be enhanced by optimizing the mass of ["'In-DTPA-Arg'jSP. This 
phenomenon is similar to our previously reported findings on the binding of ['''In-
DTPA-D-Phe'joctreotide to somatostatin receptor-positive tissues (35,36). Howe-
ver, the tissue-specific bell-shaped function of ["'In-DTPA-D-Phe'joctreotide 
uptake versus the injected mass of [DTPA-D-Phe'joctreotide was explained in part 
by the homologous upregulation of the somatostatin receptors. It is unknown if 
SPR is (up-or down)regulated by SP, but it has been reported that SPR is down-
regulated by SP-antagonists (37). 
In vivo metabolism of 1"'In-DTPA-Arg'jSP in the rat revealed a renal 
clearance of 50 % of the injected radioactivity in 30 min, and a rapid enzymatic 
degradation of the radiopharmaceutical, resulting in an effective tlh of the intact 
radiopharmaceutical in blood of = 3 min. The presence of the DTPA-group in 
['''In-DTPA-Arg'jSP does not seem to afJect the biological t1h in serum, since 
similar half-lives have been reported for serum in dogs (2.1 min) (25) and humans 
(1.6 min) (3). Less than 10 % of the injected dose was found intact in the urine, 
during the first 30 min after injection of the radiopharmaceutical, which is another 
indication of the rapid degradation of the radiopharmaceutical. These data are also 
in contrast to previous reported findings with l"'ln-DTPA-D-Phe'joctreotide (23) 
and 1"'ln-DTPA-D-Phe'jRC-160 (17) scintigraphy in rat~, where a larger fraction 
of the radiopharmaceutical was excreted intact in the urine. Nevertheless, salivary 
glands, arthritic joints, and the SPR + tumour were visualized by gamma camera 
120 
scintigraphy. These data suggests that the receptor-ligand interactions in vivo must 
be very rapid, since the concentration of intact radiopharmaceutical in the circulati-
on rapidly diminishes. 
Sendide was reported to be a potent and selective NK, receptor antagonist 
(15), but in our hands 1"'In-DTPA-Tyr'jsendide did not show selective binding 
characteristics to the NK, receptor, neither in the in vitro experiments, nor in vivo. 
The intravenously administered ["'In-DTPA-Tyr'jsendide in rats revealed 
rapid clearance, but no specific binding to the SPR + salivary glands or to any part 
of the gastrointestinal tract was observed. 
The binding characteristics of l"'In-DTPA-Arg'JSP to the human SPR is 
currently under investigation, since discrepancies between the potencies of several 
SP analogs in different species have been reported, and the amino acids sequences 
of rat and human differ by < \0% (for reviews see refs.: 2,38). Different forms 
of SPR are also reported in rat submaxillary gland (the former nomenclature of 
submandibular) (39). Before human application, the pharmacological properties of 
radiolabelled and unlabelled [DTPA-Arg'ISP have to be investigated thoroughly, 
since SP is known to exert various unwanted cardiovascular effects. The groups of 
Schaffalatzky (3) and Coiro (40-42), however, have demonstrated that such side 
effects do not occur when SP is infused at low rates (1.5 pmol.min".kt) into 
humans. However, SP antagonists may be more attractive radiopharmaceuticals for 
imaging SPR + processes. 
CONCLUSION 
['"In-DTPA-Arg'ISP can be used successfully to visualize SPR+ processes 
in vivo by gamma camera scintigraphy. Further studies in patients with immunolo-
gical disorders need to be performed, with special attention for SPR + disorders as 
proven by autoradiography. We currently investigate patients with inflammatory 
bowel disease or brain tumours. 
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CHAPTER 9 
THYMUS SCINTIGRAPHY WITH rIIlIn-DTPA-ArgIJSUBSTANCE P 
Martin P VanHagen, Wout AP Breeman, Pieter TE Postema, Elly J van den 
Anker-Lugtenburg, Cees Robers, Steven WJ Lamberts, Dik J Kwekkeboom, 
Theo J Visser, Eric P Krenning 
Departments of Immunology, Nuclear Medicine, Internal Medicine III, 
Hematology and Anaesthesiology. University Hospital "D(jkzigt", 
Rotterdam, The Netherlands 
ABSTRACT 
Substance P (SP) is an II-amino acid neuropeptide and plays an important role 
in modulating pain transmission through neurokinin I and 2 receptors. SP and 
other tachykinins playa role in the pathogenesis of inflammatory diseases as well. 
In this study we present results concerning the metabolism of the SP analogue 
pIlIn-DTPA-Argl]SP in men and the visualization of the thymus in patients with 
immune mediated diseases. 
Patients and Methods. Ten selected patients, with inflammatory bowel disease 
(5), ophthalmic Graves' disease (I), sarcoidosis (I), Sjogren's syndrome (I), 
rheumatoid arthritis (I), and systemic lupus erythematosus (I) were investigated. 
During and after infusion of 200 MBq (2,5 fLg) pIlIn-DTPA-Argl]SP i.v. and 
blood pressure, heart rate and oxygen saturation were monitored. Radioactivity was 
measured in blood, urine and feces during 48 h after injection. Planar and Single 
Photon Emission Tomography (SPECT) images were obtained 4 and 24 h post 
injection. 
Results. After administration of r111 In-DTPA-Arg1]SP a transient flush was 
observed in all patients. Degradation of IIIIIn-DTPA-Argl]SP started in the tirst 
minutes after administration, resulting in a half-life of 10 min for the total plasma 
radioactivity and of 4 min for the intact radiopharmaceutical, as identitied with 
HPLC. Urinary excretion amounted in > 95 % of the radioactivity within 24 h post 
injection, and up to 0.05 % was found in the feces up to 60 h. In all patients 
uptake of radioactivity was found in the parotid glands, areolae of the mammae (in 
women), liver, kidneys, and urine bladder. In 7 patients a high uptake of rllIn-
DTPA-Argl]SP was observed in the thymus. 
In conclusion: rIlIIn-DTPA-ArgllSP is a new radiopharmaceutical and de'l'ite 
its short half-life it can be used to visualize the thymus. This may contribute to the 
investigation of the role of thymus in immune related diseases. Also, inflammatory 
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sites in various diseases could be visualized. The exact role of /'''In-DTPA-
Arg'jSP as a radiopharmaceutical in inflammatory diseases remains to be 
established. 
INTRODUCTION 
Substance P (SP) is an l1-amino acid neuropeptide and is known as a 
powerful member of a family of tachykinins which are characterized by the C-
terminal sequence Phe-X-Gly-Leu-Met-NH, (1). It has been well established that 
SP plays an impOltant role in modulating pain transntission from peripheral and 
central primary afferents through neurokinin I and 2 receptors. 
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Figure 1. The total plasma (e), peptide bound ( ... ) and cell bound (0) 
radioactivity during 48 h after injection 
SP and other tachykinins may playa role in the pathogenesis of inflammatory 
diseases (2-7). SP was shown to induce degranulation of mast cells in vitro, 
regulate chemotaxis, release lysosomal enzymes from macrophages, regulate T cell 
and B cell expansion and production of immunoglobulins (8-11). The thymus 
seems to be involved in immune mediated diseases. Lymphofollicular hyperplasia 
of the thymus has been described in autoimmune diseases such as myasthenia 
gravis, systentic lupus erythematosus, scleroderma, rheumatoid arthritis, 
Hashimoto's thyreoiditis and Sjogren's syndrome (12-15). 
Recently, SP was detected in the peptidergic neurons which innervate the thymus. 
Further NK' receptors were demonstrated in the thymus using autoradiography 
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(16,17). Large numbers of high-affinity substance Preceptors (SPR) are found in 
surgical specimen obtained from patients with inflammatory bowel disease. The 
SP-binding NKI receptor is expressed by arterioles and venules located in the 
submucosa, muscularis mucosa, external longitudinal muscle, and serosa (4). 
We developed a scintigraphic technique using an IlIln labelled SP analogue, (rllln-
DTPA-ArgljSP), to visualize affected tissues in immune disorders, e.g. the 
thymus. In this study results are presented concerning the metabolism of IIlln 
labelled fDTPA-Arg'jsubstance P and the scintigraphic detection of the thymus in 
immune mediated diseases. This may contribute to the understanding of the role of 
the thymus in immune disorders. 
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Figure 2. Cumulative urinary excretion pattern of total (8) and peptide-bound 
(0) radioactivity during 48 h after injection, and (A) shows the radioactivity in 
the urinary bladder 
PATIENTS AND METHODS 
Patients 
Ten selected patients were investigated after informed consent by the patient 
and approval of the medical ethics committee of our institution. Five with 
inflammatory bowel disease, one with ophthalmic Graves' disease, one with 
sarcoidosis, one with Sjogren's syndrome, one with rheumatoid arthritis and one 
with systemic lupus erythematosus. The diagnosis was established according to the 
clinical presentation and histopathologic examination of gastrointestinal biopsies in 
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the patients with inflammatory bowel disease and by liver biopsy in the patient 
with sarcoidosis. In rheumatoid arthritis, Sjogren's syndrome and systemic lupus 
erythematosus the diagnosis was made according to the internationally accepted 
diagnostic criteria. The patient with Graves' disease had lowered serum thyroid 
stimulating hormone concentration and elevated serum free thyroxine and specific 
thyroid-stimulating immunoglobulin concentrations. Uptake of radioactivity was 
investigated in 6 "control patients", 3 with carcinoid tumors, I with lung 
carcinoma and 2 with non-Hodgkin's lymphoma. 
Radiopharmaceuticals 
[DTPA-Arg'JSP was labelled with "'InCI, (370 MBq/mL in HCl, pH= 1.5 -
1.9, Mallinckrodt, Petten, The Netherlands), up to a specific activity of 150 MBq 
"'In per p,g !DTPA-Arg'jSP. Quality control by instant thin layer chromatography 
(ITLC, Silica-gel) and SEP-PAK C" reversed-phase extraction were performed 
essentiaslly as described earlier (18,19). High performance liquid chromatography 
(HPLC) was done using a Waters 600E multisolvent delivery system, connected to 
a p,Bondapak C" reversed-phase column (300 * 3.9 mm, particle size 10 p,m). 
Elution was carried out at a flow of 1.5 mLimin with a linear gradient of 10 to 50 
% acetonitril in 0.1 % trifluoroacetic acid in 30 min, and the latter composition 
was kept constant for another 5 min. 
The radiochemical purity of the radiolabelled SP analogue was greater than 98 %. 
Although it is not excluded that additional groups of the peptide participate in '" In 
complexation, the labelled product is referred to as L'''ln-DTPA-Arg'jSP. 
Imaging 
In our study 2.5 p,g !'''In-DTPA-Arg'jSP (200 MBq) was infused 
intravenously in 10 minutes. In all patients blood pressure, heart rate and oxygen 
saturation of the blood were monitored. Planar and SPECT images were obtained 
with a large field gamma camera equipped with a medium-energy parallel-hole 
collimator. SPECT analysis was performed with a Wiener filter on original data. 
Preset time for images obtained 24 hand 48 h after iI\jection of [,"In-DTPA-
Arg'jSP was 15 min. Planar images were obtained from the head and neck, chest, 
upper abdomen and lower abdomen. SPECT studies were performed 4 h or 24 h 
after injection of the radiopharmaceutical. 
Measurement of radioactivity in blood, urine and feces 
Radioactivity in blood, urine and feces was measured with an LKB-1282-
Compugamma system 01' a GeLi-detector equipped with a multi-channel analyser 
(Series 40, Canberra). Blood was collected in EDT A-containing tubes and 
immediately cooled on ice. Since SP is readily metabolized by various enzymes in 
blood, samples were immediately centrifugated at 0" C, and plasma was 
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fractionated on SEP-PAK C" columns. Using the separation technique described 
previously (19), r"'In-DTPA-Arg1jSP binds to SEP-PAK C" stationary phase and 
is only eluted with ethanol, while 111In-DTPA is not retained on SEP-PAK C" 
columns. The radioactivity in plasma and urine samples, which was eluted with 
ethanol from the SEP-PAK C" column, is termed peptide-bound radioactivity but 
was not further characterized. Blood samples were collected directly before and 2, 
5, 10, 20, and 40 min and 1, 4, 20 and 48 h after infusion. Urine was collected 
from the time of injection in two 3-h intervals and thereafter in intervals of 6 h 
until 48 h after injection. If feasible, feces was collected until 72 h after injection. 
The chemical status of the radionuclide in blood and urine was analysed as a 
function of time using the SEP-PAK C", HPLC and PD-1O gel filtration 
techniques as described previously (18,19). 
Figure 3. Accumulation of radioactivity in the thymus and salivary glands of a 
patient with liver sarcoidosis (anterior view of the chest, 24 h post injection) 
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RESULTS 
After administration of ['''In-DTPA-Arg'lSP a transient flush was observed in 
all patients. In one patient with Crohn's disease and anaemia, significant 
hypotension was observed associated with bradycardia. This patient recovered after 
30 seconds in Trendelenburg's position, suggesting the presence of a vasovagal 
collaps. 
In Fig. 1 the time courses of total and peptide-bound radioactivity in plasma are 
presented until 50 h after administration. The average plasma radioactivity 
decreased rapidly after injection of ["'In-DTPA-Arg'JSP. Degradation of ['''In-
DTPA-Arg'lSP started in the first minutes after administration, resulting in a half-
life of 10 min for total plasma radioactivity and of 4 min for the intact 
radiopharmaceutical, as identified with HPLC. 
Renal excretion resulted in the excretion of > 90% of the radioactivity in the 
urine within 24 h post injection as shown in Fig. 2. Up to 0.05 % was found in 
the feces until 60 h post injection. 
In all patients uptake of radioactivity was found in the salivary glands, liver, 
kidneys, urine bladder and in women the areolae of the mammae were visualized 4 
h post injection. The uptake of radioactivity at these sites was supposed to be due 
to receptor binding (parotid and areolae) or to metabolism (liver, kidneys, urine 
bladder) of the radionuclide labelled SP analogue. Deposition of radioactivity at 
other sites was considered due to other causes, which may be pathology related. [n 
7 patients a high uptake of l"'In-DTPA-Arg'jSP was found in the thymus. The 
highest uptake of radioactivity in the thymus was observed in the two patients with 
liver sarcoidosis and Sjogren's syndrome (Fig. 3). CT-scanning of the thorax 
confirmed an enlarged thymus in both patients. In patients with systemic lupus 
erythematosus, ophthalmic Graves' disease, rheumatoid arthritis and two patients 
with inflammatory bowel disease the thymus was visualized as well. No uptake of 
radioactivity in the thymus was observed in 3 patients with carcinoid tumors, I 
with lung carcinoma and 2 with non-Hodgkin's lymphoma. In addition to the 
thymus, in the patient with Sjogren's syndrome, the affected parotid glands showed 
an high uptake of radioactivity which was not observed in other patients. In the 
patient with unilateral ophthalmic Graves' disease, high uptake of radioactivity was 
observed in the eye mostly affected (Fig. 4). In 3 out of 5 patients with 
inflammatory bowel disease accumulation of radioactivity was found at the sites of 
inflammation (data not shown). 
DISCUSSION 
SP is found in the central nervous system as well as in peripheral neuronal 
circuits. It is involved in the regulation of growth hormone, ACTH and prolactin 
production (20,21). In the peripheral nervous system SP is found in the primary 
afferent neurons (A-delta pain fibers and C-fibers) that are involved in the 
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transmission of noxious stimuli. Bioactive SP has been infused intravenously in 
humans in doses of 0 .5- \.5 pmol.kg·' .min-' over 60 min or 0.5-8.0 pmol.kg-'. min-' 
over 20 min without serious side effects. (20,22). A very short half-life of 1.6 min 
was measured indicating a very high metabolic clearance. In normal plasma SP is 
degraded by enzymatic hydrolysis involving multiple proteases (23) . 
Figure 4. Uptake of radioactivity in a patient with unilateral ophthalmic Graves' 
disease (SPECT, 24 h post injection) 
In this study the fOTPA-Arg'jSP was injected in patients with immune 
mediated diseases. In lout of JO patients hypotension was observed with the 
clinical impression a vasovagal collaps caused the hypotension. After administra-
tion of f" 'In-OTPA-Arg'jSP a transient flush was observed in all patients. 
A very short half-life of JO min for plasma radioactivity and of 4 min for the 
intact radiopharmaceutical was measured. Radioactivity was excreted almost 
exclusively by the kidneys resulting in a low accumulation of radioactivity in the 
intestinal tract. Despite, the high degradation rate of this radiopharmaceutical it 
could visualize affected tissues for instance the thymus and tissues e.g. salivary 
glands, which are well-known to be SP receptor positive. 
In 7 patients with immune mediated diseases the thymus was visualized. In the 
"control" patients no thymus could be visualized, suggesting a high receptor 
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expression in immune mediated diseases. SPR have been described recently to be 
present in the thymus, but their role is still obscure. SP has been identified in 
nerve fibers of sensory origin in the thymus. The outer cortex of the human 
thymus contains an one to two cell thick layer that is immunoreactive with antisera 
against SP. In this region the most immature and recently migrated thymocytes are 
found emphasizing the role of of neuropeptides in regulating the microenvironment 
for T cell development (16). The gene encoding both SP and neurokinin-A was 
shown to be expressed in rat thymus, especially in a subpopulation of cells in the 
medulla (17). 
Also, the thymus is known to play an important role in another immune 
mediated disease, myasthenia gravis. Microscopy of thymuses revealed in 70 % a 
follicular hyperplasia of the medulla containing germinal centres resembling a 
stimulated lymph node (24,25). It may be that primary sensitization against the 
acetylcholine receptor which plays a crucial role in myasthenia gravis, occurs in 
the thymus. The reason why SP-receptors are present in the thymus of patients 
with immune mediated disease, as suggested in our patients, is obscure, but may 
mean that a similar process of sensitization as is hypothesized in myasthenia 
gravis, takes place in other auto-immune diseases as well. 
Besides the thymus, inflammation sites in two patients with inflammatory 
bowel disease, the affected orbit in ophthalmic Graves' disease, the salivary glands 
in Sjogren's syndrome and the joint' in rheumatoid arthritis were visualized. 
Although in patient' with innammatory bowel disease accumulation of radioactivity 
due to gut stenosis cannot be ruled out, the very low excretion of ["'In-DTPA-
Arg'lSP into the bowel « 0.05 %) does not favor this explanation. Therefore, this 
accumulation is most likely due to the presence of SPR at the sites of inflammation 
in these patients. 
SP is supposed to be involved in inflammatory bowel disease, upregulation of 
receptor binding sites at the venules and muscle was previously shown by 
autoradiography (4). In these patients a high-expression of SPR was observed in 
comparison with control patients (1000-2000 times normal). 
SPR were described in inflammatory synovitis in rat and human (6,7). l"'Ii-
labelled SP binding to microvascular endothelium paralleled the distribution of SP 
immunoreactive nerves and had the characteristics of the NK-J receptor (6). 
In this study we present our preliminary results concerning the use of 1'''ln-
DTPA-AI"g'JSP as a new radiopharmaceutical which has a very short half-life in 
the circulation. The thymus, which is usually involuted after puberty, expressed 
enough SPR to allow in vivo visualization. The role of the thymus in auto-immune 
diseases is obscure, only enlargement of thymus has been described in these 
diseases. Further investigations are necessary to evaluate the role of SPR 
expression in the thymus in these diseases. Also, inflammatory sites in various 
diseases could be visualized by SPR scintigraphy. The exact role of I'''ln-DTPA-
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Arg']SP as a radiopharmaceutical in autoimmune inflammatory diseases remains to 
be established. 
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APPENDIX I 
RADIOTHERAPY WITH A RADIOLABELLED SOMATOSTATIN 
ANALOGUE, IHlln-DTPA-D-Phe'IOCTREOTIDE. 
A case history 
Eric P Krenning, Peter PM Kooij, Wil1em H Bakker, Wout AP Breeman, 
Pieter TE Postema, Dik J Kwekkeboom, H Yoe Oei, Marion de Jong, 
Theo J Visser, Ambroos EM Reijs, Steven WJ Lamberts 
Departments of N udear Medicine and Internal Medicine III, 
University Hospital "Dijkzigt", Rotterdam, The Netherlands 
INTRODUCTION 
In 1987, we started octreotide receptor scintigraphy in humans. After a few 
years of using the radioiodinated [Tyr'joctreotide (I), we switched to [Wln-DTPA-
D-Phe'joctreotide, which has many advantages over the radioiodinated compound 
(2,3). Patients with various forms of cancer, both dassical1y known as of neuro-
endocrine and of non-endocrine nature, have been investigated (4). 
The application of these new peptide-receptor agents in scintigraphy, and of 
many others which wil1 become available in the near future, such as substance P 
and bombesin or their derivatives, might evoke a combination of optimism and 
pessimism. After al1, the presence of receptors determines the possibility to detect 
the abnormality or tumour by peptide receptor scintigraphy. Thus, the classical 
"oncept of false positives and false negatives really is not applicable to visualizati-
'n by means of peptide receptor scintigraphy (5). This technique allows primarily 
n interpretation with regard to receptor presence and not to anatomical abnormal-
·ies, as is the case with CT, ultrasound and MRI. Only at a second stage, after 
showing the localization of an abnormal density of receptors, one might conclude 
the presence of an anatomical abnormality expressing the peptide receptors, e.g. a 
primary pancreatic islet cell tumour expressing somatostatin receptors. However, 
when peptide receptor scintigraphy does not demonstrate (a) lesion(s), suggesting 
that a tumour or (several of the) metastases do not express (anymore) a certain 
peptide receptor, this also might be of paramount importance with regard to 
therapeutic advice to the patient. Dedifferentiation of a tumour is accompanied by 
loss of a given peptide receptor and this information influences the oncologist's 
therapeutic decisions. An example is the choice between the use of somatostatin 
analogues or cytostatic drugs in patients with neuro-endocrine tumours, that are 
well-differentiated or have become anaplastic, respectively (6,7). With future 
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(radio)therapy using (radio)labelled peptide(-derivatives), the presence (in the 
individual patient!) of several undifferentiated metastases, that do not bind a given 
(radio)ligand as opposed to the well-differentiated metastases, necessitates (an) 
additional appJication(s) of a (radio)Jigand with appropriate binding characteristics 
for the undifferentiated tumours, possibly by injection of a "cocktail" of (radiola-
belled) ligands. Thus, mapping of the presence, including the localization of the 
tumours and of the distribution of peptide-receptors on all metastases in the 
individual patient by peptide receptor scintigraphy may become an attractive, non-
invasive, harmless, easy-to-perform tool for an individual therapeutic approach of 
the cancer patient. 
INTERNAL CONVERSION 
80m Br 
125 I 
111 In 
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electron 
X-Ray 
auger electron 
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Figure 1. Schematic representation of gamma-ray emission ("internal conversion ") 
leading to the ejection of conversion-electrons (nuclear photons trans]er their 
energy to orbital electrons, which are then ejected from the atom, thereby leaving 
an electron vacancy, indicated with the small open circle) and Auger-electrons (the 
latter by X-ray photon interaction with an loosely bound outer electron). The 
maximum particle range of conversion- and Auger-electrons emitted by "'In is 
indicated in Table I 
In this report we present a patient with an inoperable, metastasized glucago-
noma in whom peptide receptor radiotherapy with Auger- and conversion-electrons 
emitting [JI'In-DTPA-D-Phe'Joctreotide, affects the growth of the tumour and the 
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circulating glucagon levels. Because of their more appropriate physical characteris-
tics, future nuclear mdiotherapy is directed to the use of (X- or JI-particles emitting 
radionuclide labelled peptides. 
Selection qf radionuclide for radiotherapy with the radiolabelled somatostatin 
analogue [DTPA-D-Phe'Joctreotide 
For radiotherapeutic applications several radionuclides have been proposed 
and investigated to be coupled to IDTPA-D-Phe'loctreotide. Radiolabelled IDTPA-
D-Phe'Joctreotide has an appropriate distribution profile in humans for this 
purpose. At the moment, theoretically suitable JI-emitting radionuclides are not 
available in pure form or show a dissociation from the chelated peptide in serum. 
Therefore, we decided to investigate the antiproliferative effect of the Auger- and 
conversion-electrons of "'In-labelled fDTPA-D-Phe'loctreotide. Figure 1 and 
Tables 1-2 illustrate the origin and the main physical characteristics of these elec-
trons, respectively. 
Table 1. Physical chnracteristics qfthe radionuclide: WIn (tf.'i = 2.83 d) 
emission-type 
gamma-photons 
conversion electrons 
Auger electrons 
E (keY) 
171 - 245 
144 - 245 
0.5 - 25 
R(l'm) 
200 - 550 
0.Q2 - 10 
Table 2. Energies (E) and yields of conversion- and Auger-electrons of wIn 
conversion 
conversion 
Auger 
Auger 
Auger 
MATERIALS AND METHODS 
E (keY) 
145 - 170 
218 - 245 
19 - 25 
2.6 - 3.6 
0.5 
Yield (%) 
10 
6 
16 
102 
191 
fDTPA-D-Phe'Joctreotide and '''InCI, (DRN 4901, 370 MBq/ml in HCL, 
pH = 1.5 - 1.9) were obtained from Mallinckrodt Medical BY (Petten, The 
Netherlands). fDTPA-D-Phe']octreotide was labelled with WIn as has been 
described elsewhere (2). Doses ranged from 1590 MBq to 4810 MBq '''In, which 
137 
Radiotherapy with l'''In-DTPA-D-PheIJoctreotide 
were coupled with amount. of lDTPA-D-Phe1joctreotide ranging from 10 to 120 
J.'g. The protocol of llllln-DTPA-D-Phe1joctreotide scintigraphy has been described 
previously (4). Radiotherapy with llllIn-DTPA-D-Phe1Joctreotide was applied after 
informed consent by the patient and approval by the medical ethics committee of 
our institution. 
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Figure 2. Results of various treatments, including radiotherapy with fllln-DTPA-
D-Phe1joctreotide, in a patient with a metastasized inoperable glucagonoma. From 
611990 to 5/1992 increasing doses of (not radiolabelled) octreotide (300 to 1500 
J.'g/day) were used and from 2/1992 to 111993 Interferon-a (3.1rf units three 
times/week). Because of persistent increase in size of tumour volume during this 
medical treatment, fllln-DTPA-D-PheIJoctreotide was administered from 6 to 
9/1992 (in 5 doses, total 15022 MBq) and in 2/1993 (2664 MBq) and 3/1993 
(2590 MBq). The use of octreotide had been stopped b~fore this radiotherapy. 
Tumour volume is volume of all abdominal tumours in cc, according to volume 
measurements of tumours found with whole abdominal CT scanning; glucagon and 
r-glutamyl traniferase are serum levels 
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Case 
The patient is a 55 years old female, who underwent two abdominal tumour 
operations in 1988 and 1989, including partial pancreatectomy, splenectomy and 
dissection of para-aortal lymph nodes. At the second operation liver metastases 
were not present. Histology showed a neuro-endocrine tumour with positive 
immuno-histochentistry for glucagon, pancreatic polypeptide, somatostatin, 
calcitonin, ACTH, gastrin and Carcino embryonic antigen. The patient had been 
referred to our hospital because of the demonstration of somatostatin receptors on 
the recurrent metastases according to octreotide scintigraphy. The patient never 
experienced signs or symptoms of a hormone producing neuro-endocrine tumour. 
Only elevated serum levels of glucagon were found. Since the excellent clinical 
condition of the patient at the time of referral, it was decided not to treat her with 
cytostatics. Treatment with increasing doses of octreotide was started. Eventually 
therapy with interferon-a was started. Since no antiproliferative effect was 
observed during this medical treatment, it was decided to investigate the effect of 
therapeutic doses of ['"In-DTPA-D-Phe'Joctreotide. Neither acute nor longterm 
side-effects, including on renal, pituitary and bone marrow functions, were 
observed up to half a year after the last administration of a radiotherapeutic dose of 
[ lHln-DTPA-D-Phe'Joctreotide (data not shown). Figure 2 illustrates the time 
schedules of treatments applied to this patient and their effects on tumour size and 
both glucagon and y-glutamyl transferase serum levels. Figures 3 - 5 show 
examples of CT scans related to time, and of J'"In-DTPA-D-Phe']octreotide 
scintigrams. It is evident that both the tumour load, glucagon and y-glutamyl 
transferase levels react benifically to radiotherapy. The decrease in glucagon levels 
is only transient. In accordance with the decline in y-glutamyl transferase levels 
the CT-scan of the liver shows a clear decrease in the size of liver metastases. 
Dosimetry of /"'In-DTPA-D-Phe'joctreotide accumulation 
Accumulation of [lHln-DTPA-D-Phe'Joctreotide in the organs with signifi-
cant uptake, i.e. liver and kidneys, and one selected abdominal tumour (mass ~ 
300 g) were calculated as described before (3). Because of the high radiotherapeu-
tic doses of ['"In-DTPA-D-Phe']octreotide that were given, it was possible to scan 
the patient over a long period. An example of the course of the radioactivity is 
given in Figure 6. The amount of radioactivity in the liver and the tumour showed 
a slow decrease (biological halHife > 700 h), whereas the radioactivity in the 
kidney has a biological half-life of about 270 h. A total of 20 GBq (550 mCi) 
l'"In-DTPA-D-Phe'Joctreotide was given intravenously in seven administrations 
(Figure 2). Because of the fact that the patient had a nephrostomy drain on the left 
side, only 35 % of the produced urine entered the bladder. The urine was not 
collected for measurements of radioactivity. For these reasons the dose to the 
urinary bladder was estimated using the results described previously (3). The thus 
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Figure 3. CT scanning of the here reported case with metastasized inoperable 
glucagonoma, views are .from two levels Qf the liver and related to time: row 1 = 
23 july 1990; row 2 = 3 june 1991; row 3 = 4 may 1992; row 4 = 17 december 
1992 and row 5 = 30 august 1993 
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estimated dose to the urinary bladder wall was 1.3 Gy. Using the MIRDOSE2-
program, the calculated doses on the liver and kidneys were 2.4 and 5 Gy, 
respectively (3). As the tumour had about the same mass as the kidneys (on the 
basis of the CT scans), and the radiation dose to the tumour is for more than 95% 
caused by the radioactivity in the tumour, the S-factor for the kidneys was used for 
the calculation of the dose on the tumour. The estimated apparent radiation dose to 
the tumour was 13 Gy. 
Figure 4. 
Planar r"'In-DTPA-
D- Phe' 1 oetreoti de 
scintigraphy of the 
here 
reponed case with 
metastasized inopera-
ble glucagonoma. 
Images a and bare 
anterior and posterior 
thoraei e-abdominal 
views, respectively. 
Note the many "hot"-
SpOTS at the various 
sites, representing 
metastases of the 
glueagonoma 
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Figure 5. 
Three-dimensional re-
presentation of the 
upper abdomen (pos-
terior views) of the 
here reponed case 
with metastasized 
inoperable glucago-
noma after injection 
with "'" Tc-colloid (a) 
and I"'ln-DTPII-D-
Phe'joctreotide (b). 
These scintigrams 
have been carried out 
bejore the second 
period of radiothera-
py with f"'fn -DTPA-
D-Phe' loctreotide. 
Note the large "cold" 
area in the upper part 
of the right lobe of 
the liver on the col-
loid scan and the 
presence of radioaeti-
vity in this area on 
the I"'ln-DTPII-D-
Phe'Joctreotide scan. 
This difference is 
explained by the 
presence of somatos-
tatin receptor expres-
sing tumour tissue. 
Furthermore, the 
I'" In-DTPA -D-Phe' -
Joctreotide image 
shows many "hot "-
spots at various sites. 
representing metasta-
ses of the glucagono-
ma 
6 ,---------------------------------------, 
5 
4 
2 
, 
, 
, 
, 
~----------------
o ~ __ J_ __ ~ __ ~ ____ L_ __ ~ __ ~ ____ L_ __ ~ __ ~ 
o 50 100 150 200 250 300 350 400 450 
h p,i. 
-- kidneys liver ----- tumor 
Figure 6. 1he percentage uptake in the kidneys, liver and abdominal tumour area 
after a treatment dose of /"'In-DTPA-D-Phc /octreotide as function of time after 
injection 
DISCUSSION 
Scintigraphy with 1'"In-DTPA-D-Phe'Joctreotide of the glucagonoma in our 
patient showed an intense accumulation of radioactivity in the tumour, indicating 
the expression of a high number of octreotide receptors, Despite the presence of 
octreotide receptors on the metastases, growth of the tumours continued during 
octreotide treatment, although a modest antiproliferative effect at an octreotide 
dose of 1500 I'g/day could not be excluded in retrospect. Also during treatment 
with the combination of a high dose of octreotide and interferon-a tumour volume 
continued to increase, Only after a cumulative dose of 20 GBq 1'"In-DTPA-D-
Phe' Joctreotide, a decrease in total tumour volume in the abdomen of about 20 
percent was observed, Furthermore, after both episodes (in 1992 and 1993) of 
[HIln-DTPA-D-Phe'joctreotide radiotherapy a (transient) decline in glucagon and y-
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glutamyl transferase serum levels was observed. Possibly, these changes in serum 
markers can be regarded as signs of an antiproliferative effect of the high doses of 
["'In-DTPA-D-Phe'joctreotide. Such an effect might be comparable to the decline 
in thyroglobulin levels, which is frequently observed after successful treatment 
with radioactive iodine for thyroid cancer. It is unlikely that the peptide of ["'In-
DTPA-D-Phe']octreotide itself induced this effect, because of the interval of 
several weeks between administration of radioligand and the collection of the 
serum sample for glucagon measurement. 
Intense and homogeneous di~tribution of somatostatin receptors On most 
glucagonomas is demonstrated by f"'I-Tyr'joctreotide autoradiography (not shown). 
Of course this is advantageous for peptide receptor therapy with f"'In-DTPA-D-
Phe'joctreotide and might partly explain its effect in this case. The apparent radi-
ation dose to the tumour (13 Gy) is calculated according to conventional dosime-
try. The application of conventional dosimetry is validated by the fact that the 
range of several of the ionizing particles emitted is much longer than the average 
tumour cell diameter. Because of the fact that "'In is also an Auger-electron 
emitter (range 0.02 - 10 I'm), the actual radiation dose may be much higher when 
the "'In-labelled pharmaceutical is internalized into the cell (Tables 1 and 2). The 
estimated apparent radiation dose to the tumour (assuming a tumour volume on the 
basis of the CT scan) with the performed radiotherapy with ['''In-DTPA-D-
Phe']octreotide is relatively low. It is tempting to speculate that the observed 
response to this radiotherapy (because of the abundance of Auger electrons with a 
very short particle range) indicates that the ['''In-DTPA-D-Phe'loctreotide is 
internalized into the tumour cell. In vitro tests will have to confirm this hypothesis. 
If f"'In-DTPA-D-Phe'joctreotide is not internalized, but only binds to its receptors 
at the plasma membrane with the observed long residence time, then it may be 
concluded that the contribution of the conversion electrons (with their longer 
particle range than the Auger electrons) to the radiotherapeutic effect of ['''In-
DTPA-D-Phe'loctreotide is more important. 
However, in general, '''In is not the most appropriate radionuclide for this 
objective, in asmuch as it lacks the preferable higher energies of a- and 6-parti-
cles. It is to be expected that the radiotherapeutic use of radionuclides with those 
higher energies, coupled to small peptides, leads to higher radiation doses and 
more appropriate particle ranges. Also tumours with an inhomogeneous distribution 
of peptide receptors may then respond in a favourable way to this kind of treat-
ment. '''Tb is one of the radionuclides, which is a candidate, because it emits 6-
particles and is able to bind to the chelator DTPA without dissociation in blood. 
Both peptide receptor scintigraphy and peptide receptor therapy with 
radiolabelled peptides(-derivatives), like hormones and growth factors, are at the 
moment in their infancy. Nevertheless, the body distribution of small radiolabelled 
peptides in humans and the results of scintigraphy with ['''In-DTPA-D-Phe'loctreo-
144 
tide are promising for peptide receptor scintigraphy and peptide receptor therapy . 
Peptide receptor scintigraphy might not only become a diagnostic localizing tool 
for most cancer types and their metastases, but it will also form the basis for 
peptide receptor therapy with radiolabelled peptides. In general, the kidneys are the 
most critical organs for radiotherapy with radio labelled peptides. Investigations are 
being performed to lower the renal accumulation of radioactivity by interrupting 
the tubular reabsorption of these radioligands by 1. infusion of amino acids, 
mainly lysine and arginine and 2. transient A TP lowering in renal tubular cells 
(8,9). Nevertheless, the tolerable radiation dose of the kidneys seems already to be 
relatively high (10,11). Furthermore, by decreasing the renal accumulation of 
radioactivity, the cumulative dose of radiolabelled peptides for peptide receptor 
therapy can be increased, thereby optimizing the ultimate radiation dose to the 
tumour(s). It is hoped that the latter can also be reached in the future by inducing 
an up-regulation of the receptor density. 
In conclusion, it is to be expected that the arsenal of treatment modalities in 
oncology in the near future will be extended by peptide receptor therapy using 
radiolabelled peptides (-derivatives), which are more or less derived from native 
substances. This contrasts to the larger mouse monoclonal antibodies (10,11), of 
which the application leads to a higher background radiation and also the forming 
of human anti-mouse antibodies if administered repeatedly (12). 
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ABSTRACT 
f'"ln-DTPA-D-Phe'joctreotide (OctreoScan") is a radiopharmaceutical that 
binds to the somatostatin receptor present in certain tissues. It is being used for 
scintigraphic imaging of somatostatin receptor-positive lesions, such as gastro-
intestinal pancreatic tumours, neuroblastoma, pheochromocytoma, breast cancer, 
Hodgkin's lymphoma and small cell lung cancer. New fields of application of 
radiolabelled somatostatin analogs are e.g. intraoperative scanning using gamma 
rays emitting radiolabelled somatostatin analogues and the potential use of radiola-
belled peptide for radiotherapy. However, for these two purposes, "'In will not be 
the radionuclide of first choice. While its characteristics are favourable for 
scintigraphy (gamma rays of 174 and 247 keV), they are not optimal for intraope-
rative scanning. This because of the high background radiation due to the relatively 
hard gamma rays emitted by '"In. Furthermore, for the second field of investigati-
on, radiotherapy, a beta rays emitting radionuclide is more suitable. The characte-
ristics of I6'Tb are quite ideal for intraoperative scanning: low gamma energy rays 
(with peaks around 46-48 and 74 key), and a half-life of nearly seven days. As for 
the potential use for radiotherapy, I6'Tb emits also hard beta rays. Therefore, the 
characteristics of fl6'Tb-DTPA-D-Phe']octreotide with respect to specific binding to 
somatostatin (octreotide) receptors on rat brain cortex membranes, biological 
activity, metabolism in isolated perfused rat livers and metabolism in vivo in 
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normal and tumour-bearing rats were determined and compared to those of I'''ln-
DTP A -D-Phe' loctreotide. 
It is concluded that based on the characteristics of "'Tb (low gamma energy 
rays with a half-life of nearly seven days, and hard beta rays) combined with the in 
vitro and in vivo studies performed with ,'''Tb-DTPA-D-Phe'joctreotide, the latter 
is a promising radiopharmaceutical for both intraoperative scanning and radiothera-
py. The latter in particular after inhibition of the renal tubular reabsorption 
process, to decrease the kidney dose during application. Further studies in patients 
need to be performed now to see if ,'''Tb-DTPA-D-Phe'joctreotide can indeed 
open new therapeutic applications for patients bearing octreotide receptor-positive 
tumours. 
INTRODUCTION 
,'''In-DTPA-D-Phe'joctreotide (OctreoScan@) is a radiopharmaceutical that 
binds to the somatostatin receptor present in certain tissues. It is being used for 
scintigraphic imaging of somatostatin receptor-positive lesions, such as gastro-
intestinal pancreatic tumours, neuroblastoma, pheochromocytoma, breast cancer, 
Hodgkin's lymphoma and small cell lung cancer (1, review). 
Since the availability of this and other radiolabelled somatostatin analogues 
for in-vivo imaging, the range of diagnostic applications under study is rapidly 
increasing. One example is the intraoperative scanning using gamma rays emitting 
radiolabelled somatostatin analogues. This technique is used to guide surgery with 
respect to the localisation of small somatostatin receptor-positive tumours using a 
small hand-held probe (2,3). Another field of application that is under examination 
is the potential use of radiolabelled peptide for radiotherapy. 
However, for these two purposes, '''In will not be the radionuclide of first 
choice. While its characteristics are favorable for scintigraphy (gamma rays of 174 
and 247 keY), they are not optimal for intraoperative scanning, because of the 
high background radiation due to the relatively hard gamma rays emitted by '" In. 
Furthermore, for radiotherapy a beta particles-emitting radionuclide is more 
suitable. 
We have now investigated whether IDTPA-D-Phe'loctreotide labelled with 
'''Tb is suitable for above-mentioned applications. The characteristics of "'Tb are 
quite ideal for intraoperative scanning: low energy gamma rays (with peaks around 
46-48 and 74 keY), and a half-life of nearly seven days. As for the potential use 
for radiotherapy, '''Tb emits also hard beta rays. Therefore, the characteristics of 
1"'Tb-DTPA-D-Phe'loctreotide with respect to specific binding to somatostatin 
(octreotide) receptors on rat brain cortex membranes, biological activity, metabo-
lism in isolated perfused rat livers and metabolism in vivo in normal and tumour-
bearing rats were determined and compared to those of l"'ln-DTPA-D-Phe'joctreo-
tide (4-6). 
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It appeared from our experiments that, like f"'In-DTPA-D-Phe'loctreotide, 
1'''Tb-DTPA-D-Phe'loctreotide was mostly cleared from the body via the kidneys. 
We found that in humans a significant amount of 1'''In-DTPA-D-Phe'Joctreotide 
accumulates in the renal parenchyma (about 7% dose, 4 h after injections), because 
of re-uptake by the tubular cells after glomerular filtration (7). This renal retention 
reduces both the scintigraphic sensitivity for detection of small tumours in the 
abdomen and the potential use of the radio labelled peptide for radiotherapy (8). 
Therefore, we recently performed studies to determine whether renal uptake of 
f'''In-DTPA-D-Phe'Joctreotide could be reduced by inhibiting tubular re-uptake in 
vivo in the rat (6). In the present study, we tested the effects of increased urinary 
flow, and administration of lysine (400 mg/kg) or of sodium maleate (400 mg/kg) 
on tubular reabsorption of ['''Tb-DTPA-D-Phe'Joctreotide in vivo in rats. 
We also investigated the influence of the labelling efficiency of [DTP A -D-
Phe'Joctreotide with '''Tb as well as of rat body weight (age) on organ distribution 
in rats. 
MATERIALS AND METHODS 
Radiolabelling and Quality Control of the Radiopharmaceutical 
fDTPA-D-Phe'loctreotide and "'TbCl, were obtained from Mallinckrodt 
Medical B.V. (Petten, The Netherlands). The radiolabelling was performed 
essentially as described for ["'In-DTPA-D-Phe'Joctreotide (4); except that 20 f.'g 
[DTPA-D-Phe'loctreotide instead of 10 f.'g and acetate instead of citrate buffer 
were used. Only when labelling efficiency was ~ 95%, the radiolabelled product 
was used for experiments, unless otherwise stated. The "'Tb was produced at the 
Free University in Brussels, Belgium, from irradiated ""Od. 
Highly purified and fatty acid free Bovine Serum Albumin (BSA; Boseral) 
was a product of Organon Teknika (Oss, The Netherlands). All other reagents 
were of the highest purity commercially available. 
In Vitro Receptor Binding Studies 
Receptor binding assays were carried out using 1"'Tb-DTPA-D-Phe'Joctreo-
tide as described previously for f'''In-DTPA-D-Phe'Joctreotide (4) using rat brain 
cortex membranes. Binding curves and Ie" for displacement of ["'Tb-DTPA-D-
Phe'loctreotide by unlabelled IDTPA-D-Phe'Joctreotide or f"'Tb-DTPA-D-
Phe'Joctreotide were calculated using the computer fitting program of Oraphpad 
(lSI software, Philadelphia, Pa., USA). 
Biological Activity 
The biological activity of 1'''Tb-DTPA-D-Phe'Joctreotide was assessed by 
measuring its potency to inhibit the secretion of rat growth hormone (rOH) from 
rat pituitary cells as described previously (4). 
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Lwlated Perjitsed Rat Liver Studies 
Livers of male Wistar rats (200-250 g body weight) were isolated and per-
fused in a recirculating system at 37 "C as described previously (9). The magneti-
cally stirred perfusion medium used in all experiments was 150 mL Krebs-Ringer 
buffer (118 mM NaC!, 5 mM Kc!, 1.1 mM MgSO" 2.5 mM CaCl" 1.2 mM 
KH,PO" and 25 mM NaHCO,) supplemented with 10 mM glucose and 1 % BSA. 
The pH of the medium was maintained at 7.43 by gassing with carbogen (95 % 
CO, and 5 % 0" 400 mUmin). The function of the liver was monitored by its 
outer appearance, measurement of hydrostatic pressure necessary to maintain a 
perfusion medium flow of 40 mUmin, bile flow, and pH of the perfusion medi-
um. Livers were preperfused for 30 min. The experiment was started by addition 
of 370 kBq of tracer to the stirred medium in the central reservoir. Subsequently, 
0.5 mL medium samples were taken at I, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 
30, 40, 50 and 60 min from a smaller medium reservoir, the height of which 
determines the hydrostatic pressure. Bile samples were collected during 10 min 
intervals. The samples were stored at - 20 "C until analysis. The chemical status of 
the radionuclide in medium and bile samples was analysed as a function of time 
using ITLC in 1 M acetic acid (PH 5). 
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Figure lA. Binding of ['''Th-DTPA-D-Phe'Joctreotide to rat brain conex membra-
nes in the presence of increasing concentrations of DTPA-octreotide (AJ or l"'Th-
DTPA-D-Pheloctreotide (*J, expressed as the percentage of binding in the absence 
of competing compound 
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Tissue Distribution and Specific Binding of /'''Tb-DTPA-D-Phe'Joctreotide in 
Normal and Tumour-bearing Rats 
Normal male Wistar or Lewis rats or tumour-bearing male Lewis rats (200-
250 g, unless otherwise stated) were placed in metabolic cages 24 h prior to the 
experiment. Tumour rats carried the transplantable rat pancreatic tumour CA20-
948, which has previously been shown to possess somatostatin receptors (10), in 
both upper hind legs. Metabolic cages were used to collect all (radioactive) urine 
produced during the experiment to follow the urinary clearance of the radioactive 
compound. The rats were fed with normal rat chow (Hope Farms, Woerden, The 
Netherlands) or with 35 g/day of rat chow suspended in water (40 gram pellets in 
100 mL water). Drinking water was always available ad lib. At t ~ Oh, rats were 
injected with 0.2 MBq (0.5 I'g) ["'Tb-DTPA-D-Phe'joctreotide into the dorsal vein 
of the penis (injected volume 200 I'L) during ether anaesthesia. The radioactivity 
was measured in a dose calibrator (VDC-202, Veenstra, loure, The Netherlands). 
In order to determine non-specific binding of the radiopharmaceutical, rats 
were injected subcutaneously with 0.5 mg octreotide in I mL 0.05 M acetic acid in 
154 mmol!L NaC!, 40 min before injection of ['''Tb-DTPA-D-Phe' loctreotide. 
Twenty h after il\jection of the radiolabelled product, rats were sacrificed and 
organs were isolated from the rats and subsequently analyzed. The tissue distributi-
on of the '''Tb-Iabelled somatostatin analogue was studied by measurement of 
radioactivity in isolated organs as well as of blood samples, using a LKB-1282-
Compu-gammasystem. 
Possible Renal Re-uptake Blockers Tested 
Lysine (400 mg/kg) and sodium maleate (400 mg/kg) were administered 
intravenously to the rats at physiological pH in volumes of 200 I'L immediately 
before I '''Tb-DTP A -D-Phe 'joctreotide injection. 
Statistical Analysis 
Results are expressed as mean ± SD of groups of at least 3 rats. Statistical 
evaluation was performed using one way analysis of variance followed by compari-
son among class means and Student's t-test, corrected for multiple pairwise 
comparisons between means. 
RESULTS 
In Vitro Receptor Binding Studies 
Rat brain cortex membranes were used to study the binding of 1"'Tb-DTPA-D-
Phe'joctreotide to octreotide receptors in the presence of increasing amounts of 
["'Tb-DTPA-D-Phe'joctreotide or unlabelled IDTPA-D-Phe'joctreotide (Figure 
lA). The binding of ['''Tb-DTPA-D-Phe'joctreotide decreased in the presence of 
increasing concentrations of both compounds, indicating that the binding process 
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was saturable and speeine. It is also shown that [DTPA-D-Phe'Joetreotide compe-
tes somewhat better than r"'Tb-DTPA-D-Phe']oetreotide. The Ie" values appeared 
to be in the nanomolar range, similar to that found for ["'In-DTPA-D-Phe']oetreo-
tide (4). 
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Figure lB. Effects of [DTPA-D-Phijoctreotide (0) and of f"Th-DTPA-D-Phe'J-
octreotide (4O) on secretion of rGHfrom cultured rat pituitary cells 
Biological Activity 
Figure IB shows the effects of IDTPA-D-Phe']octreotide and of [,"Tb-DTPA-
D-Phe'loetreotide on the secretion of rGH by cultured rat pituitary cells. The 
radiolabelled somatostatin analogue signincantly inhibited rGH secretion in a dose-
dependent manner, similar to 1"'In-DTPA-D-Phe'loctreotide (4). 
Isolated Peifused Rat Liver Studies 
In Table I is shown that after I h perfusion of isolated rat livers with [''' In-
DTPA-D-Phe']octreotide, 2.2 % of the dose was excreted in the bile, 1.7 % was 
present in the liver, whereas 95 % was still present in the perfusion medium. The 
data obtained with 1"'Tb-DTPA-D-Phe']octreotide show even less liver clearance: 
after 60 min of perfusion, only 0.09 % was excreted in the bile, and 1.4 % was 
present in the liver. 
152 
Table 1. Peptide-bound radioactivity (PBR) and non-peptide-bound radioactivity 
(NPBR), expressed as % dose, in perfUsion medium and bile after 60 min of 
perfUsion with /"%-DTPA-D-Phr!loctreotide (In-oc) or t"Tb-DTPA-D-Phe'l-
octretide (Tb-oc). TR ~ total radioactivity in % dose 
PBR (medi- NPBR PBR NPBR TR 
urn) (medium) (bile) (bile) (liver) 
In-oc 94.9 ± 0.8 0.9 ± 0.1 2.2 ± 0.2 0.2 ± 0.0 1.7 ± 0.2 
Tb-oc 99.6± 1.2* <0.1* 0.09 ± 0.0* <0.1* 1.4 ± 0.1 
* P<O.OOl versus r'In-DTPA-D-Phe'/octreotide 
Table 2A. Distribution of 0.2 MBq (0.5 M) /"'In-DTPA-D-Phe'joctreotide and 
/"'Tb-DTPA-D-Phe'joctreotide in several organs of control rats, expressed as % 
injected dose per g tissue, 20 h after administration 
Organ I "'In-DTPA-D-Phe'j- ['''Tb-DTPA-D-Phe'j-
octreotide octreotide 
blood 0.002 ± 0.0003 0.0004 ± 0.0001 * 
kidneys 1.52 ± 0.15 1.51 ± 0.11 
liver 0.061 ± 0.012 0.\3 ± 0.01 * 
pancreas 0.52 ± 0.12 0.23 ± 0.03 * 
spleen 0.03 ± 0.005 0.02 ± 0.001 * 
adrenals 0.76 ± 0.10 0.184 ± 0.02 * 
* P<O.OOl versus I'''ln-DTPA-D-Phe'joctreotide 
Tissue Distribution and Specific Binding of /"'Tb-DTPA-D-Phe'joctreotide in 
Normal and Tumour-bearing Rats in Vivo 
In Table 2 organ distribution of ['61Tb-DTPA-D-Phe'joctreotide and ['''In-
DTPA-D-Phe'Joctreotide in normal rats are shown, expressed as % of the injected 
dose (ID), 20 h after administration. It was found that there were no significant 
differences in Lewis or Wistar rats with regard to distribution of [16'Tb-DTPA-D-
Phe'joctreotide (not shown). 116'Tb-DTPA-D-Phe'joctreotide is cleared even faster 
from the blood than ["'In-DTPA-D-Phe'joctreotide: 20 h after injection only 
0.0004 % ID was found in the blood (P<O.OOI versus 1'''In-DTPA-D-Phe'joctreo-
tide). Kidney uptake of 1'61Tb-DTPA-D-Phe'joctreotide and 1"'ln-DTPA-D-
Phe'joctreotide was similarly high (1.5 % ID). Liver uptake of L16'Tb-DTPA-D-
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Phe'loctreotide was higher than that of I'"ln-DTPA-D-Phe'joctreotide (P<O.OOl), 
whereas the reverse was true for spleen, pancreas, and adrenals (P< 0.001), the 
latter two organs possessing octreotide receptors. In Table 2B is shown that uptake 
of [J6'Tb-DTPA-D-Phe'joctreotide and I'llln-DTPA-D-Phe'joctreotide in pancreas 
and adrenals represents mostly specific binding to the octreotide receptors, as 
uptake in these organs was decreased almost completely (P< 0.001) by pretreat-
ment of the rats with 0.5 mg unlabelled octreotide. 
kidneys 
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Figure 2. Organ distribution of radioactivity [with (octreotide) or without (control) 
40 min pretreatment with 0.5 mg unlabelled octreotidel in tumour-bearing rats, 20 
h after administration of [,61Tb-DTPA-D-Phe'loctreotide 
In Figure 2 organ distribution of ["'Tb-DTPA-D-Phe'joctreotide, with or 
without pretreatment with unlabelled octreotide, is depicted in tumour-bearing rats 
20 h after administration of ["'Tb-DTPA-D-Phe'joctreotide. The distribution in the 
tumour-bearing rats is the same as that seen in normal rats (Table 2A). Uptake in 
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colon, adrenals, pancreas, pitUitary, and tnmours appeared to represent mostly 
specific binding to octreotide receptors, as a major decrease was observed after 
pretreatment with unlabelled octreotide (P<O.OOI). 
Table 2B. Effect qf pretreatment (40 min) with 0.5 mg unlabelled octreotide on 
distribution of !'''Tb-DTPA-D-Phe'/octreotide and {'''In-DTPA-D-Phe'/octreotide in 
pancreas and adrenals (organs containing somatostatin receptors) of normal rats, 
expressed as % of control (= same tracer without pretreatment with unlabelled 
octreotide, see Table lA) 
Organ 
pancreas 
adtenals 
I' "In-DTPA-D-Phe' 1-
octreotide 
1.92 ± 0.20 % 
1.63 ± 0.22 % 
* P < O. 001 versus control 
* 
* 
Influence of Renal Re-uptake Blockers 
1 '''Tb-DTPA-D-Phe']-
octreotide 
4.34 ± 0.18 % 
4.52 ± 0.84 % 
* 
* 
In Figure 3 organ distribution of 1'''Tb-DTPA-D-Phe'loctreotide, 20 h after 
adntinistration, is shown in the presence or absence of lysine (400 mg/kg) or 
sodium maleate (400 mg/kg), both potent blockers of the renal reabsorption 
process of ['''In-DTPA-D-Phe'loctreotide in the proximal tubuli (6). Also for 
["'Tb-DTPA-D-Phe'loctteotide kidney uptake is inhibited significantly by both 
lysine and sodium maleate, the latter being about twice as potent as the former, 
showing that also ['''Tb-DTPA-D-Phe']octreotide is reabsorbed into the proximal 
tnbular cells of the kidney after glomerular filtration. After adntinistration of 
lysine, uptake of label in all other organs is not different from the control situati-
on, whereas after sodium maleate administration uptake of 1 '''Tb-DTPA-D-
Phe')octreotide is significantly increased compared to control (P< 0.001). 
In Figure 4, the influence of urinary flow on tnbular re-absorption of ["'Tb-
DTPA-D-Phe']octreotide is depicted. It is shown that rats that eat dry rat cbow 
(points on the left in the Figure) produce less urine (range 5.1-7.5 mL/20h) than 
rats that eat food suspended in water (points on the right in the Figure; range 12.8-
23.1 mL/20 h). However, this increase in urine production on the day of the 
experiment did not influence the amount of radioactivity in the kidneys. This was 
also true when the increase in urine production was induced by change in diet 
already 48 h before the start of the experiment (not shown). 
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kidneys 
conlr male .. te Iys 
coni. maleat .. 
Figure 3. Il!fluence of sodium maleate (400 mg/kg) or lysine (lys; 400 mg/kg) on 
organ distribution of radioactivity in control rats, 20 h qfter administration of 
['''Tb-DTPA-D-Phe1/octreotide. * P<O.OOI versus control 
Il!fl.uence of Labelling Efficiency on Organ Distribution of ['''Tb-DTPA-D-Phe' /oc-
treotide 
In Figure 5 is shown Ihat a maximal labelling efficiency is very important to 
reach an optimal organ distribution of [161Tb-DTPA-D-Phe l loctreotide. 100 % 
labelling efficiency means Ihat all radioactivity administered to Ihe rats was in Ihe 
form of j16Tb-DTPA-D-PheIJoctreotide, whereas 0 % means Ihat it consisted of 
161TbC13, in Ihe absence of [DTPA-D-Phejoctreotide. For organs not possessing 
octreotide receptors, such as liver, spleen, femur, and muscle Ihe uptake increased 
significantly wiIh decreasing labelling efficiency (P< 0.001 versus 100 % label-
ling). In Ihe kidneys, uptake is about Ihe same for all situations, showing Ihat Ihe 
Tb not bound to octreotide is taken up with about the same efficiency as [16ITb_ 
DTPA-D-PheIJoctreotide. However, for octreotide receptor-possessing organs, such 
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as pancreas, adrenal, and pituitary, it holds that a decrease in labelling efficiency 
resulted in a significant decrease of uptake of ['61Tb-DTPA-D-Phe'Joctreotide in 
these organs. 
% ID/g kidney 
2,------- ---------
• 
-1.5 
• 
0.5 
• '10 • • • 
ml urine/20 h 
-. 
• 
93% 37% 
• 
0% 
0% 
labelling efficiency of octreotide 
Figure 4. 
Influence of urinary 
flow during the expe-
riment on kidney 
uptake of radioacti-
vity in control rats, 
20 h after administ-
ration of /'''Tb-
DTPA-D-Phe'j-
octreotide 
1. liver 
* 
muscle 
NO ND 
Figure 5. Influence qf labelling efficiency qf !"'Tb-DTPA-D-Pht! /octreotide on 
organ distribution in control rats, 20 h after administration qf radiopharmaceuti-
cal; * P<O.OOl versus control; ND=not determined 
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Il?fluence of Body Weight on Organ Distribution of I'''lb-DTPA-D-Phe'loctreotide 
In Figure 6 the influence of body weight on organ distribution of ["'Tb-DTPA-
D-Phe'Joctreotide is shown, 20 h after administration. Three groups of rats with 
body weight' of 360, 200 and 120 g were tested. It is shown that no significant 
differences were found in uptake of I '''Tb-DTPA-D-Phe'Joctreotide, expressed as 
% ID/g tissue, between the 3 groups with regard to liver, kidneys and spleen, 
organs that do not possess octreotide receptors. However, in pancreas and adrenals 
a significantly lower uptake was found in the 360 g group compared to the control 
group (~ 200 g body weight). 
Q) 
::J 
(J) 
(J) 
.'" 
Q) 
o 
body weight (g) 
Figure 6. Influence of rat body weight on organ distribution of radioactivity in 
control rats, 20 h after administration of l"'lb-DTPA-D-Phe'Joctreotide; 
* P<O.OOI versus control (~ 200 g-group) 
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DISCUSSION 
The results of the binding studies demonstrate that f"'Tb-DTPA-D-Phe']octreo-
tide is a high affinity radioligand for somatostatin receptors, with an affinity 
comparable to that of ['''In-DTPA-D-Phe'joctreotide (4). This was also demonstra-
ted in the in vivo experiments in control and tumour-bearing rats after injection of 
['''Tb-DTPA-D-Phe']octreotide, in which uptake and specific binding in somatosta-
tin receptor-positive tissues and tumour were found. Somatostatin receptors are 
structurally related integral membrane glycoproteins. Recently, five different 
human somatostatin receptor types have been cloned. All subtypes bind native 
somatostatin-14 (SS,,) and SS" (pro-somatostatin with 28 aminoacids) with high 
affinity, while their affinity for numerous somatostatin analogues differ considera-
bly (11-14). Octreotide binds with high affinity to the SSTR2 (somatostatin 
receptor type 2) subtype, while this analogue has a relatively low affinity for 
SSTR3 and SSTR5 and shows no binding to SSTR subtypes 1 and 4 (1l-14). 
Octreotide scintigraphy is therefore based on the visualization of octreotide-binding 
somatostatin receptors (octreotide receptors), most probably the SSTR2. 
Rat growth hormone secretion inhibition experiments showed that ["'Tb-
DTPA-D-Phe'joctreotide has a similar potency as [HlIn-DTPA-D-Phe'[octreotide 
(4). 
The perfused rat liver is very suitable to investigate several parameters of liver 
metabolism, such as the disappearance from the perfusion medium, appearance of 
degradation products and biliary excretion. ['''Tb-DTPA-D-Phe'Joctreotide is taken 
up even less by the isolated perfused rat liver than fHlln-DTPA-D-Phe']octreotide 
as almost no tracer disappears from the perfusion medium. Furthermore, hardly 
any radioactivity is found in the liver, and excretion into the bile is negligible. In 
order to find a tumour by intraoperative scanning in vivo, the specific activity 
expressed in counts per unit of area must exceed the local background radiation. 
As ["'Tb-DTPA-D-Phe']octreotide is not cleared via the liver and thus causes no 
accumulation of radioactivity in biliary and digestive tract, this radiopharmaceutical 
would thus be suitable for scanning of tumour receptor accumulation in the upper 
abdominal region, where many of the small endocrine gastro-entero-pancreatic 
target tumours are located. 
However, the in vivo liver uptake is not in agreement with the liver perfusion 
studies; in vivo we fmd a higher liver uptake of ["'Tb-DTPA-D-Phe']octreotide 
than of f"'ln-DTPA-D-Phe'[octreotide 20 h after administration. At the moment, 
the reason for this discrepancy between in vivo and in vitro findings is not clear; it 
is possible that f"'Tb-DTPA-D-Phe'[octreotide after in vivo administration is less 
stable than f"'ln-DTPA-D-Phe'loctreotide, and that degradation products of ["'Tb-
DTPA-D-Phe'Joctreotide cause the higher liver uptake as found in vivo, in 
agreement with our findings that liver uptake of f'''Tb-DTPA-D-Phe'joctreotide 
increased when the labelling efficiency was suboptimal (Figure 5). 
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Our findings in Table 2A show that for octreotide receptor-positive organs, 
such as pancreas and adrenals, uptake of ['''Tb-DTPA-D-Phe'loctreotide is lower 
than that of I'JJln-DTPA-D-Phe'Joctreotide. However, as the clearance from the 
blood of the former compound is faster than that of the latter, tissue/blood ratio is 
higher in the case of rJ6'Tb-DTPA-D-Phe']octreotide than with I'JJIn-DTPA-D-
Phe'!octreotide. In the case of tumours this is a favourable situation for intraopera-
tive scanning. 
As for the high uptake in the kidneys: small peptides in the blood plasma are 
filtered through the glomerular capillaries in the kidneys and subsequently reabsor-
bed almost completely (~ 90 %) by the proximal tubular cells by carrier-mediated 
endocytosis. This is also the case for the radiolabelled octapeptides r'JJln-DTPA-D-
Phe'loctreotide and rJ6'Tb-DTPA-D-Phe']octreotide. After the subsequent degradati-
on process that takes place in the Iysosomes of the tubular cells, their labelled 
degradation products are "trapped" in the Iysozomes (15), causing a high dose of 
radioactivity in the kidneys. This study in vivo in rats demonstrates that the uptake 
of rJ6'Tb-DTPA-D-Phe'loctreotide by the renal tubular cells after glomerular 
filtration can be reduced by administration of lysine or sodium maleate, in favour 
of the potential use of the radiolabelled peptide for radiotherapy. As for lysine, the 
membranes of renal tubular cells contain negatively charged sites, to which 
positively charged residues of peptides or proteins are thought to bind (16). An 
inhibition of this binding process may explain the effects by administration of the 
positively charged antino acid lysine on I'JJIn-DTPA-D-Phe']octreotide re-uptake 
(6,17,18). 
The most pronounced effect on tubular re-uptake of r'6JTb-DTPA-D-Phe'Joctre-
otide in this study was exerted by sodium maleate (Figure 3). Sodium maleate has 
been used to create and study renal tubular dysfunction comparable to the human 
Fanconi's syndrome (19,20), resulting in aminoaciduria and proteinuria. This 
compound forms maleyl-CoA by reacting with succinyl-CoA, thereby reducing the 
cellular CoA supply and inhibiting the citric acid cycle in tubular cells (21). The 
resulting reduced ATP supply or the reaction of the maleyl-CoA with membrane 
proteins may inhibit a variety of renal transport systems, including peptide re-
absorption (21). The inhibitory effect of sodium maleate, as found in this study, 
thus indicates that the re-absorption process of r16'Tb-DTPA-D-Phe']octreotide into 
the renal tubular cells is energy dependent. The increase of the uptake of r'6JTb-
DTPA-D-Phe']octreotide in all organs by sodium maleate (except for the kidneys), 
as shown in Figure 3, may be explained by the inhibitory effect of this compound 
on the renal glomerular filtration rate (22). 
Increase in urine production before and during the experiment had no effect on 
the kidney uptake of [16'Tb-DTPA-D-Phe'loctreotide (Figure 4). The increase in 
urine production was induced by feeding the rats with chow suspended in water. 
However, re-uptake of peptides in the renal tubules is not influenced by an 
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increased urinary flow through the kidneys. The results found here for ['61Tb_ 
DTPA-D-Phe'Joctreotide are in agreement with those for [IIIIn-DTPA-D-PheIJoc-
treotide (6). 
Figure 5 shows that a maximal labelling efficiency of 116ITb-DTPA-D-Phe'Joc-
treotide is essential, as with decreasing efficiency the uptake in the octreotide 
receptor-positive organs decreases, whereas non-specific uptake in the other organs 
is increased. Even when labelling efficiency was 93 %, the effects on organ 
distribution were significantly different (P<O.ool) compared with 100 % labelling 
efficiency. This decreased specific binding in combination with increased non-
specific binding is of course very unfavourable for both intraoperative scanning 
and radiotherapy. 
At last, the effect of rat body weight on [I6ITb-DTPA-D-Phe
'
Joctreotide organ 
distribution is shown (Figure 6). As rats gain weight during their whole life, 
increase in body weight is paralleled by an increase in age and development. Since 
the same dose of [16ITb-DTPA-D-Phe']octreotide was administered to the different 
groups [with widely different distribution volumes], it is not surprising that uptake 
in all organs studied is highest in the low-body weight rats, while uptake is lowest 
is the high-body weight animals. However, for adrenals and pancreas, both 
octreotide receptor-positive organs, the decrease in uptake in the 360 g group was 
much more pronounced than in the octreotide receptor-negative organs. This 
finding may point to developmental changes in expression of the octreotide 
receptor in these organs, as was found for other somatostatin receptor-positive 
organs, such as the rat brain and the rat visual system (23,24). 
In conclusion: based on the characteristics of 16ITb (low energy gamma rays 
with a half-life of nearly seven days, and hard beta rays) combined with the in 
vitro binding studies, biological activity, and in vivo organ distribution of ['61Tb_ 
DTPA-D-Phe']octreotide, the latter is a promising radiopharmaceutical for both 
intraoperative scanning and radiotherapy, the latter in particular after inhibition of 
the renal tubular reabsorption process, to decrease the kidney dose during applicati-
on. Further studies in patients need to be performed now to see if [I6Tb-DTPA-D-
Phe'Joctreotide can indeed open new therapeutic applications for patients bearing 
octreotide receptor-positive tumours. 
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ABSTRACT 
Radiolabelled peptides are useful for scintigraphy of tumours contammg 
receptors for these compounds. Beta-emitting radionuclides coupled to peptides 
may be used in radiotherapeutical treatment of such tumours. 13>1 is suggested to be 
suitable for that purpose. This study deals with (a) the possibilities of radioiodinati-
on of peptides using two somatostatin analogues, fTyr'loctreotide and fDTPA-D-
Phe'jRC-160, (b) the required separations after radioiodination, and (c) the 
influence of high beta fluxes from 1311 on a peptide during radioiodination and 
purification steps. 
Based on regular therapeutic doses of "II in cancer treatment and previous 
experience with f'IlIn-DTPA-D-Phe'joctreotide, a minimal effective therapeutic 
dose of 3.7 GBq (38 nmol) "II must be coupled to a maximum of = 67 nmol 
peptide (= 100 p.g fDTPA-D-Phe'Joctreotide), representing a slight excess of 
peptide over 1311. 
After radioiodination at low and high molar peptide:iodide ratios the wanted 
radioiodinated peptide must be isolated from unwanted di-iodinated peptide and 
umeacted peptide, respectively, as well as from unreacted iodide. Radiolysis by 
high beta fluxes during labelling and separation steps was simulated by irradiating 
30 p.g fDTPA-D-Phe'joctreotide (Fig. 1) by 370 MBq 1311 in a small volume at 
about 30 % of the beta flux in the proposed real therapeutic dose. During one h 
the radiation absorbed dose amounted to 130 Gy. Irradiations were performed from 
30 min till 24 h. Afterwards, the composition of the incubation mixture was 
investigated by HPLC. In the irradiation experiments IDTPA-D-Phe'joctreotide 
was degraded rapidly (with a half-life of one h) under these conditions. Therefore, 
during separation steps the peptide will be degraded even faster under the conditi-
ons for preparation of a real therapeutic dose (3.7 GBq coupled to 67 nmol 
peptide). 
In conclusion, intact mono-iodinated "II-labelled peptides will be very hard to 
obtain in radiotherapeutic amounts. Direct labelling of the optimal amount of 
165 
Peptides for Radionuclide Therapy 
peptide containing a chelating group such as DTPA with a pure short-lived beta-
emitting radiometal (e.g. "Y) will be more convenient. Such one-step labelling can 
be performed in the presence of a suitable radiation quencher, without need of 
further radiochemical separations. 
[Tyr'loctreotide 
I 
D-Phe-Cys-Phe-D-Trp-L ys-Thr-Cys-Thr( 01) 
['" In-DTPA-D-Phe' JRC-160 
I I 
,uIn-DTPA-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2 
eU In-DTP A -D-Phe']octreotide 
I I 
"'In-DTP A -D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr( 01) 
Figure 1. Structural fonnulae of {l'yr/octreotide, fDTPA-D-Phe1JRC-160, and 
[DTPA-D-Phe1/octreotide 
INTRODUCTION 
Recently, growing attention has been paid to scintigraphic detection and 
visualization of various processes containing receptors for peptide hormones by the 
application of radiolabelled analogues of these hormones. Besides l"'I-Tyr'l-
octretide, nowadays ['UIn-DTPA-D-Phe'Joctreotide (known as Octreoscan 111®) is 
extensively used for scintigraphy of somatostatin receptor-positive tumours (1-3). 
Furthermore, an increasing number of publications report on application of other 
radioactive peptides for scintigraphic demonstration of various processes (4-9). It is 
tempting to presume that such peptides, in case of high tumour accumulation, may 
also be used for radionuclide therapy, such as "'I-iodide in the treatment of thyroid 
cancer and "'I-MIBG for therapy of neuroblastoma and phaeochromocytoma. 
Obviously, "'I has been proposed for labelling somatostatin analogues for 
radionuclide therapy of somatostatin receptor-positive tumours (10, 11). Assuming 
similar tumour accumulations and residence times, radionuclide receptor therapy 
with "'I-labelled peptides will require similar doses as being used in "'I-iodide (12) 
and "'I-MIBG therapy (13). Furthermore, usually only a limited amount of a 
bioactive peptide hormone can be administered without side-effects, which may 
become a limiting factor in the coupling of a therapeutic amount of radionuclide to 
such a peptide. Based on our experience with ['UIn-DTPA-D-Phe'Joctreotide (14, 
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15), it was estimated that an effective therapeutic dose of = 3.7 GBq (38 nmol) 
"'I had to be coupled to = 100 I'g of a = 1.5 kD somatostatin analogue (67 
nmol), i.e. nearly a 2-fold excess of peptide over radionuclide. Comparing the 
molar compound:radionuclide ratios of several regular therapeutic radiopharmaceu-
ticals, it is remarkable that the compound is always present in a large excess over 
radionuelide (Table I), even in radioiodinated monoclonal antibodies, taking into 
account that in each antibody molecule many potential iodine-accepting tyrosine 
residues are present. Compared with peptide receptor radionuelide therapy of 
endocrine tumours, other kinds of radionuclide therapy are mostly based on 
different accumulation mechanisms which are less limited by the mass of the 
radiopharmaceutical administered. As described before (16), radioiodination of 
fTyr'Joctreotide using a small excess of peptide over radionuelide resulted in a 
considerable amount of di-iodinated ITyr'joctreotide, which is unfavourable as this 
compound does not bind well to the somatostatin receptor (17). Because of the 
expected formation of di-iodinated compounds in "therapeutic" reaction mixtures of 
tyrosine-containing peptides, radiolabelling of two somatostatin analogues, 
[Tyr'joctreotide and IDTPA-D-Phe'JRC-160 (Fig. I) at different molar peptide:nu-
elide ratios was investigated by HPLC. "'I was used as a model for "'I, because of 
its well-characterized specific radioactivity. In contrast to '''I, the specific radioac-
tivity of "'I reaches the theoretical value (Table 2) due to its complete different 
production process, which means that no other iodine isotopes compete with the 
labelling. 
During the necessary HPLC and/or SEP-PAK purification steps after labelling 
on a therapeutic scale with "'I, high beta fluxes within small volumes are origina-
ted. Therefore, radiolytic effects under such circumstances were simulated by 
exposing small amounts of peptide in a small volume to '" I-beta radiation during 
various time intervals. Afterwards, the reaction mixtures were investigated by 
HPLC. 
MATERIALS AND METHODS 
Peptides 
[Tyr'joctreotide, [DTPA-D-Phe'Joctreotide and [DTPA-D-Phe'JRC-160 were 
obtained from Sandoz (Basle, Switzerland), Mallinckrodt Medical (petten, The 
Netherlands) and Sanbio (Uden, The Netherlands) respectively. 
Quality Control of Unlabelled Peptides 
The original peptides were analyzed by reversed phase, high performance liquid 
chromatography (HPLC) with a Waters 600 E multisolvent delivery system 
connected to a I'Bondapak C" reversed-phase column (300 x 3.9 mm, particle size 
10 I'm) with UV detection (254 nm). Elution was carried out at a flow of I 
mLimin with a linear !,'fadient of 40 % to 80 % (v/v) methanol in 50 mM Na-
acetate buffer (pH 5.5) in 20 min and the latter composition was maintained 
another 5 min. 
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Radioiodination of Peptides and Quality Control of Radioiodinated Peptides 
Both peptides were radioiodinated with '251 as described before (16). The 
peptides were radioiodinated under different molar peptide:radionuclide ratios. 
[Tyr']octreotide (4.3 I"g to 105 fig) was labelled with 1251 (92.5 to 370 MBq) 
corresponding to molar peptide:radionuclide ratios from 1.7 to 43. [DTPA-D-
Phe']RC-160 (1.3 I"g to 1251"g) was labelled with '251 (37 to 370 MBq) at molar 
peptide:radionuclide ratios from 1.7 to 31. 
After radiolabelling, the peptide components in the reaction mixture were 
isolated on a SEP-PAK C" reversed-phase extraction cartridge as described before 
(16), and analyzed with the HLPC-system described above. Eluted radioactivity 
was monitored on-line using a NaI probe connected to a Canberra single channel 
analyzer with a recorder. Collected fractions were measured by routine scintillation 
ounting. If the elution pattern of the radiolabelled peptide consisted of more than 
one peak, isolated peaks were concentrated and reilljected into the HPLC-system. 
Table I. Molar ligand:radionuclide ratios in therapeutic radio pharmaceuticals 
treatment of radionuclide compound excess of 
[radioactivity and [mass] compound 
mass] over 
radionuclide 
neuroblas- 1311 MIBG 
toma 3700 MBq 3.3 mg 
3.8 x 10"' mol 8 x 10"' mol 210 
various 1311 MoAb 
malignancies 3700 MBq 20mg 
3.8 x 10.8 mol I. 3 x 10·' mol 3.4 
MoAb-fragment 
20 mg 
4.0 x 10·' mol 11 
goy MoAb 
3700 MBq 20 mg 
2.1 x 10.9 mol 1.3 x 10·' mol 60 
MoAb-
fragment 
20 mg 
4.0 x 10·' mol 190 
168 
endocrine lilIn DTP A -octreotide 
tumours 3700 MBq 100 p,g 
2.2 x 10·' mol 6.7 x 10·' mol 30 
1311 peptide 
3700 MBq 100 p,g 
3.8 x 10·' mol 6.7 x 10·' mol l.75 
Simulation of Radiolysis Qf Peptides during Purijicalion Steps 
To simulate the consequences of the effect of high beta nuxes emanating from 
therapeutic amounts of "'Ion microgram amounts of peptide during the mandatory 
purification steps, a well defined amount (370 MBq) of '''I was incubated for 30 
min to 24 h at room temperature with 30 p,g [DTPA-D-Phe'Joctreotide in a small 
polyethylene cup (reaction volume 317 p,L). In I h the radiation absorbed in the 
reaction volume amounted to 130 Gy. Radiolysis under these circumstances was 
investigated by HPLC with UV detection at 254 nm. 
m 
m m 
d 
d 
d 
A B c 
Figure 2. Typical HPLC elution pallerns of the reaction mixlUres after radioiodi-
nation Qf /TyrJoctreotide III three different molar peptide:radionuclide ratios: 43 
(A). 3.5 (B), and 1.7 (C), measured by on-line gamma-counting. 
m = mono-iodinated peptide; d = di-iodinated peptide 
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RESULTS 
Peptide Composition bejore and after Radioiodination 
The HPLC-elution pattern (measured at uv 254 nm) of [Tyrjoctreotide showed 
one peak (data not shown), while those of [DTPA-D-Phe'jRC-160 and [DTPA-D-
Phe'Joctreotide consisted of 3 peaks (data not shown), corresponding to data of the 
manufacturers. 
Peptide radiolabeIIing yields amounted from 31 % to 93 % as measured by 
SEP-PAK elution, Typical examples of the radioactive peptide composition in the 
reaction mixtures with different molar peptide:radioiodide ratios are shown in Fig. 
2 ([Tyr'joctreotide) and Fig. 3 ([DTPA-D-Phe'jRC-160). Radioiodination of 
[Tyr'joctreotide yielded 96 %, 75 %, and 60 % mono-iodinated derivative at 
molar peptide:radionuclide ratios of respectively 41, 3.5, and 1.7. In case of 
(DTPA-D-Phe'jRC-160 at molar peptide:radionuclide ratios of 17 and 1.7 for the 
corresponding mono-iodinated compound respectively 82 % and 56 % were found. 
Thus, at higher molar peptide:radionuclide ratios much more mono-iodinated than 
di-iodinated peptides are formed. In the case of [DTPA-D-Phe'jRC-160) the HPLC 
elution profile of the mono-iodinated compound shows three peaks, like the 
original unlabelled compound (see above). Each of these three peaks yielded after 
reinjection into the HPLC again the same three original peaks, indicating that this 
peptide exists in three interconvertable forms (data not shown). 
m 
I m d d 
J 
A B 
Figure 3. Typical HPLC elution patterns of the reaction mixtures after radioiodi-
nation of [DTPA-D-Phi/RC-160 at two different molar peptide:radionuclide ratios: 
17 (Aj and 1.7 (Bj, measured by on-line gamma-counting. 
m = mono-iodinated peptide; d = di-iodinated peptide 
170 
o 
o 
dp 
o 
o 
dp o o 
A B c 
Figure 4. Typical HPLC elution patterns b~fore (A), after 30 min (B), and 4 h (C) 
irradiation of 30 p.g [DTPA-D-Phe'/octreotide by 370 MBq wI iodide, measured by 
UV-absorption at 254 nm. 0 ~ original peptide; dp ~ degradation products 
100 
Q) 
"C 
-0-
Q) 
0-
-
10 
0 
ro 
-c 
#. 
o 2 3 4 
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Figure 5. Remaining [DTPA-D-Phe'loctreotide after irradiation by wI as function 
of time expressed as percentage of the origininal amount, measured by UV-
absorption at 254 nm (experiment J {" /, 2 {Of, and 3 (1iIj) 
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Radiolysis by High Beta:flu:xes 
In Fig. 4 the degradation of fDTPA-D-Phe'loctreotide by the beta radiation of 
"'I is shown under circumstances (370 MBq "'I and 30 I'g peptide in 317 I'L 
reaction volume), simulating those occurring during separation steps. The figure 
shows the HPLC elution profiles of the original compound and after 30 min and 4 
h of irradiation. After irradiation new UV-peaks are formed while the peak of the 
original peptide deminishes. After 24 h no original peptide nor any degradation-
product were detectable anymore (data not shown). The irradiation experiment 
shows that the original peptide is destroyed under these conditions with a half-life 
of about I h (Fig. 5). 
DISCUSSION 
With the growing number of publications on applications of radiolabelled 
peptides for peptide receptor scintigraphy the question is raised whether such 
peptides may be used in radionuclide therapy of receptor-positive lesions. As these 
compounds are accumulated by specific, saturable receptor binding, efficient 
radionuclide receptor therapy of tumours requires an optimal mass of peptide 
labelled with a sufficient amount of a suitable radionuclide. 
Optimal Mass of Peptide 
In order to deliver the highest possible radiation dose to a tumour an optimal 
mass of peptide labelled to high specific activity needs to be administered. The 
optimal amount of peptide is dependent on various and often unknown parameters, 
such as saturation as well as possible homologous upregulation of somatostatin 
receptors at higher peptide doses (and competition with endogenous somatostatin). 
This is suggested by animal experiments, in which specific accumulation of f'''In-
DTPA-D-Phe'joctreotide in somatostatin receptor-positive tissues was enhanced by 
injecting an increased amount of peptide (18). Similar observations, although not 
expressed in absolute accumulation estimates were made in patients who showed 
enhanced visualization of tumours when they were investigated with ['''In-DTPA-
D-Phe'joctreotide during octreotide treatment (19, 20). Besides, not only saturati-
on, but also unwanted side-effects limit the administration of bioactive peptides. 
Scintigraphy after administration of ["'In-DTPA-D-Phe'joctreotide with different 
amounts of unlabelled IDTPA-D-Phe'loctreotide suggested an optimal range of that 
5-120 I'g (3.3 - 80 nmol) peptide (14, 15). A similar mass of radiolabelled 
somatostatin analogue will therefore be required for radionuclide therapy, assuming 
that its metabolic properties are comparable with that of I '''In-DTPA-D-Phe'joctre-
otide. For a somatostatin analogue of ~ 1.5 kD the presumed optimal therapeutic 
dose will amount to 67 nmol (100 I'g) peptide, since the optimal targetlnon target 
ratio with the highest radionuclide uptake (% dose) is reached with this amount of 
f'''In-DTPA-D-Phe'loctreotide during scintigraphy (14). 
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Choice of a Suitable Radionuclide 
Thusfar, radionuclide therapy is generally based on the emission of medium-
and high-energy beta particles. However, recently attention has also been paid to 
radionuclides that are commonly used for gamma camera scintigraphy. It is 
suggested that these "diagnostic" radionuclides may also tind therapeutic applicati-
ons on the basis of emission of their conversion- and Auger-electrons. Because of 
their low energy the range of these charged particles is very short and, thus, the 
radiation energy is deposited within the direct vicinity of the desintegrating 
radionuclide. This category includes among others "Ga and "'In (21-24). The 
question is whether such a radionuclide, coupled to a peptide, is sufficiently 
internalized by the cell so that the emitted low-energy particles will reach the 
nucleus. That this is the case was recently suggested by the successful treatment of 
a glucaconoma patient with ["'In-DTPA-D-Pheljoctreotide (15). However, of all 
radionuclides, 1311 has gained the most widespread use as therapeutic agent. 
Table 2. Theoretical (=lowest) and 
practical masses of 3. 7 GBq radionuclide 
Radionuclide theory 
[nmolj 
"'y 
"p 
"Ga 
6.17 
2.07 
2.91 
11 
38.3 
5.29 
2.53 
2.17 
46.0 
practice 
[nmol] 
38.2 
2.07 
133 
11 
? 
? 
2.53 
2.17 
46.0 
Labelling Peptides with 1311 
By far the most applied form 
of radionuclide therapy is the 
treatment of hyperthyroidism, 
goitre and well ditTerentiated thy-
roid carcinoma with 1311 (iodide). 
In addition, 131 1 is successfully 
used in the form of 13II_mIBG in 
therapy of neuroblastomas and 
phaeochromocytomas based on its 
accumulation in chromaffin gra-
nules of adrenergic tumour tissue 
of these tumours. 
Receptor-mediated radionucli-
de accumulation is determined by 
the affinity constant, the number 
of receptors on the tumour and 
the local concentration of the 
radioligand, which depends on 
the in vivo metabolism of the 
radiopharmaceutical. Usually, 
only a limited mass of a bioactive 
peptide can be administered to the 
patient. 
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It can therefore be calculated that radio labelled peptides must have a much higher 
radionuclide content than other regular radiotherapeuticals (Table I). Thus, for 
receptor-mediated radionuclide therapy the ligand should be labelled to a maximum 
specific activity without loss of affinity for the receptor. At the highest specific 
radioactivity commercially available the proposed 3.7 GBq U1I (38 nmol, see Table 
2) iodide may be bound to the presumed optimal mass (100 I'g = 67 nmol 
peptide). Incorporation of more than one iodine atom into the tyrosine of ITyr'loc-
treotide results in the loss of receptor binding (17). Our peptide experiment~ 
demon;trate that low excesses of peptide over radionuclide result in relatively large 
fractions of di-iodinated compounds, while a large excess of peptide over radio-
nuclide causes the formation of mainly the mono-iodinated compounds (Fig. 2 & 
3) with, of course, much peptide remaining unlabelled. Preparative HPLC-
separations will thus always be required to separate the wanted radiopeptide from 
(a) the unlabelled peptide, (b) the di-iodinated peptide, and (c) unreacted radioiodi· 
de. During the necessary purification on HPLC and/or SEP-PAK columns the 
radiopeptide is concentrated in small volumes and, hence, is subject to radio lytic 
damage (Fig. 5). Therefore, in spite of its useful application in other forms of 
radionuclide therapy, I3!I seems unsuitable for radionuclide peptide receptor 
therapy. Rather, direct radiolabelling (see later) in the presence of a suitable 
radiation quencher like gentisic acid (25), and without the need of separation steps 
will be preferred for preparing radiopeptides for therapy. 
Direct Radiolabelling of Chelator-conjugated Peptides with Radiometals 
A well-known method in the daily practice of nuclear medicine is the simple 
one-step preparation of radiopharmaceuticals that does not require additional 
purification steps. Peptides and proteins conjugated with chelators, like the 
polyaminopolycarboxylic acids EDT A, DTPA and DOTA, are suitable for such a 
one-step labelling procedure with radiometals. '''In for diagnostic purposes and 90y 
for therapeutic purposes are frequently used to label proteins conjugated with 
DTPA groups. Although the binding between this radionuclide and the chelator 
appeared to be stable in vitro, 90y turned out to be released from the DTPA-group 
in vivo, resulting in unfavourable bone accumulation of 9OY. This is especially the 
case when the DTPA group is introduced by reaction of DTPA cyclic anhydride 
with a lysine residue, as one acetic acid group is used for binding to the protein 
and, hence, is not available for 90y complexation (26). In carbon backbone-linked 
DTPA-groups such as SCN-Bz-DTPA 90y is far more tightly bound under physio-
logical conditions, probably because all five carboxyl groups participate in 90y 
complexation. In addition, peptides may also be derivatized with polyazamacrocy-
cles such as the DOT A group which bind 90y with very high affinity (27). 
Other therapeutic radiometals suitable for one-step inclusion in the DTPA-
group, like '''Tb, are not yet generally available. 
174 
By absence of a convenient suitable method for obtaining UlI-labelled peptides, 
at this moment the one-step labelling procedure using chelator-conjugated peptides 
to bind beta-decaying radiometals, like 9OY, "'mIn and "'Tb is the method of 
choice, although the avalability of ultra-pure radionuclides is still limited. Such 
radiolabelling has namely to meet the same specific activity requirements as 
described above (i.e. the highest possible activity of a radionuclide coupled to = 
67 nmol peptide), which seems possible for many short-lived radionuclides in 
absence of their isotopes and other metallic contaminants. In Table 2 the theoreti-
cal numbers of mols corresponding with 3.7 GBq of some radionuclides are 
compared with the practical attainable values. This illustrates, that certainly not all 
short-lived radionuclides will reach the high therapeutic specific activity required 
for coupling a high therapeutic radionuclide dose to a relatively small amount of 
peptide. 90Y is a good candidate in this respect, but few if any peptides are 
available conjugated with a suitable chelator such as the DOTA group. Our 
preliminary experience shows that "'Tb binds well to [DTPA-D-Phe'Joctreotide 
(unpublished results) and may be suitable for radionuclide peptide receptor therapy. 
At last, the problem of high physiological accumulation of chelator-conjugated 
radiotherapeuticals in vital organs, such as the kidneys, remains to be solved. 
CONCLUSION 
Intact mono-iodinated Ull-labelled peptides are hard to obtain in radiotherapeutic 
amounts. For peptide receptor radionuclide therapy direct labelling of a radiometal 
like 90Y or '''Tb to a chelator-conjugated peptide in the presence of a suitable 
radiation quencher appears far easier attainable, without the need for further 
separations. However, still many problems on radionuclide purity and synthesis of 
suitable chelator-conjugated peptides have to be solved. 
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GENERAL DISCUSSION, SUMMARY, AND CONCLUSIONS 
Somatostatin receptor scintigraphy has been performed since 1987, initially 
with ("'I-Tyr']octreotide and since 1989 with f'llIn-DTPA-D-Phel]octreotide. In 
general, both radiopharmaceuticals have been used at < 10 % of the maximum 
specific radioactivity. This, however, was thought to be unfavourable, because the 
established line of thought with regard to saturable processes such as receptor 
binding, is that sensitivity receptor scintigraphy can be optimized by 
a. lowering the mass of the radiotracer or 
b. by increasing the specific activity. 
This is so because unlabelled ligand will compete with the labelled ligand for 
the same receptor. Therefore, the injection of less unlabelled peptide will result in 
an increase of the % dose uptake of the radioligand. Provided that the non-specific 
binding is unaffected, the sensitivity of this technique will then indeed be 
increased. 
We thus hypothesized that the sensitivity of somatostatin receptor scintigraphy 
technique could be increased by using the lowest possible mass at the highest 
possible specific activity. Since the non-radioactive composition of 1I1InCI, has 
improved after its tlrst use in the labelling of (DTPA-D-PhelJoctreotide in 1989, 
the specific activity of [lllIn-DTPA-D-Pheljoctreotide could be increased 5-fold up 
to 185 MBq per Itg. As described in Chapter 3, the effect of injected mass of 
(DTPA-D-Pheljoctreotide labelled at various specitlc activities were investigated in 
rats. We did not find significant differences in uptake of (lllln-DTPA-D-
Phelloctreotide in somatostatin receptor-negative organs (background), and, to our 
surprise, the uptake in somatostatin receptor-positive tissues showed a tissue-
specitlc bell-shaped function of the injected mass. So, in contrast to our 
hypothesis, the uptake was not optimal at the lowest possible mass, while varying 
specitlc activity at a constant injected mass did not affect the % dose uptake. 
Since the tlndings probably extend also to somatostatin receptor-positive tumours, 
an extra parameter has become available to increase the sensitivity to detect these 
tumours. Indeed, preliminary findings in patients indicated that a specitlc activity 
higher than 220 MBq per 5 Itg fDTPA-D-Phe'joctreotide will lead to a decreased 
quality of scintigraphy, and that uptake in tumours is significantly reduced. 
Furthermore, as presented in Chapter 3, several reports suggested a positive 
effect of the prior administration of unlabelled octreotide on the percentage dose 
uptake and internalization of its radioactive counterpart. We evaluated the effects 
of the intravenous administration of 2 or 10 Itg of urdabelled octreotide or [DTPA-
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D-Phe']octreotide at various time points relative to the administration of the 
radiopharmaceutical. In all the somatostatin receptor-positive tissues, we found a 
significant change in % dose uptake of radioactivity, depending on the mass, the 
ligand and the tissue under study. In summary, these findings indicate that the 
injection of variable amounts of ligand at various time points relative to the 
injection of ['''In-DTPA-D-Phe'loctreotide may also be a means to increase the 
target to background ratio in somatostatin receptor scintigraphy. 
In Chapter 4, the binding and internalization of ["'1-Tyr']octreotide by mO\1~e 
AtT20/D 16V pituitary tumour cells and by human growth hormone-producing 
pituitary tumour cells have been investigated in order to get insight into the 
metabolism of the radioligand. Internalization of the radioligand is of special 
importance when radiotherapy of certain somatostatin receptor-positive human 
tumours with a- or B-emitting radiolabelled somatostatin analogues is considered. 
We found extensive internalization of [mI-Tyr']octreotide which was dependent on 
time, and temperature and ligand concentration. Addition of I nM unlabelled 
octreotide induced a rapid increase in membrane binding and internalization of the 
radioligand. However, in patients investigated with ["'1-Tyr']octreotide, a short 
residence time of radioactivity was found in the somatostatin receptor-positive 
target tissues. Therefore, [1311_ Tyr']octreotide will most probably not be suitable as 
a radiotherapeutical (see also Appendix 3). 
The presence of the DTPA-group in ['''In-DTPA-D-Phe'joctreotide has major 
effects on its tissue residence time. With this radiopharmaceutical, we found in 
patients a biological half-life of > 700 hours in liver and in tumours, and of ~ 
270 hours in the kidneys (see also Appendix I). These observations indicate tissue-
and structure-specific differences in metabolism for somatostatin analogues. 
In another experiment, described in Chapter 3, in vivo displacement of 
somatostatin receptor-positive tissue-associated radioactivity is observed if 
unlabelled octreotide is injected 10 min after 1'''In-DTPA-D-Phe'joctreotide, but 
not after 20 min. In conjunction with the long tissue residence time, these fmdings 
represent strong evidence for significant internalization of ["'In-DTPA-D-
Phe'joctreotide in vivo. 
Recent reports have characterized the ligand specificity of the 5 different 
somatostatin receptors sofar identified. However, little is still known about the 
tissue (tumor)-specific expression of these receptors, and, hence, the tissue 
(tumor)-specific uptake of somatostatin analogues. 
In Chapters 5, 6 and 7 the preparation, biological activity, in vivo application 
in rats and receptor scintigraphy of 1"'1- or mI_ Tyr'jRC-160, and l"'In-DTPA-D-
Phe']RC-160 are presented and compared with [mI_ or '''I-Tyr'Joctreotide, and 
["'In-DTPA-D-Phe']octreotide, respectively. The radiolabelled RC-160 analogues 
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all showed uptake and specific high-affinity binding to various somatostatin 
receptor-positive organs. In contrast to RC-160 and l"'I-Tyr'jRC-160, which do 
pass the blood-brain barrier, it was shown that f"'ln-DTPA-D-Phe'JRC-160 does 
not pass the blood-brain barrier. Compared to ["'In-DTPA-D-Phe'joctreotide, the 
main disadvantage otl'''l-Tyr'jRC-160 and ['''In-DTPA-D-Phe'jRC-160 is their 
relatively low somatostatin receptor-positive tissue to blood (background) ratio, 
implying poorer sensitivity. However, labelled RC-160 may be potentially useful 
for the scintigraphy of tumours expressing somatostatin receptor isoforms capable 
of binding RC-160 but not octreotide. Perhaps, SSTR5 is an example of such a 
RC-160-preferring somatostatin receptor. 
Several other radiolabelled peptides may have potential use as a 
radiopharmaceutical in receptor scintigraphy. The 11 amino acids-containing 
neurotransmitter substance P, which is among others involved in several 
immunological processes, is such a candidate. As described in Chapter 8 and 9, 
substance P was conjugated with a DTPA-group and labelled with "'In. ["'In-
DTPA-Arg'lsuhstance P was subsequently tested in several in vitro tests to 
establish its intact binding characteristics, and investigated as a radiopharmaceutical 
for the detection of immunological disorders in rats and in patients. In vivo 
metabolism of the radiopharmaceutical in the rat revealed a renal clearance of 50 
% of the injected radioactive dose in 30 min half-life as well as rapid enzymatic 
degradation resulting in an effective half-life of the intact radiopharmaceutical in 
blood of only = 3 min. Despite this very short half-life the visualization of normal 
substance P receptor-positive tissues, such as the salivary glands, was demonstrated 
in control rats by gamma camera scintigraphy. Pathological substance P receptor-
positive processes were also visualized in rats bearing the transplantable pancreatic 
tumour CA20948, and in rats with mycobacteria tuberculosis-induced arthritic 
joints. In analogy with the fDTPA-D-Phe'loctreotide experiments, as described in 
Chapter 3, we also found a tissue-specific bell-shaped uptake of radioactivity in 
substance P receptor-positive tissues as a function of the injected mass of [DTPA-
Arg'lsubstance P in rats. However, the clinical relevance of these fmdings is 
limited because of the side etfect~ of substance P administration to humans. 
In Chapter 9, we describe the investigation of ten selected patients with 
inflammatory bowel disease (5), ophthalmic Graves' disease (I), sarcoidosis (1), 
Sjogren's syndrome (1), systemic lupus erythematosus (I), and reumatoid arthritis 
(I) after the injection of 200 MBq (2.5 fLg) f"'ln-DTPA-Arg'jsubstance P. The 
pharmacological characteristics of the latter were evident; even during a 10 min 
intravenous infusion of 2.5 fLg ['''In-DTPA-Arg'lsubstance P a transient flush was 
observed, as was also reported for substance P in healthy volunteers. Degradation 
of f"'ln-DTPA-Arg'jsubstance P started after the first min after administration, 
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resulting in a half-life of 10 min for plasma radioactivity and of 4 min for the 
intact radiopharmaceutical, as identified by HPLC. Urinary excretion amounted to 
in > 95 % of the injected dose of radioactivity in 24 h, while as low as 0.05 % 
was found in the feces collected up to 60 h after the injection. In all patients 
uptake was found in the parotid glands, aurolae of the mammae (in women), liver, 
kidneys, and urine bladder. In seven patient~ a high uptake of r"'In-DTPA-
Arg'lsubstance P was found in the thymus. Based on these findings, we conclude 
that ,'''In-DTPA-Arg'jsubstance P is a new radiopharmaceutical and, despite its 
short half-life, can be used to visualize the thymus. This may contribute to the 
investigation of the role of thymus in immune disorders. However, after the 
pharmacological characteristics of ['''In-DTPA-Arg'lsubstance P in patients became 
evident, the search for radiolabelled substance P antagonists suitable for gamma 
camera scintigraphy was continued, but sofar, without results. Several D-amino 
acids-containing and DTPA-conjugated ;lIbstance P analogues were also 
investigated in vivo, but they showed much less specific binding to substance P 
receptor-positive tissues in vivo than ,'''In-DTPA-Arg'lsubstance P. The search for 
more stable substance P agonists may not be a useful strategy, since the 
pharmacological effects of substance P, as a consequence, will also be prolonged. 
Therefore, the intravenously administered mass of such a substance P analogue will 
have to be minimal, which may be too low for optimal tissue (tumour) uptake. 
Seven of the 10 peptide bonds of substance P are hydrolyzed by various 
peptidases, such as angiotensin converting enzyme (ACE) or neutral endopeptidase 
(NEP). Inhibitors of ACE or NEP may be an interesting addition to the 
radiopharmaceutical to prolong its half-life, but they may also potentiate the 
unwanted cardiovascular tachykinin responses. 
In the Appendix papers I, 2 and 3 we describe the development and the 
application of somatostatin analogues labelled with the Auger electron-emitter "'In, 
and the 6 electron-emitters I6ITb and 1311, respectively. In Appendix 1, a case 
history of the successful radiotherapy with [' " In-DTPA-D-Phe' joctreotide is 
presented in a patient with an inoperable metastasized glucagonoma. After a 
cumulative dose of 20 GBq rl"In-DTPA-D-Phe'loctreotide a decrease in total 
abdominal tumour volume of = 20 % was observed, combined with a (transient) 
decline in levels of glucagon and y-glutamyl transferase. These findings suggest an 
antiproliferative effect of the radiotherapy with high doses of ["'In-DTPA-D-
Phe'joctreotide. However, in general, '''In is not the most appropriate radionuclide 
for radiotherapy, since it lacks the higher energies of Cl- and 6-particles. 
Radiotherapy of tumours with an inhomogenous distribution of peptide-receptors 
will also require these higher energies. For that reason we specially evaluated the 
hard 6-emitter ,16ITb_ DTP A -D-Phe'joctreotide. 
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In Appendix 2, the in vitro receptor binding and biological activity of ["'Tb-
DTPA-D-Phe'loctreotide, its metabolism in isolated perfused rat livers and its 
tissue distribution in normal and tumour-bearing rats were investigated, and 
compared with [U'In-DTPA-D-Phe']octreotide. We found, specific high-aftlnity 
binding to the somatostatin receptor and biological activity for the "'Tb- or '''Tb-
labelled lDTPA-D-Phe']octreotide. Combined with the in vivo organ distribution, 
['''Tb-DTPA-D-Phe']octreotide might be a promising radiopharmaceutical, that can 
be used both for radiotherapy and as a tool for intraoperative scanning. 
In Appendix 3 the frequently mentioned potential use of "'I-labelled 
somatostatin analogues for radiotherapy is evaluated. This was done with special 
attention to the radiochemistry and the technical aspects of the production of 
radiotherapeuticals. 
In the presence of 370 MBq '''1, somatostatin analogues showed extensive 
radiolytic damage in aqueous solution with a haltclife of only 1 h. 
Consequently, we conclude that intact mono-iodinated "'I-labelled peptides 
will be very hard to obtain, especially if a supposed dose of 3700 MBq "'I-labelled 
peptide is required. For peptide-receptor radionuclide therapy direct labelling of a 
radiometal like 90y or "'Tb to a chelator-conjugated peptide in the presence of a 
suitable radiation quencher may be far easier to obtain. However, still many 
interesting problems on radionuclide purity and synthesis will have to be solved. 
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In/eiding 
SAMENVATTING, DlSCUSSIE EN CONCLUSIES 
ook voor de leek 
Somatostatine is een harmoon; het is onder andere aanwezig in de 
hypothalamus, de buitenste regionen van de hersenen, de hersenstam, op 
verschillende plaatsen in het maag-darm kanaal en in het pancreas (de alvleesklier). 
Bij het timctioneren van een hormoon is een receptor voor de herkenning van het 
hormoon noodzakelijk; zo wordt somatostatine herkend door specifieke 
somatostatine receptoren. In vakterminologie wordt gesproken over ligand 
(=somatostatine) en receptor. In het centraal zenuwstelsel (CZS) is somatostatine 
op deze zelfde wijze via receptoren werkzaam als een neurotransmitter, dat wil 
zeggen het is betrokken bij de communicatie in het CZS. Somatostatine is ook 
buiten het CZS via de somatostatine receptoren betrokken bij bijvoorbeeld de 
remming van de afgifte van andere hormonen, zoals groeihormoon, insuline, 
glucagon en gastrine. Deze remmende werking heeft geleid tot de behandeling met 
somatostatine van patienten met ziekten die veroorzaakt worden door te hard 
werkende k1ieren of tumoren die hormonen uitscheiden. 
Somatostatine heeft in de bloedbaan een zeer korte werkzame periode van 
± 3 minuten. Dit was een belangrijke reden om een soortgelijk peptide te maken 
die langer werkzaam was. Verscheidene van deze peptiden (analoga) worden nu 
over de gehele wereld gebruikt als geneesmiddel bij patienten met k1ieren die 
teveel hormonen uitscheiden of tumoren met somatostatine receptoren. Een van 
deze somatostatine analoga is octreotide. Een andere werkzame variant van 
octreotide is [DTPA-D-Phe'Joctreotide: dit analogon bezit een groep (chelator) die 
de mogelijkheid geeft om hieraan op een eenvoudige en snelle wijze radioaktieve 
stoffen zoals "'In ("indium-III ") te koppelen. Deze radioaktieve verbinding werd 
in het Academisch Ziekenhuis Rotterdam "Dijkzigt" ontwikkeld en wordt sinds 
1989 routinematig toegepast voor de diagnostiek bij patienten met verdenking van 
bijvoorbeeld te snel werkende k1ieren of tumoren die somatostatine receptoren 
bezitten. 
Wat is er onderzocht 
De in dit proefschrift met radioaktiviteit gelabelde (gemerkte) peptiden 
kunnen in principe op twee manieren worden gebruikt: 
I. voor de diagnostiek van onder andere tumoren met behulp van "nucIeaire 
foto's" (scintigrammen) en 
2. voor de behandeling van deze tumoren (radionucIide therapie). 
Na een inleiding wordt in dit proefschrift in hoofdstuk 3 een onderzoek met 
['''In-DTPA-D-Phe'loctreotide beschreven met als doel te onderzoeken of voor het 
aantonen van afwijkingen en tumoren aile somatostatine moleculen die zich kunnen 
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binden aan een somatostatine receptor, na inspuiting in rat of mens, radioaktief 
gemerkt dienen te zijn. Op deze manier hebben namelijk somatostatine moleculen 
die zich binden aan de somatostatine receptoren geen last van ongemerkte 
somatostatine moleculen die zich ook binden aan dezelfde receptor. En daarbij 
geldt: hoe meer receptoren gebonden zijn met gemerkte moleculen, des te beter 
zouden de afbeeldingen moeten zijn. Aangezien de kwaliteit van het "'InCI, 
("indium-lll-chioride") sinds de eerste labeling van IDTPA-D-Phe'joctreotide 
sterk is verbeterd, kon deze hypothese worden getoetst. De resultaten waren 
volkomen onverwacht: in de rat werd een relatie gevonden tussen de toegediende 
massa van het ligand ([DTPA-D-Phe'joctreotide) en de percentage dosis opname in 
somatostatine receptor-positief weefsel, maar niet tussen de "puurheid" van het in 
te spuiten gemerkt hormoon en de percentage opname. Dit aspect werd ook 
onderzocht bij patienten, en uit de voorlopige resultaten is gebleken dat ook bij de 
mens een minimum aan toegediende massa van het ligand essentieel is. 
In hoofdstuk 3 wordt ook een onderzoek beschreven waarbij een poging 
wordt gedaan de opname van het radioaktieve deel van het ['''In-DTPA-D-
Phe'joctreotide te befnvloeden met als doel de opname van radioaktiviteit in het 
weefsel selectief te verhogen. Het bleek dat de opname van radioaktiviteit in de 
verschillende somatostatine receptor-bevattende weefsels inderdaad kan worden 
befnvloed door verschillende hoeveelheden van verschillende liganden op 
verschillende tijden ten opzichte van het gemerkte ligand toe te dienen. 
[Tyr'Joctreotide is weer een andere variant van het octreotide, die ook aan 
somatostatine receptoren bindt. Met de synthese van [Tyr'loctreotide werd het 
mogel\jk octreotide te merken met radioaktief jodium. Deze eigenschap opende 
speciale onderzoekmogelijkheden in het laboratorium. Voorbeelden van radioaktief 
jodium z\in "'I ("jodium-123") , "51 en "'I. Uit eerdere onderzoeken met ["'1_ 
Tyr'joctreotide met ratten, maar ook bij patienten was gebleken dat de verbl(jftijd 
van dit radioligand kort is. Om geschikt te zijn voor radionuclide therapie, zou 
juist een langere verblijftijd gunstig zijn. Daarom mag worden aangenomen dat 
[Tyr'Joctreotide minder geschikt is voor radionuclide therapie. 
De aanwezigheid van een chelator (-DTPA) in het andere radioligand, 
["'In-DTPA-D-Phe'joctreotide, bleek belangrijke effecten op de verblijftijd van de 
radioaktiviteit in de weefsels te hebben. Uit onderzoeken bij patienten is gebleken 
dat de biologische halfwaarde tijd van "'In in de lever en in de tumor meer dan 
700 uren bedraagt, en in de nieren ongeveer 270 uren. Hieruit blijkt ook al een 
verschil in stofwisseling in deze weefsels en ook voor de twee radioliganden. Dit 
zou octreotide-liganden met een DTPA-groep geschikter maken voor radionuclide 
therapie. 
In een ander experiment, beschreven in hoofdstuk 3, is verdringing van 
radioaktiviteit uit weefsels gevonden indien 10 minuten na toediening van het 
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radioligand een hoeveelheid van het niet gemerkte ligand wordt toegediend. Dit 
treedt niet op indien het ongemerkte ligand 20 minuten later wordt toegediend. 
Samen met de genoemde langere verblijftijd van de radioaktiviteit in de weefsels 
suggereren deze waamemingen dat er opname van radioaktiviteit in de weefsels 
plaatsvindt, wanneer [U'In-DTPA-D-Phe'joctreotide gebmikt word!. Dit is 
uiteraard van belang wanneer soortgelijke stoffen voor radionuclide therapie 
gebmikt gaan worden, teneinde de kern van de kankercellen te bestralen. 
Voor de eventuele ontwikkeling van radionuclide therapie met 
[Tyr'joctreotide of IDTPA-D-Phe'loctreotide gemerkt met de daarvoor geschikte 
radioaktieve stoffen, is verdere verdieping van de kennis vereist over de lokalisatie 
en de verblijftijd in de cel van het radioaktieve dee! van deze verbindingen. Deze 
onderzoeken zijn beschreven in hoofdstuk 4 en werden uitgevoerd met cellen van 
de hypofyse {"hersenaanhangsel"). Deze cellen bezitten een hoge dichtheid aan 
somatostatine receptoren. Het bleek dat een zeer geringe toevoeging (1 nM) van 
het octreotide aan de hypofysecellen de hoeveelheid van het aantal somatostatine 
receptoren op de membraan van de hypofyse cellen snel deed toenemen, en dat er 
tevens een versnelde opname van het radio ligand werd waargenomen. Dit 
fenomeen is wellicht ook de verklaring van de waamemingen uit hoofdstuk 3 
waarbij een minimum aan toegediende massa van het ligand vereist is om een 
hogere opname van radioaktiviteit in somatostatine receptor bevattend weefsel te 
realiseren. 
In de literatuur zijn enkele studies beschreven betreffende een ander 
somatostatine analogon, een cyclisch octapeptide RC-l60, dat veel overeenkomsten 
vertoont met octreotide. De receptor bindende eigenschappen van het RC-160 
zouden superieur zijn aan octreotide in tumoren van de borst, eierstokken, 
exocriene alvleesklier, prostaat en de dikke darm. Bovendien ZQU RC-l60, in 
tegenstelling tot octreotide de barriere tussen bloed en hersenen kunnen passeren. 
Deze eigenschappen waren aanleiding om de mogelijkheden van RC-l60 te 
onderzoeken. De resultaten hiervan zijn beschreven in de hoofdstukken 5, 6 en 7. 
RC-l60 en het nieuw gesynthetiseerde [DTPA-D-Phe'JRC-l60, en de beide 
radioliganden '''I-RC-l60 en [U'In-DTPA-D-Phe'JRC-l60 vertoonden aile, in vitro, 
receptor bindende eigenschappen en biologische aktiviteit. Bij proeven met dieren 
werden de bindende eigenschappen bevestigd. De eigenschappen van RC-l60 en 
[DTPA-D-Phe'JRC-l60 waren in ons testsysteem vergel~ikbaar met die van 
octreotide, respectievelijk fDTPA-D-Phe'joctreotide. Bovendien was door de 
toevoeging van de polaire DTPA-groep aan het [DTPA-D-Phe'jRC-l60 de barriere 
tussen de bloed en hersenen weer een barriere voor dit radioligand. Vooral de 
langzamere klaring van radioaktiviteit van ["'In-DTPA-D-Phe'jRC-l60 uit de 
somatostatine receptor-ontbrekende weefsels en het bloed, vergeleken met ["'In-
DTPA-D-Phe'joctreotide, resulteert in een lagere verhouding van de stapeling van 
radioaktiviteit in de somatostatine receptor bevattende weefsels ten opzichte van 
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achtergrond (bloed) en dus ook in een minder gunstige atbeelding op het 
scintigram. Ondanks de minder goede eigenschappen van RC-160 ten opzichte van 
octreotide, z(jn er theoretisch nog steeds mogelijkbeden voor diagnostische en 
radionuclide therapeutische toepassingen voor RC-J60 en lDTPA-D-Phe'jRC-160. 
Dit geldt voor de tumoren die bepaalde vormen van de somatostatine receptor 
hebben en die octreotide niet en RC-160 mogelijk weI kunnen binden. 
Verschillende radioaktief gemerkte peptiden zijn potentieel kandidaat voor 
receptor scintigrafie. Een voorbeeld hiervoor is substance P. Dit is een 
neurotransmitter die onder andere betrokken is bij verschillende immunologische 
processen. 
In de hoofdstukken 8 en 9 worden de onderzoeken beschreven met 
substance P waaraan een DTP A-groep is gekoppeld. Hierdoor is ook bij deze stof 
een directe, snelle labeling met '''In mogelijk. De receptor bindende eigenschappen 
van het ["'In-DTPA-Arg'jsllbstance P werden onderzocht en bleken intact te z(jn 
gebleven. Substance P wordt in het Iichaam door verschillende enzymen snel 
atgebroken en voor ["'In-DTPA-Arg'jsubstance P geldt dit eveneens. De 
halfwaarde tijd van het intacte ["'In-DTPA-Arg'jsubstance P in bloed van rat en 
mens is 3-4 minuten. De speekselklieren in rat en mens vertonen een hoge 
dichtheid aan substance P receptoren, en ondanks de korte halfwaarde tijd is het 
toch mogelijk om deze weefsels zichtbaar Ie maken op het scintigram. In de rat 
werden ook andere weefsels met een bewezen verhoogde substance P receptor-
expressie onderzocht en ook deze weefsels konden worden afgebeeld. Hoewel de 
onderzoeken met ['''In-DTPA-Arg'jsubstance P bij de mens nog beperkt zijn, 
werden ook in de mens afwijkingen op de scintigrammen gevonden met een 
duidelijk (oorzakelijk) verband met het ziektebeeld. Dat de biologische aktiviteit 
van het (radio)ligand bewaard is gebleven wordt duidelijk waargenomen: iedere 
patient krijg! bij de toediening van ± 2,5 I'g ['''In-DTPA-Arg'jsubstance Peen 
kortdurende flush ("opvlieger"). Ontstekingen bij verschiIIende ziekten konden 
eveneens duideIijk afgebeeld worden. Bij een deel van de onderzochte patienten 
was de thymus (zwezerik) opvallend zichtbaar. B(i verschiIIende autoimmuun-
ziekten is vergroting van de thymus beschreven; de rol van de thymus bij deze 
ziektebeelden is echter nog onduideIijk. De plaats van ['''In-DTPA-Arg'lsubstance 
P in de scintigrafie van bijvoorbeeld ontstekingen en de rol van de thymus bij 
autoimmuun-ziekten zal in de toekomst nog moeten worden bepaald. 
In de appendix hoofdstukken I, 2 en 3 worden de ontwikkelingen en de 
toepassingen beschreven van somatostatine analoga die gemerkt zijn met de 
radioaktieve stoffen '''In, "'Tb ("terbium-161 ") en "'1. De fysische verschillen 
tussen deze radioaktieve stoffen zijn groot. Ten eerste heeft "'In een aantal soorten 
van straling, zoals gamma-straling waar in de nucleaire geneeskunde gebruik van 
wordt gemaakt voor atbeeldingen op het scintigram. De tweede belangrijke soort 
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van straling van lllIn vormen de Auger- en conversie-elektronen; deze straling is 
ongeschikt voor afbee1den in de nucleaire geneeskunde. Deze elektronen zijn weI 
geschikt voor therapeutische toepassingen, maar aIleen als het uiteenvallende 
radionuclide op de juiste plaats terecht komI. Deze elektronen hebben namelijk een 
relatief korte dracht ("reikwijdte"), dat wil zeggen dat deze energierijke elektronen 
vaak niet verder reiken dan een zeer klein deel van een cel of tumor. De juiste 
plaats voor de therapie is in dit geval in of vlakbij de celkern, want dit deel van de 
cel is het meest gevoelig voor het uiteindelijke doel: het toebrengen van 
onherstelbare stralingsschade. Hiermee zijn we terug bij het onderwerp uit 
hoofdstuk 4, waarbij het belang van de kennis van de lokalisatie en verblijftijd van 
het radionuclide werd aangegeven. 
In het appendix hoofdstuk I wordt melding gemaakt van de eerste en 
bemoedigende therapeutische toepassing van ["'In-DTPA-D-Phe']octreotide bij een 
patient met tumoren die niet verwijderd konden worden. De behandeling is in 
delen uitgevoerd met een totale dosis van 20 GBq ["'In-DTPA-D-Phe'joctreotide. 
Er werd een verkleining van de tumor in de buik van 20 % waargenomen, 
gecombineerd met een tijdelijke daling van stoffen in het bloed die door de tumor 
werden gemaakt. De voortgang van deze nieuwe therapie wordt op het moment in 
internationaal verband verder ontwikkeld. 
Ondanks dit succes geldt in het algemeen dat '" In niet het ideale 
radionuclide is voor therapeutische toepassingen. Het radionuclide i6'Tb heef! niet 
aileen de reeds eerder genoemde gamma-straling, maar ook beta-straling. Deze 
hoog-energetische beta-straling heef! een veel grotere dracht dan de Auger- en 
conversie-elektronen van bijvoorbeeld IIIIn. Bovendien is door deze grotere dracht 
van het i6'Tb de mogelijke niet-gelijke verdeling van de somatostatine receptoren in 
een tumor niet meer beperkend. De cellen in een tumor die geen expressie van 
somatostatine receptoren vertonen kunnen nu toch via een "kruisvuur" vanuit de 
belendende cellen die weI radioaktiviteit hebben opgenomen worden bestraald. De 
onderzoeken met [DTPAj-gemerkte peptiden met '61 Tb zijn gaande. De receptor-
bindende eigenschappen en de biologische aktiviteit van het fi6'Tb-DTPA-D-
Phe'Joctreotide zijn intact gebleken, en de resultaten van de studies naar de 
verdeling van de radioaktiviteit in de organen in de rat zijn hoopgevend. 
Bovendien is het stralingsniveau rondom een met [I6'Tb-DTPA-D-Phe']octreotide 
ingespoten patient laag. Met speciale richtingsgevoelige stralings-detectie 
apparatuur zijn er mogelijkbeden voor de anatomische plaatsbepaling van kleine 
tumoren tijdens een operatie. 
In het appendix hoofdstuk 3 worden de mogelijkbeden van de produktie en 
de toepasbaarheid van het l3'I-gemerkte [Tyr']octreotide en voor de therapie met 
dergelijke radioaktieve peptiden beschreven. Speciale aandacht is besteed aan de 
radiochemie en aan de technische aspecten van deze produktie. Een aantal 
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somatostatine analoga bleken in een waterig milieu, in een klein volume en in de 
aanwezigheid van 370 MBq "'I, sterk onderhevig te zijn aan radiolyse 
(stralingsschade), resulterend in een halfwaarde tijd van deze peptiden van 1 uur. 
Dientengevolge concluderen W\j dat therapeutische hoeveelheden van zelfs 3700 
MBq "'I van het intacte mono-g"jodeerde lTyr'loctreotide of andere analoga 
moeilijk, zo niet onmogelijk kunnen worden geproduceerd. Radioaktieve peptiden 
voor de radionuclide therapie van tumoren zijn wellicht eenvoudiger en beter te 
produceren via een directe labeling van een -chelator groep bevattend peptide met 
een radiometaal zoals 90y ("Yttrium-90") of '''Tb. Dit zal bijvoorbeeld ook kunnen 
gebeuren in de aanwezigheid van een stof die de schade van radio lyse weet te 
beperken, een zogenaamde "quencher". Ook wat dit onderwerp betreft is nog 
verder onderzoek vereist. 
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weg nag vele jaren kunnen doorgaan. 
De stagiaires van het Zadkine College hebben op allerlei wijzen de 
helpende hand toegestoken en z\jn van groot belang geweest bij de voortgang van 
het onderzoek. Reno Mekes, Marieke Steeneken, Annelies Dahrs, Vincent-
Elvis Versendaal en Michael Schaar nogmaals bedankt. 
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Ina Loeve, Thijs van Aken, Margreet Vlastuin, Bert Bernard en Edgar 
Rolleman, jullie enthousiaste inbreng leidde tot een efficient verloop bij de dier 
experimenten. 
Hans Starn, dat na onze jarenlange samenwerking op Cardiochemie en 
Biochemie er een "boekje" van mijn hand verschijnt, kan je niet hebben verbaasd. 
Iij hebt me altijd weten te stimuleren in studie en werk, eerst via ing naar nu dr. 
Ik stel het zeer op prijs dat je mijn paranimf wilt zijn. 
Mijn ouders, ik wil jullie bedanken voor de vele geboden mogeljikbeden en 
ik ben blij dat jullie "dit" nog mogen meemaken. 
Als laatste mijn Meiden: Lieneke, Iris en Ike, die mij aile ruimte en tijd 
hebben gegeven om dit "boekje" te realiseren. Ik verheug me alweer op het 
gezamelijk varen en vogels kijken, en ook om weer thuis en echt "aanwezig" te 
ZIJfl. 
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CURRICULUM VITAE 
W.A.P. Breeman werd op 11 september 1951 geboren te Rotterdam geboren. Zijn 
jeugd bracht hij door op Cura<;ao (Nederlandse Antillen). De middelbare 
schoolopleiding startte hij aan het Peter Stuyvesant College (Cura<;ao), en werd 
vanaf 1965 voortgezet aan de HBS in Oud-Beijerland. Na het vervullen van zijn 
militaire dienstplicht begon h(j de avondstudie aan het van 't Hoff instituut te 
Rotterdam. Het diploma HTS-chemie werd in 1979 behaald. Gedurende 1969-1976 
werd werkervaring als analist opgedaan in verschillende laboratoria. Vanaf 1976 
was hij verbonden aan de Medische Faculteit van de Erasmus Universiteit te 
Rotterdam, tot 1980 op het lahoratorium van de afdeling Cardiochemie (Thorax-
centrum, hoofd van de afdeling dr J.W. de Jong), en aansluitend tot 1983 op de 
afdeling Biochemie I (hoofd van de afdeling Prof. dr W.e. Hiilsmann). In 1977 
behaalde hij het "C"-diploma Deskundigheid Slralenbescherming aan het 
Interuniversitair Reactor Instituut te Delft. Vanaf 1983 is h(j werkzaam binnen de 
afdeling Nucleaire Geneeskunde van het Academisch Ziekenhuis Rotterdam. 
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Nieuwsgierigheid is niets anders 
dan ijdelheid. Meestal wil men aileen iets 
weten om erover te kunnen meepraten. Men 
zou geen zeereizen maken als men er nooit 
over zou kunnen vertellen, want aileen het 
plezier van het reizen is niet genoeg. 
Pensees, Blaise Pascal, 1623-1662. 
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